epidermal growth factor receptor antagonist - Ontology Report - Rat Genome Database

Submit Data | Help | Video Tutorials | News | Publications | Download | REST API | Citing RGD | Contact

Advanced Search (OLGA)

CHEBI ONTOLOGY - ANNOTATIONS

{{ watchLinkText }}

The Chemical Entities of Biological Interest (ChEBI) ontology is downloaded weekly from EMBL-EBI at http://www.ebi.ac.uk/chebi/. The data is made available under the Creative Commons License (CC BY 3.0, http://creativecommons.org/licenses/by/3.0/). For more information see: Degtyarenko et al. (2008) ChEBI: a database and ontology for chemical entities of biological interest. Nucleic Acids Res. 36, D344–D350.

Term:	epidermal growth factor receptor antagonist	go back to main search page
Accession:	CHEBI:74440	browse the term
Definition:	An antagonist at the epidermal growth factor receptor.
Synonyms:	related_synonym:	EGFR antagonoist; EGFR antagonoists; EGFR inhibitor; EGFR inhibitors; epidermal growth factor receptor antagonists; epidermal growth factor receptor inhibitor; epidermal growth factor receptor inhibitors
	xref:	Wikipedia:Epidermal_growth_factor_receptor

show annotations for term's descendants Sort by:
Rat (340) Mouse (343) Human (348) Chinchilla (0) Bonobo (0) Dog (0) Squirrel (0) Pig (3) Green Monkey (0) Naked Mole-rat (0) All
Genes (340)

dacomitinib

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

cytochrome P450, family 2, subfamily d, polypeptide 4

multiple interactions
affects metabolic processing

Quinidine affects the reaction [CYP2D6 protein polymorphism affects the metabolism of dacomitinib]

NCBI chr 7:113,882,584...113,891,754
Ensembl chr 7:113,881,618...113,891,759

G

epidermal growth factor receptor

multiple interactions

dacomitinib inhibits the reaction [EGFR protein results in increased phosphorylation of EGFR protein]

NCBI chr14:91,176,979...91,349,722
Ensembl chr14:91,177,067...91,344,382

erlotinib hydrochloride

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

ATP binding cassette subfamily G member 2

multiple interactions

Erlotinib Hydrochloride inhibits the reaction [ABCG2 gene mutant form results in decreased susceptibility to Mitoxantrone]; Erlotinib Hydrochloride inhibits the reaction [ABCG2 protein results in decreased susceptibility to Mitoxantrone]; Erlotinib Hydrochloride inhibits the reaction [ABCG2 protein results in increased export of Methotrexate]; Erlotinib Hydrochloride inhibits the reaction [ABCG2 results in increased export of Methotrexate]

PMID:18829547 PMID:19232821

NCBI chr 4:87,676,241...87,802,757
Ensembl chr 4:87,745,319...87,802,409

G

acetyl-CoA carboxylase alpha

increases phosphorylation

Erlotinib Hydrochloride results in increased phosphorylation of ACACA protein

NCBI chr10:69,014,261...69,276,453
Ensembl chr10:69,014,170...69,276,457

G

adhesion G protein-coupled receptor E1

multiple interactions

[Interleukin 1 Receptor Antagonist Protein co-treated with Erlotinib Hydrochloride] results in decreased expression of ADGRE1 protein

NCBI chr 9:2,242,476...2,398,000
Ensembl chr 9:2,242,474...2,398,000

G

AKT serine/threonine kinase 1

decreases phosphorylation
multiple interactions

Erlotinib Hydrochloride results in decreased phosphorylation of AKT1 protein
Erlotinib Hydrochloride inhibits the reaction [Derp2 allergen, Dermatophagoides pteronyssinus results in increased phosphorylation of AKT1 protein]

PMID:21195724 PMID:30623574

NCBI chr 6:131,713,716...131,735,319
Ensembl chr 6:131,713,720...131,733,921

G

apoptotic peptidase activating factor 1

multiple interactions

[Erlotinib Hydrochloride co-treated with Arsenic Trioxide] results in increased expression of APAF1 mRNA

NCBI chr 7:25,494,143...25,579,540
Ensembl chr 7:25,494,609...25,579,540

G

amphiregulin

affects response to substance

AREG protein affects the susceptibility to Erlotinib Hydrochloride

NCBI chr14:16,972,185...16,981,443
Ensembl chr14:16,972,187...16,981,535

G

ARF GTPase 1

decreases response to substance

ARF1 mRNA results in decreased susceptibility to Erlotinib Hydrochloride

NCBI chr10:43,997,983...44,014,461
Ensembl chr10:43,997,986...44,014,434

G

activating transcription factor 4

increases expression

Erlotinib Hydrochloride results in increased expression of ATF4 protein

NCBI chr 7:111,804,135...111,806,457
Ensembl chr 7:111,804,183...111,806,446

G

autophagy related 5

decreases response to substance
increases expression

ATG5 protein results in decreased susceptibility to Erlotinib Hydrochloride
Erlotinib Hydrochloride results in increased expression of ATG5 protein

PMID:21655094 PMID:23917044

NCBI chr20:47,798,217...47,889,216
Ensembl chr20:47,798,290...47,889,209

G

autophagy related 7

increases expression

Erlotinib Hydrochloride results in increased expression of ATG7 protein

NCBI chr 4:147,718,663...147,925,656
Ensembl chr 4:147,718,752...147,925,593

G

ATM serine/threonine kinase

multiple interactions

Erlotinib Hydrochloride promotes the reaction [Arsenic Trioxide results in increased expression of ATM mRNA]

NCBI chr 8:53,828,741...53,932,773
Ensembl chr 8:53,831,093...53,932,437

G

ATR serine/threonine kinase

multiple interactions
increases expression

Erlotinib Hydrochloride promotes the reaction [Arsenic Trioxide results in increased expression of ATR mRNA]
Erlotinib Hydrochloride results in increased expression of ATR mRNA

NCBI chr 8:96,426,704...96,524,152
Ensembl chr 8:96,426,724...96,524,136

G

Axl receptor tyrosine kinase

decreases response to substance
multiple interactions

AXL results in decreased susceptibility to Erlotinib Hydrochloride
[amuvatinib results in decreased activity of AXL protein] which results in increased susceptibility to Erlotinib Hydrochloride; [GSK 1363089 results in decreased activity of AXL protein] which results in increased susceptibility to Erlotinib Hydrochloride

NCBI chr 1:81,265,088...81,296,278
Ensembl chr 1:81,265,088...81,296,265

G

BCL2-associated agonist of cell death

multiple interactions

Erlotinib Hydrochloride promotes the reaction [Arsenic Trioxide results in increased expression of BAD mRNA]

NCBI chr 1:204,133,502...204,142,829
Ensembl chr 1:204,131,501...204,142,823

G

BCL2 associated X, apoptosis regulator

multiple interactions

Erlotinib Hydrochloride promotes the reaction [Arsenic Trioxide results in increased expression of BAX mRNA]

NCBI chr 1:95,940,001...95,945,407
Ensembl chr 1:95,938,808...95,945,368

G

Bcl-2 binding component 3

multiple interactions
increases expression

[Erlotinib Hydrochloride co-treated with Arsenic Trioxide] results in increased expression of BBC3 mRNA; Erlotinib Hydrochloride promotes the reaction [Resveratrol results in increased expression of BBC3 protein]; Resveratrol promotes the reaction [Erlotinib Hydrochloride results in increased expression of BBC3 protein]

PMID:25895606 PMID:29274334

NCBI chr 1:77,013,281...77,022,509
Ensembl chr 1:77,014,543...77,022,509

G

BCL2, apoptosis regulator

increases expression
multiple interactions

Erlotinib Hydrochloride results in increased expression of BCL2 mRNA; Erlotinib Hydrochloride results in increased expression of BCL2 protein
[Erlotinib Hydrochloride co-treated with Arsenic Trioxide] results in decreased expression of BCL2 mRNA; [Niclosamide inhibits the reaction [Erlotinib Hydrochloride results in increased expression of BCL2 protein]] which results in increased susceptibility to Erlotinib Hydrochloride; Niclosamide inhibits the reaction [Erlotinib Hydrochloride results in increased expression of BCL2 protein]

PMID:23894143 PMID:29274334

NCBI chr13:22,689,783...22,853,920
Ensembl chr13:22,684,989...22,853,743
Ensembl chr13:22,684,989...22,853,743

G

Bcl2-like 11

multiple interactions
increases expression

Harmine promotes the reaction [Erlotinib Hydrochloride results in increased expression of BCL2L11 protein]

NCBI chr 3:115,366,783...115,404,068
Ensembl chr 3:115,366,646...115,404,068

G

Bcl2-like 2

increases expression
multiple interactions

Erlotinib Hydrochloride results in increased expression of BCL2L2 mRNA; Erlotinib Hydrochloride results in increased expression of BCL2L2 protein
[Niclosamide inhibits the reaction [Erlotinib Hydrochloride results in increased expression of BCL2L2 protein]] which results in increased susceptibility to Erlotinib Hydrochloride; Niclosamide inhibits the reaction [Erlotinib Hydrochloride results in increased expression of BCL2L2 protein]

NCBI chr15:28,346,449...28,361,627
Ensembl chr15:28,356,807...28,361,624

G

beclin 1

decreases response to substance

BECN1 protein results in decreased susceptibility to Erlotinib Hydrochloride

NCBI chr10:86,231,387...86,246,742
Ensembl chr10:86,231,388...86,246,742

G

baculoviral IAP repeat-containing 5

multiple interactions
decreases expression

[Erlotinib Hydrochloride co-treated with Arsenic Trioxide] results in decreased expression of BIRC5 mRNA; Erlotinib Hydrochloride inhibits the reaction [Betulinic Acid results in decreased expression of BIRC5 protein]; Erlotinib Hydrochloride promotes the reaction [Resveratrol results in decreased expression of BIRC5 protein]; Resveratrol promotes the reaction [Erlotinib Hydrochloride results in decreased expression of BIRC5 protein]

PMID:25895606 PMID:29274334 PMID:30136359

NCBI chr10:103,072,530...103,081,382
Ensembl chr10:103,073,408...103,081,380

G

BCL2 interacting protein 3

multiple interactions

Erlotinib Hydrochloride inhibits the reaction [bafilomycin A1 results in increased expression of BNIP3 protein]

NCBI chr 1:193,708,164...193,725,348
Ensembl chr 1:193,708,167...193,725,359

G

B-Raf proto-oncogene, serine/threonine kinase

decreases activity

Erlotinib Hydrochloride results in decreased activity of BRAF protein mutant form

NCBI chr 4:68,375,484...68,510,652
Ensembl chr 4:68,384,649...68,510,463

G

BRCA1, DNA repair associated

multiple interactions

[Erlotinib Hydrochloride results in decreased activity of EGFR protein] which results in decreased phosphorylation of BRCA1 protein

NCBI chr10:86,417,441...86,477,762
Ensembl chr10:86,418,000...86,477,304

G

caspase 3

increases cleavage
multiple interactions
increases activity

Erlotinib Hydrochloride results in increased cleavage of CASP3 protein
[TWIST1 protein results in decreased susceptibility to Erlotinib Hydrochloride] which results in decreased cleavage of CASP3 protein
Erlotinib Hydrochloride results in increased activity of CASP3 protein
Erlotinib Hydrochloride promotes the reaction [resveratrol results in increased activity of CASP3 protein]; resveratrol promotes the reaction [Erlotinib Hydrochloride results in increased activity of CASP3 protein]

PMID:23125191 PMID:25895606 PMID:30171258

NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648

G

C-C motif chemokine ligand 2

multiple interactions

[Erlotinib Hydrochloride results in decreased susceptibility to Erlotinib Hydrochloride] which results in decreased expression of CCL2 mRNA; [Erlotinib Hydrochloride results in decreased susceptibility to Erlotinib Hydrochloride] which results in increased expression of CCL2 mRNA

NCBI chr10:67,005,424...67,007,222
Ensembl chr10:67,005,424...67,007,226

G

cyclin B1

multiple interactions

[Erlotinib Hydrochloride co-treated with Arsenic Trioxide] results in decreased expression of CCNB1 mRNA

NCBI chr 2:31,912,190...31,921,163
Ensembl chr 2:31,912,193...31,921,172

G

cyclin D1

multiple interactions

Erlotinib Hydrochloride inhibits the reaction [sodium arsenite results in increased expression of CCND1 protein]

NCBI chr 1:200,089,002...200,098,524
Ensembl chr 1:200,089,002...200,098,602

G

Cd69 molecule

decreases expression

Erlotinib Hydrochloride results in decreased expression of CD69 protein

NCBI chr 4:162,725,446...162,733,364
Ensembl chr 4:162,725,446...162,733,542

G

cadherin 1

multiple interactions
decreases expression

Erlotinib Hydrochloride promotes the reaction [Deoxycholic Acid results in decreased glycosylation of and results in increased degradation of CDH1 protein]; Erlotinib Hydrochloride results in decreased glycosylation of and results in increased degradation of CDH1 protein
Erlotinib Hydrochloride results in decreased expression of CDH1 mRNA; Erlotinib Hydrochloride results in decreased expression of CDH1 protein
DDIT3 mutant form inhibits the reaction [Erlotinib Hydrochloride results in decreased expression of CDH1 protein]

PMID:22223758 PMID:24768708

NCBI chr19:34,492,371...34,561,775
Ensembl chr19:34,492,371...34,561,775

G

cyclin-dependent kinase 4

decreases phosphorylation

Erlotinib Hydrochloride results in decreased phosphorylation of CDK4 protein

NCBI chr 7:62,886,124...62,889,562
Ensembl chr 7:62,883,105...62,942,403

G

cyclin-dependent kinase 6

multiple interactions
decreases expression

Betulinic Acid promotes the reaction [Erlotinib Hydrochloride results in decreased expression of CDK6 protein]

NCBI chr 4:30,637,650...30,829,688
Ensembl chr 4:30,646,460...30,829,634

G

cyclin-dependent kinase inhibitor 1A

increases expression
multiple interactions

Erlotinib Hydrochloride results in increased expression of CDKN1A mRNA
Erlotinib Hydrochloride promotes the reaction [Arsenic Trioxide results in increased expression of CDKN1A mRNA]

NCBI chr20:7,149,177...7,159,727
Ensembl chr20:7,149,217...7,159,585

G

checkpoint with forkhead and ring finger domains

multiple interactions

CHFR protein affects the susceptibility to [Cisplatin co-treated with Erlotinib Hydrochloride]

NCBI chr12:46,504,497...46,538,104
Ensembl chr12:46,504,497...46,538,014

G

chordin-like 2

multiple interactions

[Gemcitabine co-treated with Erlotinib Hydrochloride] affects the expression of CHRDL2 protein

NCBI chr 1:154,343,201...154,370,651
Ensembl chr 1:154,343,201...154,370,640

G

colony stimulating factor 3

increases secretion

Erlotinib Hydrochloride results in increased secretion of CSF3 protein

NCBI chr10:83,660,787...83,664,569
Ensembl chr10:83,661,207...83,663,603

G

catenin beta 1

multiple interactions
affects phosphorylation
decreases expression

[Betulinic Acid co-treated with Erlotinib Hydrochloride] results in decreased expression of CTNNB1 protein
Erlotinib Hydrochloride affects the phosphorylation of CTNNB1 protein
Erlotinib Hydrochloride results in decreased expression of CTNNB1 protein

PMID:30136359 PMID:34463000

NCBI chr 8:120,640,008...120,667,110
Ensembl chr 8:120,639,995...120,667,111

G

C-X-C motif chemokine ligand 11

multiple interactions

[Gemcitabine co-treated with Erlotinib Hydrochloride] affects the expression of CXCL11 protein

NCBI chr14:15,689,432...15,692,207
Ensembl chr14:15,689,424...15,692,271

G

cytochrome P450, family 19, subfamily a, polypeptide 1

decreases activity

Erlotinib Hydrochloride results in decreased activity of CYP19A1 protein

NCBI chr 8:54,552,978...54,580,375
Ensembl chr 8:54,553,165...54,580,758

G

cytochrome P450, family 1, subfamily a, polypeptide 1

decreases activity

Erlotinib Hydrochloride results in decreased activity of CYP1A1 protein

NCBI chr 8:58,096,021...58,102,130
Ensembl chr 8:58,096,077...58,102,125

G

cytochrome P450, family 1, subfamily b, polypeptide 1

decreases activity

Erlotinib Hydrochloride results in decreased activity of CYP1B1 protein

NCBI chr 6:15,342,312...15,350,886
Ensembl chr 6:15,342,344...15,350,917

G

cytochrome P450, family 2, subfamily b, polypeptide 3

increases expression

Erlotinib Hydrochloride results in increased expression of CYP2B6 mRNA

NCBI chr 1:81,652,762...81,732,153
Ensembl chr 1:81,652,787...81,732,143

G

cytochrome P450, family 3, subfamily a, polypeptide 2

decreases activity
increases expression

Erlotinib Hydrochloride results in decreased activity of CYP3A4 protein
Erlotinib Hydrochloride results in increased expression of CYP3A4 mRNA

NCBI chr12:9,207,978...9,230,064
Ensembl chr12:9,015,383...9,285,008

G

cytochrome P450, family 51

increases response to substance

CYP51A1 mRNA results in increased susceptibility to Erlotinib Hydrochloride

NCBI chr 4:30,036,956...30,055,410
Ensembl chr 4:30,036,865...30,055,410
Ensembl chr 6:30,036,865...30,055,410

G

DNA-damage inducible transcript 3

increases expression
multiple interactions

Erlotinib Hydrochloride results in increased expression of DDIT3 protein
DDIT3 mutant form inhibits the reaction [Erlotinib Hydrochloride results in decreased expression of CDH1 protein]; DDIT3 mutant form inhibits the reaction [Erlotinib Hydrochloride results in increased expression of IL6 mRNA]; DDIT3 mutant form inhibits the reaction [Erlotinib Hydrochloride results in increased secretion of IL6 protein]

NCBI chr 7:63,115,645...63,121,203
Ensembl chr 7:63,116,380...63,121,201

G

DENN domain containing 6B

decreases expression

Erlotinib Hydrochloride results in decreased expression of DENND6B mRNA

NCBI chr 7:120,261,679...120,273,667
Ensembl chr 7:120,261,679...120,273,494

G

dual specificity phosphatase 1

multiple interactions

[Erlotinib Hydrochloride results in decreased susceptibility to Erlotinib Hydrochloride] which results in increased expression of DUSP1 mRNA

NCBI chr10:16,680,478...16,683,275

G

epidermal growth factor

multiple interactions

Erlotinib Hydrochloride inhibits the reaction [EGF promotes the reaction [TGFB1 results in decreased susceptibility to Cisplatin]]; Erlotinib Hydrochloride inhibits the reaction [EGF promotes the reaction [TGFB1 results in decreased susceptibility to Gemcitabine]]; Erlotinib Hydrochloride inhibits the reaction [EGF protein results in decreased susceptibility to Crizotinib]; Erlotinib Hydrochloride inhibits the reaction [EGF protein results in increased activity of ELK1 protein]; Erlotinib Hydrochloride inhibits the reaction [EGF protein results in increased phosphorylation of EGFR protein]; Erlotinib Hydrochloride inhibits the reaction [EGF protein results in increased phosphorylation of ELK1 protein]; Erlotinib Hydrochloride promotes the reaction [EGF protein binds to EGFR protein]
Erlotinib Hydrochloride inhibits the reaction [EGF protein results in increased phosphorylation of MAPK1 protein]; Erlotinib Hydrochloride inhibits the reaction [EGF protein results in increased phosphorylation of MAPK3 protein]

PMID:21613822 PMID:21787763 PMID:22553343 PMID:25625231 PMID:27427493 More...

NCBI chr 2:218,219,408...218,302,359
Ensembl chr 2:218,219,415...218,302,064

G

epidermal growth factor receptor

affects response to substance
decreases expression
decreases phosphorylation
decreases activity
multiple interactions
decreases response to substance

EGFR protein affects the susceptibility to Erlotinib Hydrochloride; EGFR protein mutant form affects the susceptibility to Erlotinib Hydrochloride
Erlotinib Hydrochloride results in decreased expression of EGFR protein modified form
Erlotinib Hydrochloride results in decreased phosphorylation of EGFR protein
Erlotinib Hydrochloride results in decreased activity of EGFR protein
[Erlotinib Hydrochloride results in decreased activity of EGFR protein] which results in decreased expression of RAD50 protein; [Erlotinib Hydrochloride results in decreased activity of EGFR protein] which results in decreased expression of RAD51 protein; [Erlotinib Hydrochloride results in decreased activity of EGFR protein] which results in decreased phosphorylation of BRCA1 protein; EGFR gene mutant form results in increased susceptibility to [Gemcitabine co-treated with Cisplatin co-treated with Erlotinib Hydrochloride]; Erlotinib Hydrochloride inhibits the reaction [Arsenic Trioxide results in increased phosphorylation of and results in increased activity of EGFR protein]; Erlotinib Hydrochloride inhibits the reaction [Derp2 allergen, Dermatophagoides pteronyssinus results in increased phosphorylation of EGFR protein]; Erlotinib Hydrochloride inhibits the reaction [EGF protein results in increased phosphorylation of EGFR protein]; Erlotinib Hydrochloride inhibits the reaction [EGFR protein mutant form results in increased expression of FOXG1 mRNA]; Erlotinib Hydrochloride inhibits the reaction [EGFR protein mutant form results in increased expression of FOXG1 protein]; Erlotinib Hydrochloride inhibits the reaction [EGFR protein mutant form results in increased expression of SOX9 mRNA]; Erlotinib Hydrochloride inhibits the reaction [EGFR protein mutant form results in increased expression of SOX9 protein]; Erlotinib Hydrochloride inhibits the reaction [Particulate Matter analog results in increased phosphorylation of EGFR protein]; Erlotinib Hydrochloride inhibits the reaction [sodium arsenite results in increased phosphorylation of EGFR protein]; Erlotinib Hydrochloride promotes the reaction [Deoxycholic Acid results in decreased glycosylation of and results in decreased expression of EGFR protein]; Erlotinib Hydrochloride promotes the reaction [EGF protein binds to EGFR protein]; Erlotinib Hydrochloride results in decreased activity of and results in decreased phosphorylation of EGFR protein; Erlotinib Hydrochloride results in decreased glycosylation of and results in decreased expression of EGFR protein
EGFR protein mutant form results in decreased susceptibility to Erlotinib Hydrochloride

PMID:12907618 PMID:16407879 PMID:16891461 PMID:19168569 PMID:21080748 More...

NCBI chr14:91,176,979...91,349,722
Ensembl chr14:91,177,067...91,344,382

G

eukaryotic translation initiation factor 2 subunit alpha

increases expression

Erlotinib Hydrochloride results in increased expression of EIF2S1 protein modified form

NCBI chr 6:97,672,829...97,697,499
Ensembl chr 6:97,672,766...97,706,225

G

ETS transcription factor ELK1

multiple interactions

Erlotinib Hydrochloride inhibits the reaction [EGF protein results in increased activity of ELK1 protein]; Erlotinib Hydrochloride inhibits the reaction [EGF protein results in increased phosphorylation of ELK1 protein]

PMID:25625231 PMID:30364229

NCBI chr X:1,138,826...1,155,713
Ensembl chr X:1,139,756...1,155,713

G

erb-b2 receptor tyrosine kinase 3

decreases response to substance

ERBB3 mRNA results in decreased susceptibility to Erlotinib Hydrochloride

NCBI chr 7:994,549...1,015,876
Ensembl chr 7:996,225...1,015,525

G

estrogen receptor 1

multiple interactions

Erlotinib Hydrochloride affects the expression of and affects the phosphorylation of ESR1 protein

NCBI chr 1:41,106,335...41,499,104
Ensembl chr 1:41,210,475...41,495,002

G

forkhead box G1

multiple interactions
decreases expression

Erlotinib Hydrochloride inhibits the reaction [EGFR protein mutant form results in increased expression of FOXG1 mRNA]; Erlotinib Hydrochloride inhibits the reaction [EGFR protein mutant form results in increased expression of FOXG1 protein]
Erlotinib Hydrochloride results in decreased expression of FOXG1 protein

NCBI chr 6:66,674,797...66,677,611
Ensembl chr 6:66,666,587...66,678,607

G

forkhead box O3

decreases phosphorylation

Erlotinib Hydrochloride results in decreased phosphorylation of FOXO3 protein

NCBI chr20:45,669,708...45,764,606
Ensembl chr20:45,672,995...45,764,561

G

growth differentiation factor 15

multiple interactions

[Gemcitabine co-treated with Erlotinib Hydrochloride] affects the expression of GDF15 protein

NCBI chr16:18,804,457...18,808,043
Ensembl chr16:18,805,239...18,808,055

G

guanosine monophosphate reductase

decreases expression

Erlotinib Hydrochloride results in decreased expression of GMPR mRNA

NCBI chr17:19,151,820...19,189,626
Ensembl chr17:19,151,815...19,189,621

G

glycogen synthase kinase 3 beta

decreases expression

Erlotinib Hydrochloride results in decreased expression of GSK3B protein modified form

NCBI chr11:62,498,997...62,648,665
Ensembl chr11:62,504,316...62,648,646

G

H2A.X variant histone

multiple interactions
increases expression

Erlotinib Hydrochloride promotes the reaction [Resveratrol results in increased expression of H2AX protein modified form]; Resveratrol promotes the reaction [Erlotinib Hydrochloride results in increased expression of H2AX protein modified form]

NCBI chr 8:44,671,907...44,673,262
Ensembl chr 8:44,671,786...44,673,239
Ensembl chr 4:44,671,786...44,673,239

G

heparin-binding EGF-like growth factor

multiple interactions

Erlotinib Hydrochloride inhibits the reaction [HBEGF protein results in decreased susceptibility to crizotinib]

NCBI chr18:28,106,284...28,116,167
Ensembl chr18:28,105,760...28,116,441

G

interferon induced transmembrane protein 3

decreases expression

Erlotinib Hydrochloride results in decreased expression of IFITM3 mRNA

NCBI chr 1:196,111,026...196,112,135
Ensembl chr 1:196,111,043...196,112,203

G

interferon gamma

decreases secretion

Erlotinib Hydrochloride results in decreased secretion of IFNG protein

NCBI chr 7:53,903,339...53,907,375
Ensembl chr 7:53,903,337...53,907,375

G

interleukin 17F

increases expression

Erlotinib Hydrochloride results in increased expression of IL17F mRNA

NCBI chr 9:23,190,094...23,201,482
Ensembl chr 9:23,190,100...23,201,482

G

interleukin 1 alpha

multiple interactions

[Erlotinib Hydrochloride results in decreased susceptibility to Erlotinib Hydrochloride] which results in increased expression of IL1A mRNA

NCBI chr 3:116,526,601...116,537,055
Ensembl chr 3:116,526,604...116,536,822

G

interleukin 1 beta

multiple interactions
increases secretion

[Erlotinib Hydrochloride results in decreased susceptibility to Erlotinib Hydrochloride] which results in increased expression of IL1B mRNA
Erlotinib Hydrochloride results in increased secretion of IL1B protein

NCBI chr 3:116,577,005...116,583,386
Ensembl chr 3:116,577,010...116,583,415

G

interleukin 1 receptor type 1

multiple interactions

[Erlotinib Hydrochloride results in decreased susceptibility to Erlotinib Hydrochloride] which results in decreased expression of IL1R1 mRNA

NCBI chr 9:42,504,917...42,580,958
Ensembl chr 9:42,504,735...42,579,937

G

interleukin 1 receptor type 2

multiple interactions

[Erlotinib Hydrochloride results in decreased susceptibility to Erlotinib Hydrochloride] which affects the expression of IL1R2 mRNA

NCBI chr 9:42,384,280...42,424,726
Ensembl chr 9:42,384,433...42,424,725

G

interleukin 1 receptor accessory protein

multiple interactions

[Erlotinib Hydrochloride results in decreased susceptibility to Erlotinib Hydrochloride] which results in increased expression of IL1RAP mRNA

NCBI chr11:74,062,999...74,199,530
Ensembl chr11:74,070,304...74,199,530

G

interleukin 1 receptor antagonist

multiple interactions

[Erlotinib Hydrochloride results in decreased susceptibility to Erlotinib Hydrochloride] which affects the expression of IL1RN mRNA; [Erlotinib Hydrochloride results in decreased susceptibility to Erlotinib Hydrochloride] which results in decreased expression of IL1RN mRNA; [Erlotinib Hydrochloride results in decreased susceptibility to Erlotinib Hydrochloride] which results in decreased secretion of IL1RN protein

NCBI chr 3:7,111,567...7,127,451
Ensembl chr 3:7,111,550...7,127,445

G

interleukin 2

decreases secretion

Erlotinib Hydrochloride results in decreased secretion of IL2 protein

NCBI chr 2:120,004,862...120,009,566
Ensembl chr 2:120,004,862...120,009,566

G

interleukin 25

increases expression

Erlotinib Hydrochloride results in increased expression of IL25 mRNA

NCBI chr15:28,408,766...28,412,157
Ensembl chr15:28,408,842...28,411,893

G

interleukin 2 receptor subunit alpha

decreases expression

Erlotinib Hydrochloride results in decreased expression of IL2RA protein

NCBI chr17:66,849,974...66,898,665
Ensembl chr17:66,849,974...66,898,697

G

interleukin 6

increases expression
increases secretion
multiple interactions

Erlotinib Hydrochloride results in increased expression of IL6 mRNA
Erlotinib Hydrochloride results in increased secretion of IL6 protein
Erlotinib Hydrochloride inhibits the reaction [Derp2 allergen, Dermatophagoides pteronyssinus results in increased expression of IL6 mRNA]; Erlotinib Hydrochloride inhibits the reaction [Derp2 allergen, Dermatophagoides pteronyssinus results in increased secretion of IL6 protein]; Interleukin 1 Receptor Antagonist Protein inhibits the reaction [Erlotinib Hydrochloride results in increased secretion of IL6 protein]
DDIT3 mutant form inhibits the reaction [Erlotinib Hydrochloride results in increased expression of IL6 mRNA]; DDIT3 mutant form inhibits the reaction [Erlotinib Hydrochloride results in increased secretion of IL6 protein]

PMID:24768708 PMID:27738319 PMID:30623574

NCBI chr 4:5,214,602...5,219,178
Ensembl chr 4:5,213,394...5,219,178

G

interleukin-1 receptor-associated kinase 1

multiple interactions

[Erlotinib Hydrochloride results in decreased susceptibility to Erlotinib Hydrochloride] which results in decreased expression of IRAK1 mRNA

NCBI chr X:151,768,621...151,778,521
Ensembl chr X:151,768,777...151,778,521

G

integrin subunit beta 1

decreases expression

Erlotinib Hydrochloride results in decreased expression of ITGB1 mRNA

NCBI chr19:56,705,123...56,753,199
Ensembl chr19:56,705,171...56,753,195

G

Janus kinase 2

decreases phosphorylation

Erlotinib Hydrochloride results in decreased phosphorylation of JAK2 protein

NCBI chr 1:226,995,334...227,054,381
Ensembl chr 1:226,995,334...227,054,189

G

potassium voltage-gated channel subfamily H member 2

affects activity
decreases activity

Erlotinib Hydrochloride affects the activity of KCNH2 protein
Erlotinib Hydrochloride results in decreased activity of KCNH2 protein

PMID:23707608 PMID:35680041

NCBI chr 4:10,826,834...10,859,009
Ensembl chr 4:10,826,928...10,859,008

G

KIT ligand

multiple interactions

[Gemcitabine co-treated with Erlotinib Hydrochloride] affects the expression of KITLG protein

NCBI chr 7:34,896,075...34,977,215
Ensembl chr 7:34,896,053...34,977,214

G

KRAS proto-oncogene, GTPase

increases response to substance

KRAS protein results in increased susceptibility to Erlotinib Hydrochloride

NCBI chr 4:178,185,418...178,218,484

G

lactate dehydrogenase A

increases secretion

Erlotinib Hydrochloride results in increased secretion of LDHA protein

NCBI chr 1:97,371,823...97,381,247
Ensembl chr 1:97,366,021...97,433,472

G

microtubule-associated protein 1 light chain 3 beta

multiple interactions

Erlotinib Hydrochloride promotes the reaction [Betulinic Acid results in increased expression of MAP1LC3B protein modified form]

NCBI chr19:49,665,795...49,673,655
Ensembl chr19:49,665,791...49,677,690
Ensembl chr16:49,665,791...49,677,690

G

mitogen activated protein kinase 1

decreases phosphorylation
multiple interactions

Erlotinib Hydrochloride results in decreased phosphorylation of MAPK1 protein
Erlotinib Hydrochloride inhibits the reaction [Particulate Matter analog results in increased phosphorylation of MAPK1 protein]
Erlotinib Hydrochloride inhibits the reaction [EGF protein results in increased phosphorylation of MAPK1 protein]
Erlotinib Hydrochloride inhibits the reaction [Alprenolol results in increased phosphorylation of MAPK1 protein]; Erlotinib Hydrochloride inhibits the reaction [carvedilol results in increased phosphorylation of MAPK1 protein]

PMID:18787115 PMID:18980991 PMID:21195724 PMID:27427493 PMID:28101945

NCBI chr11:83,957,813...84,023,629
Ensembl chr11:83,957,813...84,023,616

G

mitogen activated protein kinase 3

decreases phosphorylation
multiple interactions

Erlotinib Hydrochloride results in decreased phosphorylation of MAPK3 protein
Erlotinib Hydrochloride inhibits the reaction [Particulate Matter analog results in increased phosphorylation of MAPK3 protein]
Erlotinib Hydrochloride inhibits the reaction [EGF protein results in increased phosphorylation of MAPK3 protein]
Erlotinib Hydrochloride inhibits the reaction [Alprenolol results in increased phosphorylation of MAPK3 protein]; Erlotinib Hydrochloride inhibits the reaction [carvedilol results in increased phosphorylation of MAPK3 protein]

PMID:18787115 PMID:18980991 PMID:21195724 PMID:27427493 PMID:28101945

NCBI chr 1:181,366,646...181,372,863
Ensembl chr 1:181,366,637...181,372,863

G

MCL1 apoptosis regulator, BCL2 family member

decreases expression
multiple interactions

Erlotinib Hydrochloride results in decreased expression of MCL1 protein
resveratrol promotes the reaction [Erlotinib Hydrochloride results in decreased expression of MCL1 protein]

NCBI chr 2:183,219,137...183,235,676
Ensembl chr 2:183,219,220...183,222,303

G

MET proto-oncogene, receptor tyrosine kinase

multiple interactions
decreases phosphorylation

[Erlotinib Hydrochloride co-treated with Dasatinib] results in decreased phosphorylation of MET protein
Erlotinib Hydrochloride results in decreased phosphorylation of MET protein

PMID:21106725 PMID:23894143

NCBI chr 4:45,790,456...45,898,139
Ensembl chr 4:45,790,791...45,897,876

G

MHC class I polypeptide-related sequence B

increases expression

Erlotinib Hydrochloride results in increased expression of MICB protein

NCBI chr 1:78,495,779...78,513,030
Ensembl chr 1:78,495,779...78,512,827

G

matrix metallopeptidase 14

multiple interactions

Erlotinib Hydrochloride inhibits the reaction [Acrolein results in increased expression of MMP14 mRNA]

NCBI chr15:27,887,795...27,897,020
Ensembl chr15:27,887,727...27,899,864

G

matrix metallopeptidase 2

multiple interactions

[Erlotinib Hydrochloride co-treated with Arsenic Trioxide] results in decreased expression of MMP2 mRNA

NCBI chr19:14,154,657...14,182,870
Ensembl chr19:14,154,657...14,182,870

G

matrix metallopeptidase 9

multiple interactions

[Erlotinib Hydrochloride co-treated with Arsenic Trioxide] results in decreased expression of MMP9 mRNA

NCBI chr 3:153,684,158...153,692,118
Ensembl chr 3:153,683,858...153,692,120

G

methylsterol monooxygenase 1

decreases response to substance
multiple interactions

MSMO1 protein results in decreased susceptibility to Erlotinib Hydrochloride
MSMO1 protein inhibits the reaction [Erlotinib Hydrochloride results in decreased expression of RPS6 protein modified form]

NCBI chr16:24,980,680...24,997,927
Ensembl chr16:24,980,697...24,998,016

G

mechanistic target of rapamycin kinase

decreases phosphorylation
multiple interactions

Erlotinib Hydrochloride results in decreased phosphorylation of MTOR protein
resveratrol promotes the reaction [Erlotinib Hydrochloride results in decreased phosphorylation of MTOR protein]

PMID:21655094 PMID:25895606

NCBI chr 5:158,884,856...158,994,311
Ensembl chr 5:158,884,804...158,994,311

G

mucin 5AC, oligomeric mucus/gel-forming

multiple interactions

Erlotinib Hydrochloride inhibits the reaction [Acrolein results in increased expression of MUC5AC mRNA]

PMID:18006877 PMID:19661247

NCBI chr 1:196,864,336...196,896,475
Ensembl chr 1:196,864,336...196,896,475

G

MYC proto-oncogene, bHLH transcription factor

affects expression

Erlotinib Hydrochloride affects the expression of MYC protein

NCBI chr 7:93,593,705...93,598,633
Ensembl chr 7:93,593,705...93,598,630

G

MYD88, innate immune signal transduction adaptor

multiple interactions

[Erlotinib Hydrochloride results in decreased susceptibility to Erlotinib Hydrochloride] which affects the expression of MYD88 mRNA

NCBI chr 8:119,074,439...119,078,508
Ensembl chr 8:119,074,437...119,079,415

G

NFKB inhibitor alpha

multiple interactions

[Erlotinib Hydrochloride results in decreased susceptibility to Erlotinib Hydrochloride] which affects the expression of NFKBIA mRNA

NCBI chr 6:72,858,713...72,861,941
Ensembl chr 6:72,858,712...72,861,941

G

nucleolar protein 10

decreases expression

Erlotinib Hydrochloride results in decreased expression of NOL10 mRNA

NCBI chr 6:40,144,217...40,225,353
Ensembl chr 6:40,144,235...40,225,353

G

NADPH oxidase 4

multiple interactions
decreases response to substance
increases expression

Erlotinib Hydrochloride results in increased expression of and results in increased stability of NOX4 mRNA
NOX4 protein results in decreased susceptibility to Erlotinib Hydrochloride
Erlotinib Hydrochloride results in increased expression of NOX4 protein

NCBI chr 1:140,900,886...141,078,844
Ensembl chr 1:140,901,097...141,077,406

G

nuclear receptor subfamily 1, group I, member 2

multiple interactions

Erlotinib Hydrochloride binds to and results in increased activity of NR1I2 protein

NCBI chr11:62,460,213...62,496,665
Ensembl chr11:62,460,213...62,496,658

G

nuclear receptor subfamily 1, group I, member 3

affects localization

Erlotinib Hydrochloride affects the localization of NR1I3 protein mutant form

NCBI chr13:83,632,940...83,638,193
Ensembl chr13:83,632,899...83,637,906

G

NAD(P) dependent 3-beta-hydroxysteroid dehydrogenase NSDHL

decreases response to substance

NSDHL protein results in decreased susceptibility to Erlotinib Hydrochloride

NCBI chr X:150,775,034...150,807,161
Ensembl chr X:150,775,080...150,807,142

G

oncostatin M

multiple interactions

[Gemcitabine co-treated with Erlotinib Hydrochloride] affects the expression of OSM protein

NCBI chr14:79,103,638...79,108,500
Ensembl chr14:79,104,344...79,108,313

G

poly (ADP-ribose) polymerase 1

increases cleavage
increases expression
multiple interactions

Erlotinib Hydrochloride results in increased cleavage of PARP1 protein
Erlotinib Hydrochloride results in increased expression of PARP1 protein modified form
[TWIST1 protein results in decreased susceptibility to Erlotinib Hydrochloride] which results in decreased cleavage of PARP1 protein; Harmine promotes the reaction [Erlotinib Hydrochloride results in increased cleavage of PARP1 protein]; Resveratrol promotes the reaction [Erlotinib Hydrochloride results in increased expression of PARP1 protein modified form]; TWIST1 protein inhibits the reaction [Erlotinib Hydrochloride results in increased cleavage of PARP1 protein]

PMID:23125191 PMID:25895606 PMID:30171258

NCBI chr13:92,307,593...92,339,406
Ensembl chr13:92,307,586...92,339,404

G

phosphatidylinositol-4,5-bisphosphate 3-kinase, catalytic subunit alpha

multiple interactions

Erlotinib Hydrochloride inhibits the reaction [carvacrol results in increased phosphorylation of PIK3CA protein]

NCBI chr 2:115,175,275...115,249,034
Ensembl chr 2:115,174,984...115,249,032

G

PML nuclear body scaffold

increases expression
decreases response to substance
increases localization

Erlotinib Hydrochloride results in increased expression of PML protein
PML protein results in decreased susceptibility to Erlotinib Hydrochloride
Erlotinib Hydrochloride results in increased localization of PML protein

NCBI chr 8:58,627,347...58,661,927
Ensembl chr 8:58,628,837...58,658,971

G

prostaglandin-endoperoxide synthase 2

multiple interactions

[Erlotinib Hydrochloride results in decreased susceptibility to Erlotinib Hydrochloride] which results in increased expression of PTGS2 mRNA

NCBI chr13:62,163,936...62,172,193
Ensembl chr13:62,163,932...62,172,188

G

protein tyrosine phosphatase, non-receptor type 9

decreases expression
decreases response to substance

Erlotinib Hydrochloride results in decreased expression of PTPN9 protein
PTPN9 mutant form results in decreased susceptibility to Erlotinib Hydrochloride

NCBI chr 8:57,391,290...57,472,352
Ensembl chr 8:57,391,259...57,470,952

G

RAD50 double strand break repair protein

multiple interactions

[Erlotinib Hydrochloride results in decreased activity of EGFR protein] which results in decreased expression of RAD50 protein

NCBI chr10:37,809,353...37,861,309
Ensembl chr10:37,808,726...37,861,396

G

RAD51 recombinase

multiple interactions

[Erlotinib Hydrochloride results in decreased activity of EGFR protein] which results in decreased expression of RAD51 protein

NCBI chr 3:106,099,753...106,125,038
Ensembl chr 3:106,100,381...106,125,035

G

Raf-1 proto-oncogene, serine/threonine kinase

decreases phosphorylation

Erlotinib Hydrochloride results in decreased phosphorylation of RAF1 protein

NCBI chr 4:148,679,534...148,740,265
Ensembl chr 4:148,679,530...148,740,317

G

RB transcriptional corepressor 1

decreases phosphorylation
multiple interactions
decreases expression

Erlotinib Hydrochloride results in decreased phosphorylation of RB1 protein
Betulinic Acid promotes the reaction [Erlotinib Hydrochloride results in decreased expression of RB1 protein modified form]; Erlotinib Hydrochloride promotes the reaction [Betulinic Acid results in decreased expression of RB1 protein modified form]

PMID:21195724 PMID:30136359

NCBI chr15:48,371,295...48,502,473
Ensembl chr15:48,371,296...48,502,302

G

RELA proto-oncogene, NF-kB subunit

multiple interactions

Erlotinib Hydrochloride inhibits the reaction [carvacrol results in increased phosphorylation of RELA protein]; Erlotinib Hydrochloride inhibits the reaction [Particulate Matter analog results in increased acetylation of RELA protein]

PMID:28101945 PMID:32535744

NCBI chr 1:202,925,001...202,935,484
Ensembl chr 1:202,924,945...202,935,484

G

ribosomal protein S6

decreases phosphorylation
decreases expression
multiple interactions

Erlotinib Hydrochloride results in decreased phosphorylation of RPS6 protein
Erlotinib Hydrochloride results in decreased expression of RPS6 protein modified form
MSMO1 protein inhibits the reaction [Erlotinib Hydrochloride results in decreased expression of RPS6 protein modified form]

PMID:23125191 PMID:23440206

NCBI chr 5:101,371,716...101,374,576
Ensembl chr 5:101,371,136...101,374,602
Ensembl chr 5:101,371,136...101,374,602

G

ribosomal protein S6 kinase B1

decreases phosphorylation
multiple interactions

Erlotinib Hydrochloride results in decreased phosphorylation of RPS6KB1 protein
resveratrol promotes the reaction [Erlotinib Hydrochloride results in decreased phosphorylation of RPS6KB1 protein]

PMID:21655094 PMID:25895606

NCBI chr10:71,323,777...71,367,908
Ensembl chr10:71,323,777...71,367,908

G

selenium binding protein 1

decreases expression

Erlotinib Hydrochloride results in decreased expression of SELENBP1 mRNA

NCBI chr 2:182,494,004...182,504,594
Ensembl chr 2:182,493,978...182,504,594

G

siah E3 ubiquitin protein ligase 2

decreases expression

Erlotinib Hydrochloride results in decreased expression of SIAH2 mRNA

NCBI chr 2:142,913,924...142,931,752
Ensembl chr 2:142,914,003...142,931,950

G

snail family transcriptional repressor 1

multiple interactions

[Erlotinib Hydrochloride co-treated with Arsenic Trioxide] results in decreased expression of SNAI1 mRNA

NCBI chr 3:156,248,479...156,252,969
Ensembl chr 3:156,248,485...156,252,969

G

snail family transcriptional repressor 2

multiple interactions

[Erlotinib Hydrochloride co-treated with Arsenic Trioxide] results in decreased expression of SNAI2 mRNA

NCBI chr11:86,182,788...86,186,203
Ensembl chr11:86,181,909...86,186,200

G

suppressor of cytokine signaling 3

increases expression

Erlotinib Hydrochloride results in increased expression of SOCS3 mRNA

NCBI chr10:103,193,909...103,197,322
Ensembl chr10:103,193,537...103,197,787

G

SRY-box transcription factor 9

multiple interactions
decreases expression

Erlotinib Hydrochloride inhibits the reaction [EGFR protein mutant form results in increased expression of SOX9 mRNA]; Erlotinib Hydrochloride inhibits the reaction [EGFR protein mutant form results in increased expression of SOX9 protein]
Erlotinib Hydrochloride results in decreased expression of SOX9 protein

NCBI chr10:97,806,485...97,811,994
Ensembl chr10:97,806,485...97,811,994

G

sequestosome 1

increases expression

Erlotinib Hydrochloride results in increased expression of SQSTM1 protein

NCBI chr10:34,525,517...34,536,670
Ensembl chr10:34,525,519...34,536,673

G

SRC proto-oncogene, non-receptor tyrosine kinase

decreases phosphorylation

Erlotinib Hydrochloride results in decreased phosphorylation of SRC protein

NCBI chr 3:146,091,969...146,139,492
Ensembl chr 3:146,091,841...146,139,476

G

signal transducer and activator of transcription 3

increases phosphorylation
decreases expression
increases response to substance
decreases response to substance
multiple interactions

Erlotinib Hydrochloride results in increased phosphorylation of STAT3 protein
Erlotinib Hydrochloride results in decreased expression of STAT3 protein modified form
STAT3 mutant form results in increased susceptibility to Erlotinib Hydrochloride
STAT3 mRNA results in decreased susceptibility to Erlotinib Hydrochloride
[Betulinic Acid co-treated with Erlotinib Hydrochloride] results in decreased expression of STAT3 protein modified form; [Niclosamide inhibits the reaction [Erlotinib Hydrochloride results in increased phosphorylation of STAT3 protein]] which results in increased susceptibility to Erlotinib Hydrochloride; Niclosamide inhibits the reaction [Erlotinib Hydrochloride results in increased phosphorylation of STAT3 protein]

PMID:23125191 PMID:23894143 PMID:30136359

NCBI chr10:85,811,206...85,863,057
Ensembl chr10:85,811,218...85,863,057

G

terminal nucleotidyltransferase 5C

decreases expression

Erlotinib Hydrochloride results in decreased expression of TENT5C mRNA

NCBI chr 2:187,853,026...187,875,260
Ensembl chr 2:187,853,024...187,894,744

G

transcription factor AP-2 alpha

multiple interactions

Erlotinib Hydrochloride inhibits the reaction [TFAP2A protein binds to ULBP1 promoter]; Tetradecanoylphorbol Acetate inhibits the reaction [Erlotinib Hydrochloride inhibits the reaction [TFAP2A protein binds to ULBP1 promoter]]

PMID:21499124 PMID:21951556

NCBI chr17:24,028,716...24,047,507
Ensembl chr17:24,024,432...24,047,507

G

transforming growth factor alpha

multiple interactions

Erlotinib Hydrochloride inhibits the reaction [TGFA protein results in decreased susceptibility to crizotinib]

NCBI chr 4:118,618,043...118,700,897
Ensembl chr 4:118,618,269...118,700,894

G

transforming growth factor, beta 1

multiple interactions

Erlotinib Hydrochloride inhibits the reaction [EGF promotes the reaction [TGFB1 results in decreased susceptibility to Cisplatin]]; Erlotinib Hydrochloride inhibits the reaction [EGF promotes the reaction [TGFB1 results in decreased susceptibility to Gemcitabine]]

NCBI chr 1:81,196,532...81,212,848
Ensembl chr 1:81,196,532...81,212,847

G

transmembrane p24 trafficking protein 2

decreases response to substance

TMED2 mRNA results in decreased susceptibility to Erlotinib Hydrochloride

NCBI chr12:32,052,542...32,061,628
Ensembl chr12:32,052,543...32,071,903

G

TNF superfamily member 8

multiple interactions

[Gemcitabine co-treated with Erlotinib Hydrochloride] affects the expression of TNFSF8 protein

NCBI chr 5:77,250,942...77,277,364
Ensembl chr 5:77,251,373...77,277,421

G

toll interacting protein

multiple interactions

[Erlotinib Hydrochloride results in decreased susceptibility to Erlotinib Hydrochloride] which results in increased expression of TOLLIP mRNA

NCBI chr 1:196,961,585...196,984,252
Ensembl chr 1:196,950,771...196,983,625

G

tumor protein p53

multiple interactions
increases expression

Erlotinib Hydrochloride promotes the reaction [Arsenic Trioxide results in increased expression of TP53 mRNA]; Erlotinib Hydrochloride promotes the reaction [Resveratrol results in increased expression of TP53 protein]; Resveratrol promotes the reaction [Erlotinib Hydrochloride results in increased expression of TP53 protein]

PMID:25895606 PMID:29274334

NCBI chr10:54,300,070...54,311,525
Ensembl chr10:54,300,048...54,311,524

G

TNF receptor associated factor 6

multiple interactions

[Erlotinib Hydrochloride results in decreased susceptibility to Erlotinib Hydrochloride] which results in increased expression of TRAF6 mRNA

NCBI chr 3:87,963,517...87,988,316
Ensembl chr 3:87,963,514...87,983,507

G

twist family bHLH transcription factor 1

increases expression
decreases response to substance
multiple interactions

Erlotinib Hydrochloride results in increased expression of TWIST1 protein
TWIST1 protein results in decreased susceptibility to Erlotinib Hydrochloride
[TWIST1 protein results in decreased susceptibility to Erlotinib Hydrochloride] which results in decreased cleavage of PARP1 protein; TWIST1 protein inhibits the reaction [Erlotinib Hydrochloride results in increased cleavage of PARP1 protein]
[TWIST1 protein results in decreased susceptibility to Erlotinib Hydrochloride] which results in decreased cleavage of CASP3 protein

NCBI chr 6:50,674,910...50,676,904
Ensembl chr 6:50,674,678...50,677,653

G

thymidylate synthetase

decreases expression
multiple interactions

Erlotinib Hydrochloride results in decreased expression of TYMS protein
Betulinic Acid promotes the reaction [Erlotinib Hydrochloride results in decreased expression of TYMS protein]; Erlotinib Hydrochloride promotes the reaction [Betulinic Acid results in decreased expression of TYMS protein]

NCBI chr 9:113,313,454...113,329,551
Ensembl chr 9:113,313,452...113,329,536

G

UL16 binding protein 1

increases expression
multiple interactions

Erlotinib Hydrochloride results in increased expression of ULBP1 mRNA; Erlotinib Hydrochloride results in increased expression of ULBP1 protein
Erlotinib Hydrochloride inhibits the reaction [TFAP2A protein binds to ULBP1 promoter]; Tetradecanoylphorbol Acetate inhibits the reaction [Erlotinib Hydrochloride inhibits the reaction [TFAP2A protein binds to ULBP1 promoter]]; Tetradecanoylphorbol Acetate inhibits the reaction [Erlotinib Hydrochloride results in increased expression of ULBP1 mRNA]

PMID:21499124 PMID:21951556

NCBI chr 1:1,694,255...1,716,160

G

X-box binding protein 1

increases expression

Erlotinib Hydrochloride results in increased expression of XBP1 protein modified form

NCBI chr14:80,390,629...80,395,713
Ensembl chr14:80,390,643...80,395,693

gefitinib

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

ATP binding cassette subfamily B member 11

decreases activity

gefitinib results in decreased activity of ABCB11 protein

PMID:20829430 PMID:23956101

NCBI chr 3:54,016,854...54,112,797
Ensembl chr 3:54,017,127...54,112,730

G

ATP binding cassette subfamily G member 2

multiple interactions

[[gefitinib results in decreased activity of EGFR protein] which affects the localization of ABCG2 protein] which results in decreased export of Doxorubicin; [gefitinib results in decreased activity of EGFR protein] which affects the localization of ABCG2 protein; gefitinib inhibits the reaction [ABCG2 protein results in decreased susceptibility to Doxorubicin]

NCBI chr 4:87,676,241...87,802,757
Ensembl chr 4:87,745,319...87,802,409

G

actin alpha 2, smooth muscle

multiple interactions
decreases expression

[Gefitinib co-treated with CCL2 protein] results in increased expression of ACTA2 protein; [Gefitinib results in increased secretion of CCL2 protein] which results in increased expression of ACTA2 protein
Gefitinib results in decreased expression of ACTA2 protein

NCBI chr 1:231,746,527...231,759,307
Ensembl chr 1:231,746,548...231,759,554

G

adenosine A1 receptor

decreases expression

gefitinib results in decreased expression of ADORA1 mRNA

NCBI chr13:45,658,872...45,695,821
Ensembl chr13:45,658,872...45,695,801

G

AKT serine/threonine kinase 1

multiple interactions
increases phosphorylation
decreases phosphorylation
decreases expression

Gefitinib affects the reaction [ON123300 results in decreased phosphorylation of AKT1 protein]; Gefitinib inhibits the reaction [Dinoprostone results in increased phosphorylation of AKT1 protein]; Gefitinib inhibits the reaction [EGF protein results in increased phosphorylation of AKT1 protein]; Gefitinib results in decreased expression of and results in decreased phosphorylation of AKT1 protein; leptomycin B inhibits the reaction [Gefitinib results in decreased phosphorylation of AKT1 protein]; Methionine inhibits the reaction [Gefitinib results in increased phosphorylation of AKT1 protein]
Gefitinib results in decreased expression of AKT1 mRNA
Gefitinib inhibits the reaction [Cadmium Chloride results in increased phosphorylation of AKT1 protein]; Gefitinib inhibits the reaction [Folic Acid results in increased phosphorylation of AKT1 protein]; Gefitinib promotes the reaction [Urethane results in increased phosphorylation of AKT1 protein]; Methionine inhibits the reaction [Gefitinib promotes the reaction [Urethane results in increased phosphorylation of AKT1 protein]]

PMID:17805209 PMID:19233551 PMID:23255615 PMID:23948867 PMID:24568969 More...

NCBI chr 6:131,713,716...131,735,319
Ensembl chr 6:131,713,720...131,733,921

G

androgen receptor

multiple interactions

Gefitinib inhibits the reaction [bisphenol A promotes the reaction [EGFR protein binds to AR protein]]

NCBI chr X:63,104,771...63,273,934
Ensembl chr X:63,104,771...63,273,925

G

amphiregulin

affects response to substance
multiple interactions
decreases response to substance

AREG protein affects the susceptibility to gefitinib
Gefitinib inhibits the reaction [[Promegestone co-treated with AREG protein] results in increased phosphorylation of MAPK1 protein]; Gefitinib inhibits the reaction [[Promegestone co-treated with AREG protein] results in increased phosphorylation of MAPK3 protein]; Gefitinib inhibits the reaction [Irinotecan metabolite results in increased expression of AREG mRNA]; Gefitinib inhibits the reaction [Irinotecan results in increased expression of AREG mRNA]
AREG protein results in decreased susceptibility to gefitinib

PMID:15496427 PMID:15723263 PMID:16230376 PMID:18980991 PMID:21258428

NCBI chr14:16,972,185...16,981,443
Ensembl chr14:16,972,187...16,981,535

G

autophagy related 5

increases expression

gefitinib results in increased expression of ATG5 protein

NCBI chr20:47,798,217...47,889,216
Ensembl chr20:47,798,290...47,889,209

G

autophagy related 7

increases expression

gefitinib results in increased expression of ATG7 protein

NCBI chr 4:147,718,663...147,925,656
Ensembl chr 4:147,718,752...147,925,593

G

aurora kinase A

decreases response to substance
multiple interactions

AURKA results in decreased susceptibility to gefitinib
[AURKA results in increased degradation of NFKBIA protein] which results in decreased susceptibility to Gefitinib; [TP53 protein results in decreased expression of AURKA protein] which results in increased susceptibility to Gefitinib

NCBI chr 3:161,128,309...161,144,524
Ensembl chr 3:161,128,313...161,144,390

G

apoptosis and caspase activation inhibitor

affects response to substance

AVEN protein affects the susceptibility to gefitinib

NCBI chr 3:99,299,009...99,431,635
Ensembl chr 3:99,298,930...99,431,634

G

BCL2-associated agonist of cell death

multiple interactions

[cucurbitacin B co-treated with Gefitinib] results in increased expression of BAD mRNA

NCBI chr 1:204,133,502...204,142,829
Ensembl chr 1:204,131,501...204,142,823

G

BCL2-antagonist/killer 1

multiple interactions

[cucurbitacin B co-treated with Gefitinib] results in increased expression of BAK1 mRNA; [cucurbitacin B co-treated with Gefitinib] results in increased expression of BAK1 protein

NCBI chr20:5,100,480...5,109,669
Ensembl chr20:5,100,480...5,109,264

G

BCL2 associated X, apoptosis regulator

increases expression
multiple interactions

Gefitinib results in increased expression of BAX mRNA; Gefitinib results in increased expression of BAX protein
[cucurbitacin B co-treated with Gefitinib] results in increased expression of BAX mRNA; [cucurbitacin B co-treated with Gefitinib] results in increased expression of BAX protein

PMID:26183715 PMID:32370496

NCBI chr 1:95,940,001...95,945,407
Ensembl chr 1:95,938,808...95,945,368

G

BCL2, apoptosis regulator

multiple interactions

[cucurbitacin B co-treated with Gefitinib] results in decreased expression of BCL2 mRNA; [cucurbitacin B co-treated with Gefitinib] results in decreased expression of BCL2 protein

NCBI chr13:22,689,783...22,853,920
Ensembl chr13:22,684,989...22,853,743
Ensembl chr13:22,684,989...22,853,743

G

Bcl2-like 1

multiple interactions

[cucurbitacin B co-treated with Gefitinib] results in decreased expression of BCL2L1 mRNA

NCBI chr 3:141,253,508...141,304,582
Ensembl chr 3:141,253,523...141,303,479
Ensembl chr 1:141,253,523...141,303,479

G

Bcl2-like 11

increases response to substance
multiple interactions

BCL2L11 protein results in increased susceptibility to gefitinib
[cucurbitacin B co-treated with Gefitinib] results in increased expression of BCL2L11 mRNA

PMID:20237869 PMID:26183715

NCBI chr 3:115,366,783...115,404,068
Ensembl chr 3:115,366,646...115,404,068

G

beclin 1

multiple interactions

[MIR578 affects the susceptibility to Gefitinib] which affects the expression of BECN1 protein; SOCS2 protein affects the reaction [[MIR578 affects the susceptibility to Gefitinib] which affects the expression of BECN1 protein]

NCBI chr10:86,231,387...86,246,742
Ensembl chr10:86,231,388...86,246,742

G

baculoviral IAP repeat-containing 5

increases expression
decreases expression
multiple interactions

gefitinib results in increased expression of BIRC5 protein
Gefitinib results in decreased expression of BIRC5 protein
leptomycin B promotes the reaction [Gefitinib results in decreased expression of BIRC5 protein]; tyrphostin AG 1024 inhibits the reaction [Gefitinib results in increased expression of BIRC5 protein]

PMID:17473213 PMID:28942004 PMID:36807944

NCBI chr10:103,072,530...103,081,382
Ensembl chr10:103,073,408...103,081,380

G

BCL2 interacting protein 3

multiple interactions

gefitinib inhibits the reaction [bafilomycin A1 results in increased expression of BNIP3 protein]

NCBI chr 1:193,708,164...193,725,348
Ensembl chr 1:193,708,167...193,725,359

G

caspase 1

increases activity
multiple interactions

Gefitinib metabolite results in increased activity of CASP1 protein
N-acetyl-tyrosyl-valyl-alanyl-aspartyl chloromethyl ketone inhibits the reaction [Gefitinib metabolite results in increased activity of CASP1 protein]

NCBI chr 8:2,587,812...2,597,403
Ensembl chr 8:2,587,831...2,597,383

G

caspase 3

increases expression
increases cleavage
multiple interactions

gefitinib results in increased expression of CASP3 mRNA; gefitinib results in increased expression of CASP3 protein
Gefitinib results in increased cleavage of CASP3 protein
Gefitinib results in increased expression of CASP3 protein modified form
[Gefitinib results in increased secretion of CCL2 protein] inhibits the reaction [Gefitinib results in increased expression of CASP3 protein modified form]
[cucurbitacin B co-treated with Gefitinib] results in increased cleavage of CASP3 protein; EGFR gene mutant form promotes the reaction [Gefitinib results in increased cleavage of and results in increased activity of CASP3 protein]; Gefitinib results in increased cleavage of and results in increased activity of CASP3 protein

PMID:23523951 PMID:26183715 PMID:27084042 PMID:27639429 PMID:33248157

NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648

G

caspase 8

increases cleavage

Gefitinib results in increased cleavage of CASP8 protein

NCBI chr 9:60,263,863...60,312,542
Ensembl chr 9:60,264,075...60,312,542

G

caveolin 1

increases expression

gefitinib results in increased expression of CAV1 mRNA; gefitinib results in increased expression of CAV1 protein

NCBI chr 4:45,640,624...45,673,708
Ensembl chr 4:45,634,918...45,673,705

G

C-C motif chemokine ligand 2

increases secretion
increases expression
multiple interactions

Gefitinib results in increased secretion of CCL2 protein
Gefitinib results in increased expression of CCL2 mRNA
[Gefitinib co-treated with CCL2 protein] results in increased expression of ACTA2 protein; [Gefitinib co-treated with CCL2 protein] results in increased expression of COL1A1 protein; [Gefitinib results in increased secretion of CCL2 protein] inhibits the reaction [Gefitinib results in increased expression of CASP3 protein modified form]; [Gefitinib results in increased secretion of CCL2 protein] inhibits the reaction [Gefitinib results in increased expression of PARP1 protein modified form]; [Gefitinib results in increased secretion of CCL2 protein] which results in decreased expression of CDH1 protein; [Gefitinib results in increased secretion of CCL2 protein] which results in increased expression of ACTA2 protein; [Gefitinib results in increased secretion of CCL2 protein] which results in increased expression of COL1A1 protein; [Gefitinib results in increased secretion of CCL2 protein] which results in increased expression of FN1 protein; [Gefitinib results in increased secretion of CCL2 protein] which results in increased expression of VIM protein; cucurbitacin B inhibits the reaction [Gefitinib results in increased expression of CCL2 mRNA]

NCBI chr10:67,005,424...67,007,222
Ensembl chr10:67,005,424...67,007,226

G

cyclin B1

multiple interactions

Gefitinib results in decreased expression of and affects the localization of CCNB1 protein

NCBI chr 2:31,912,190...31,921,163
Ensembl chr 2:31,912,193...31,921,172

G

cyclin D1

decreases expression
multiple interactions

Gefitinib results in decreased expression of CCND1 protein
[cucurbitacin B co-treated with Gefitinib] results in decreased expression of CCND1 mRNA; [cucurbitacin B co-treated with Gefitinib] results in decreased expression of CCND1 protein
gefitinib inhibits the reaction [Cadmium Chloride results in increased expression of CCND1 mRNA]; gefitinib inhibits the reaction [Cadmium Chloride results in increased expression of CCND1 protein]

PMID:16740687 PMID:17513607 PMID:23948867 PMID:26183715

NCBI chr 1:200,089,002...200,098,524
Ensembl chr 1:200,089,002...200,098,602

G

cyclin D3

decreases expression

gefitinib results in decreased expression of CCND3 protein

NCBI chr 9:13,394,161...13,400,341
Ensembl chr 9:13,394,169...13,489,371

G

CD14 molecule

multiple interactions

2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [gefitinib promotes the reaction [arsenic trioxide results in increased expression of CD14 protein]]; [gefitinib promotes the reaction arsenic trioxide] which results in increased expression of CD14 mRNA; gefitinib promotes the reaction [arsenic trioxide results in increased expression of CD14 protein]; SB 203580 inhibits the reaction [gefitinib promotes the reaction [arsenic trioxide results in increased expression of CD14 protein]]

NCBI chr18:28,335,522...28,337,383
Ensembl chr18:28,335,340...28,337,261

G

cadherin 1

multiple interactions
increases expression

[Gefitinib results in increased secretion of CCL2 protein] which results in decreased expression of CDH1 protein
Gefitinib results in increased expression of CDH1 protein

PMID:33248157 PMID:38517198

NCBI chr19:34,492,371...34,561,775
Ensembl chr19:34,492,371...34,561,775

G

cyclin-dependent kinase 1

increases phosphorylation

Gefitinib results in increased phosphorylation of CDK1 protein

NCBI chr20:19,266,226...19,281,417
Ensembl chr20:19,266,248...19,281,408

G

cyclin-dependent kinase 6

multiple interactions
decreases expression

Betulinic Acid promotes the reaction [Gefitinib results in decreased expression of CDK6 protein]

NCBI chr 4:30,637,650...30,829,688
Ensembl chr 4:30,646,460...30,829,634

G

cyclin-dependent kinase inhibitor 1A

increases expression
multiple interactions
decreases expression

gefitinib results in increased expression of CDKN1A protein
leptomycin B inhibits the reaction [gefitinib results in decreased expression of CDKN1A protein]

PMID:17513607 PMID:28942004

NCBI chr20:7,149,177...7,159,727
Ensembl chr20:7,149,217...7,159,585

G

cyclin-dependent kinase inhibitor 1B

multiple interactions
increases expression
decreases expression

[cucurbitacin B co-treated with Gefitinib] results in increased expression of CDKN1B protein; Gefitinib promotes the reaction [[Zoledronic Acid co-treated with 4-(5-(4-chlorophenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl)benzenesulfonamide] results in decreased expression of CDKN1B protein]
Gefitinib results in increased expression of CDKN1B protein
gefitinib results in decreased expression of CDKN1B

PMID:14679152 PMID:16322342 PMID:16740687 PMID:17513607 PMID:26183715

NCBI chr 4:167,760,067...167,765,177
Ensembl chr 4:167,760,181...167,764,982

G

cyclin-dependent kinase inhibitor 2B

increases expression

gefitinib results in increased expression of CDKN2B mRNA; gefitinib results in increased expression of CDKN2B protein

NCBI chr 5:104,009,839...104,019,082
Ensembl chr 5:104,010,680...104,019,050

G

ceramide transporter 1

affects response to substance

CERT1 protein affects the susceptibility to Gefitinib

NCBI chr 2:27,882,546...27,987,090
Ensembl chr 2:27,882,555...27,987,074

G

cell growth regulator with ring finger domain 1

increases expression

gefitinib results in increased expression of CGRRF1 mRNA

NCBI chr15:20,088,564...20,109,042
Ensembl chr15:20,088,571...20,109,037

G

claudin 2

multiple interactions

[gefitinib co-treated with naphthalene] affects the expression of CLDN2 mRNA

NCBI chr X:103,459,870...103,473,794
Ensembl chr X:103,459,780...103,474,838

G

collagen type I alpha 1 chain

decreases expression
multiple interactions

Gefitinib results in decreased expression of COL1A1 protein
[Gefitinib co-treated with CCL2 protein] results in increased expression of COL1A1 protein; [Gefitinib results in increased secretion of CCL2 protein] which results in increased expression of COL1A1 protein

NCBI chr10:79,883,622...79,900,625
Ensembl chr10:79,883,622...79,900,624

G

coronin 1C

affects response to substance

CORO1C protein affects the susceptibility to gefitinib

NCBI chr12:42,713,024...42,785,179
Ensembl chr12:42,712,991...42,785,179

G

cytochrome c, somatic

affects localization

gefitinib affects the localization of CYCS protein

NCBI chr 4:79,651,894...79,653,994
Ensembl chr 4:79,651,378...79,654,054
Ensembl chr18:79,651,378...79,654,054

G

cytochrome P450, family 1, subfamily a, polypeptide 1

increases response to substance
decreases activity
increases expression

CYP1A1 protein results in increased susceptibility to gefitinib
Gefitinib results in decreased activity of CYP1A1 protein
Gefitinib results in increased expression of CYP1A1 mRNA

PMID:28652202 PMID:32370496 PMID:33814510

NCBI chr 8:58,096,021...58,102,130
Ensembl chr 8:58,096,077...58,102,125

G

cytochrome P450, family 1, subfamily b, polypeptide 1

decreases activity

Gefitinib results in decreased activity of CYP1B1 protein

NCBI chr 6:15,342,312...15,350,886
Ensembl chr 6:15,342,344...15,350,917

G

cytochrome P450, family 2, subfamily d, polypeptide 4

affects metabolic processing

CYP2D6 protein affects the metabolism of Gefitinib; CYP2D6 protein polymorphism affects the metabolism of Gefitinib

PMID:15788367 PMID:34936353

NCBI chr 7:113,882,584...113,891,754
Ensembl chr 7:113,881,618...113,891,759

G

cytochrome P450, family 2, subfamily f, polypeptide 4

decreases expression

gefitinib results in decreased expression of CYP2F1 mRNA

NCBI chr 1:82,416,107...82,429,897
Ensembl chr 1:82,416,130...82,429,896

G

cytochrome P450, family 3, subfamily a, polypeptide 2

affects metabolic processing

CYP3A4 protein affects the metabolism of Gefitinib

NCBI chr12:9,207,978...9,230,064
Ensembl chr12:9,015,383...9,285,008

G

cytochrome P450, family 3, subfamily a, polypeptide 9

affects metabolic processing

CYP3A5 protein affects the metabolism of gefitinib

NCBI chr12:16,806,222...16,846,428
Ensembl chr12:16,806,207...16,846,422

G

DnaJ heat shock protein family (Hsp40) member B1

increases secretion

Gefitinib metabolite results in increased secretion of DNAJB1 protein

NCBI chr19:24,522,731...24,526,419
Ensembl chr19:24,522,717...24,526,458

G

dual specificity phosphatase 3

affects response to substance

DUSP3 protein affects the susceptibility to gefitinib

NCBI chr10:86,920,014...86,933,739
Ensembl chr10:86,920,014...86,933,962

G

dual specificity phosphatase 9

decreases expression

gefitinib results in decreased expression of DUSP9 mRNA

NCBI chr X:151,351,897...151,355,822
Ensembl chr X:151,351,897...151,355,821

G

E2F transcription factor 1

decreases expression

gefitinib results in decreased expression of E2F1 mRNA; gefitinib results in decreased expression of E2F1 protein

PMID:17094457 PMID:18347146

NCBI chr 3:143,064,535...143,075,362
Ensembl chr 3:143,049,478...143,075,361

G

endothelin receptor type B

multiple interactions

gefitinib inhibits the reaction [TGFA protein results in decreased expression of EDNRB mRNA]

NCBI chr15:80,640,839...80,672,115
Ensembl chr15:80,643,043...80,672,115

G

epidermal growth factor

multiple interactions

Gefitinib inhibits the reaction [EGF affects the localization of MAPK1]; Gefitinib inhibits the reaction [EGF affects the localization of MAPK3]; Gefitinib inhibits the reaction [EGF protein results in increased expression of MMP9 protein]; Gefitinib inhibits the reaction [EGF protein results in increased phosphorylation of AKT1 protein]; Gefitinib inhibits the reaction [EGF protein results in increased phosphorylation of and results in increased activity of EGFR protein]; Gefitinib inhibits the reaction [EGF protein results in increased phosphorylation of and results in increased activity of ERBB2 protein]; Gefitinib inhibits the reaction [EGF protein results in increased phosphorylation of and results in increased activity of MAPK1 protein]; Gefitinib inhibits the reaction [EGF protein results in increased phosphorylation of and results in increased activity of MAPK3 protein]; Gefitinib inhibits the reaction [EGF protein results in increased phosphorylation of EGFR protein]; Gefitinib inhibits the reaction [EGF protein results in increased phosphorylation of MAPK1 protein]; Gefitinib inhibits the reaction [EGF protein results in increased phosphorylation of MAPK3 protein]; Gefitinib inhibits the reaction [EGF protein results in increased phosphorylation of RELA protein]; Gefitinib inhibits the reaction [EGF protein results in increased phosphorylation of STAT3 protein]; Gefitinib inhibits the reaction [EGF results in increased activity of MAPK1 protein]; Gefitinib inhibits the reaction [EGF results in increased activity of MAPK3 protein]; Gefitinib inhibits the reaction [EGF results in increased phosphorylation of and results in increased activity of EGFR protein]; Gefitinib inhibits the reaction [EGF results in increased phosphorylation of EGFR protein]; Gefitinib inhibits the reaction [EGF results in increased phosphorylation of STAT3 protein]; Gefitinib promotes the reaction [EGF protein binds to EGFR protein]; Gefitinib promotes the reaction [Hydrocortisone inhibits the reaction [EGF protein results in increased abundance of Dinoprostone]]; Gefitinib promotes the reaction [Resveratrol inhibits the reaction [EGF protein results in increased expression of MMP9 mRNA]]; Gefitinib promotes the reaction [Resveratrol inhibits the reaction [EGF protein results in increased expression of PLAU mRNA]]; Resveratrol promotes the reaction [Gefitinib inhibits the reaction [EGF protein results in increased expression of MMP9 mRNA]]; Resveratrol promotes the reaction [Gefitinib inhibits the reaction [EGF protein results in increased expression of PLAU mRNA]]
gefitinib inhibits the reaction [EGF protein results in increased phosphorylation of EGFR protein]

PMID:15841081 PMID:16243822 PMID:17805209 PMID:17898861 PMID:18927496 More...

NCBI chr 2:218,219,408...218,302,359
Ensembl chr 2:218,219,415...218,302,064

G

epidermal growth factor receptor

decreases response to substance
decreases activity
multiple interactions
decreases phosphorylation
decreases expression
increases response to substance
affects response to substance

EGFR gene mutant form results in decreased susceptibility to Gefitinib; EGFR protein mutant form results in decreased susceptibility to Gefitinib
Gefitinib results in decreased activity of EGFR protein
Gefitinib inhibits the reaction [astragaloside VI results in increased expression of and results in increased phosphorylation of EGFR protein]; Gefitinib inhibits the reaction [HBEGF protein inhibits the reaction [sodium arsenite results in decreased phosphorylation of and results in decreased activity of EGFR protein]]
Gefitinib results in decreased phosphorylation of EGFR protein
gefitinib results in decreased phosphorylation of EGFR protein
gefitinib results in decreased expression of EGFR protein modified form
[Gefitinib results in decreased activity of EGFR protein] which results in increased susceptibility to naphthalene; Gefitinib inhibits the reaction [Cadmium Chloride results in increased phosphorylation of EGFR protein]; Gefitinib inhibits the reaction [EGF protein results in increased phosphorylation of EGFR protein]; Gefitinib inhibits the reaction [Folic Acid results in increased phosphorylation of EGFR protein]; Gefitinib promotes the reaction [Urethane results in increased phosphorylation of EGFR protein]; Gefitinib results in decreased phosphorylation of and results in decreased activity of EGFR protein; Methionine inhibits the reaction [Gefitinib promotes the reaction [Urethane results in increased phosphorylation of EGFR protein]]
Gefitinib results in decreased expression of EGFR protein modified form
[[Gefitinib results in decreased activity of EGFR protein] which affects the localization of ABCG2 protein] which results in decreased export of Doxorubicin; [cucurbitacin B co-treated with Gefitinib] results in decreased phosphorylation of EGFR protein; [Gefitinib co-treated with betulin] results in decreased expression of and results in decreased phosphorylation of EGFR protein; [Gefitinib co-treated with Oxaliplatin] results in decreased phosphorylation of EGFR protein; [Gefitinib promotes the reaction [EGFR protein binds to EGFR protein]] which results in decreased activity of EGFR protein; [Gefitinib results in decreased activity of EGFR protein] which affects the localization of ABCG2 protein; [ITGB1 protein results in increased activity of EGFR protein] which results in decreased susceptibility to Gefitinib; [Methionine co-treated with Gefitinib] results in decreased phosphorylation of EGFR protein; Betulinic Acid promotes the reaction [Gefitinib results in decreased expression of EGFR protein modified form]; EGFR gene mutant form promotes the reaction [Gefitinib results in decreased expression of SQSTM1 protein]; EGFR gene mutant form promotes the reaction [Gefitinib results in increased cleavage of and results in increased activity of CASP3 protein]; Gefitinib inhibits the reaction [bisphenol A promotes the reaction [EGFR protein binds to AR protein]]; Gefitinib inhibits the reaction [bisphenol A promotes the reaction [EGFR protein binds to ESR2 protein]]; Gefitinib inhibits the reaction [bisphenol A results in increased phosphorylation of EGFR protein]; Gefitinib inhibits the reaction [EGF protein results in increased phosphorylation of and results in increased activity of EGFR protein]; Gefitinib inhibits the reaction [EGF protein results in increased phosphorylation of EGFR protein]; Gefitinib inhibits the reaction [EGF results in increased phosphorylation of and results in increased activity of EGFR protein]; Gefitinib inhibits the reaction [EGF results in increased phosphorylation of EGFR protein]; Gefitinib inhibits the reaction [EGFR protein results in decreased susceptibility to Docetaxel]; Gefitinib inhibits the reaction [Gemcitabine results in increased phosphorylation of and results in increased degradation of EGFR protein]; Gefitinib inhibits the reaction [Irinotecan metabolite results in increased phosphorylation of and results in increased activity of EGFR protein]; Gefitinib inhibits the reaction [Irinotecan results in increased phosphorylation of and results in increased activity of EGFR protein]; Gefitinib inhibits the reaction [tetrachlorodian results in increased expression of EGFR mRNA]; Gefitinib inhibits the reaction [Tobacco Smoke Pollution results in increased phosphorylation of EGFR protein]; Gefitinib promotes the reaction [EGF protein binds to EGFR protein]; Gefitinib promotes the reaction [EGFR protein binds to EGFR protein]; Gefitinib promotes the reaction [IGF1R protein binds to EGFR protein]; Gefitinib results in decreased activity of [EGFR protein binds to EGFR protein]; Gefitinib results in decreased activity of [EGFR protein binds to ERBB2 protein]; Gefitinib results in decreased expression of and results in decreased phosphorylation of EGFR protein; KRAS protein affects the reaction [EGFR protein affects the susceptibility to Gefitinib]; osimertinib inhibits the reaction [EGFR protein mutant form results in decreased susceptibility to Gefitinib]
EGFR gene mutant form results in increased susceptibility to gefitinib; EGFR gene polymorphism results in increased susceptibility to gefitinib; EGFR protein mutant form results in increased susceptibility to gefitinib
EGFR gene mutant form affects the susceptibility to Gefitinib; EGFR protein affects the susceptibility to Gefitinib; EGFR protein mutant form affects the susceptibility to Gefitinib

PMID:13680161 PMID:14679152 PMID:15660382 PMID:15723263 PMID:15841081 More...

NCBI chr14:91,176,979...91,349,722
Ensembl chr14:91,177,067...91,344,382

G

erythropoietin receptor

increases expression

gefitinib results in increased expression of EPOR mRNA

NCBI chr 8:20,489,678...20,494,257
Ensembl chr 8:20,489,678...20,494,257

G

epidermal growth factor receptor pathway substrate 15

increases expression

gefitinib results in increased expression of EPS15 mRNA

NCBI chr 5:124,045,865...124,146,221
Ensembl chr 5:124,045,926...124,146,221

G

erb-b2 receptor tyrosine kinase 2

multiple interactions
decreases phosphorylation

gefitinib inhibits the reaction [EGF protein results in increased phosphorylation of and results in increased activity of ERBB2 protein]; gefitinib results in decreased activity of [EGFR protein binds to ERBB2 protein]
gefitinib results in decreased phosphorylation of ERBB2 protein

PMID:16243822 PMID:17898861

NCBI chr10:83,411,197...83,435,078
Ensembl chr10:83,411,313...83,435,078

G

ERCC excision repair 1, endonuclease non-catalytic subunit

multiple interactions
affects response to substance

ERCC1 gene polymorphism affects the susceptibility to [gefitinib co-treated with Cisplatin]
ERCC1 gene polymorphism affects the susceptibility to gefitinib

NCBI chr 1:78,971,310...79,007,963
Ensembl chr 1:78,996,390...79,007,963

G

estrogen receptor 1

decreases phosphorylation

gefitinib results in decreased phosphorylation of ESR1 protein

NCBI chr 1:41,106,335...41,499,104
Ensembl chr 1:41,210,475...41,495,002

G

estrogen receptor 2

increases expression
multiple interactions

gefitinib results in increased expression of ESR2 protein
Gefitinib inhibits the reaction [bisphenol A promotes the reaction [EGFR protein binds to ESR2 protein]]

PMID:20005069 PMID:29383186

NCBI chr 6:94,858,438...94,909,630
Ensembl chr 6:94,809,547...94,908,919

G

Fas ligand

multiple interactions
increases response to substance

benzyloxycarbonyl-valyl-alanyl-aspartyl-fluoromethane inhibits the reaction [Gefitinib results in increased susceptibility to FASLG protein]

NCBI chr13:74,151,519...74,172,760
Ensembl chr13:74,154,954...74,162,215

G

fibroblast growth factor 6

increases expression

gefitinib results in increased expression of FGF6 mRNA

NCBI chr 4:159,854,913...159,863,447
Ensembl chr 4:159,854,913...159,863,447

G

fibroblast growth factor receptor 3

decreases expression

Gefitinib results in decreased expression of FGFR3 mRNA

NCBI chr14:76,987,242...77,002,671
Ensembl chr14:76,987,993...77,003,341

G

fibronectin 1

multiple interactions

[Gefitinib results in increased secretion of CCL2 protein] which results in increased expression of FN1 protein

NCBI chr 9:73,196,044...73,264,695
Ensembl chr 9:73,196,044...73,264,678

G

Fos proto-oncogene, AP-1 transcription factor subunit

multiple interactions

Gefitinib inhibits the reaction [tetrachlorodian results in increased expression of FOS mRNA]

NCBI chr 6:105,121,170...105,124,036
Ensembl chr 6:105,121,170...105,124,036

G

forkhead box F1

multiple interactions

gefitinib inhibits the reaction [TGFA protein results in decreased expression of FOXF1 mRNA]

NCBI chr19:49,153,949...49,157,741
Ensembl chr19:49,153,699...49,157,738

G

forkhead box O3

increases response to substance
increases expression
multiple interactions

FOXO3 protein results in increased susceptibility to gefitinib
Gefitinib results in increased expression of FOXO3 mRNA; Gefitinib results in increased expression of FOXO3 protein; Gefitinib results in increased expression of FOXO3 protein modified form
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one promotes the reaction [Gefitinib results in increased expression of FOXO3 mRNA]
gefitinib results in decreased phosphorylation of and affects the localization of FOXO3 protein

PMID:18089711 PMID:32370496

NCBI chr20:45,669,708...45,764,606
Ensembl chr20:45,672,995...45,764,561

G

growth arrest and DNA-damage-inducible, alpha

increases expression

gefitinib results in increased expression of GADD45A mRNA

NCBI chr 4:96,154,789...96,157,091
Ensembl chr 4:96,154,789...96,157,115

G

growth arrest and DNA-damage-inducible, gamma

decreases expression

gefitinib results in decreased expression of GADD45G mRNA

NCBI chr17:13,376,842...13,378,587
Ensembl chr17:13,376,839...13,378,610

G

glycyl-tRNA synthetase 1

increases expression

Gefitinib results in increased expression of GARS1 mRNA

NCBI chr 4:84,171,596...84,212,609
Ensembl chr 4:84,171,596...84,212,609

G

glutamate-cysteine ligase, catalytic subunit

affects response to substance

GCLC protein affects the susceptibility to gefitinib

NCBI chr 8:78,629,899...78,668,547
Ensembl chr 8:78,630,127...78,668,544

G

glial fibrillary acidic protein

multiple interactions

gefitinib inhibits the reaction [HBEGF protein inhibits the reaction [sodium arsenite results in decreased expression of GFAP protein]]

NCBI chr10:87,852,891...87,861,631
Ensembl chr10:87,852,890...87,861,589

G

G protein subunit beta 2

decreases expression

gefitinib results in decreased expression of GNB2 mRNA

NCBI chr12:19,159,002...19,164,021
Ensembl chr12:19,158,973...19,164,019

G

glycine N-methyltransferase

multiple interactions

[gefitinib co-treated with naphthalene] affects the expression of GNMT mRNA

NCBI chr 9:14,254,675...14,258,028
Ensembl chr 9:14,254,675...14,258,434

G

G protein-coupled estrogen receptor 1

multiple interactions

Gefitinib inhibits the reaction [tetrachlorodian results in increased expression of GPER1 mRNA]

NCBI chr12:15,217,217...15,222,679
Ensembl chr12:15,217,442...15,221,889

G

glutamic--pyruvic transaminase

increases secretion

Gefitinib results in increased secretion of GPT protein

NCBI chr 7:108,416,646...108,419,495
Ensembl chr 7:108,416,642...108,419,494

G

glycogen synthase kinase 3 beta

decreases expression

Gefitinib results in decreased expression of GSK3B protein modified form

NCBI chr11:62,498,997...62,648,665
Ensembl chr11:62,504,316...62,648,646

G

guanylate cyclase 2E

decreases expression

gefitinib results in decreased expression of GUCY2D mRNA

NCBI chr10:53,954,918...53,975,576
Ensembl chr10:53,959,010...53,974,067

G

hepatitis A virus cellular receptor 1

multiple interactions

Gefitinib promotes the reaction [Folic Acid results in increased expression of HAVCR1 protein]

NCBI chr10:31,118,667...31,151,730
Ensembl chr10:31,119,088...31,151,698

G

heparin-binding EGF-like growth factor

multiple interactions

gefitinib inhibits the reaction [irinotecan metabolite results in increased expression of HBEGF mRNA]; gefitinib inhibits the reaction [irinotecan results in increased expression of HBEGF mRNA]
gefitinib inhibits the reaction [HBEGF protein inhibits the reaction [sodium arsenite results in decreased expression of GFAP protein]]; gefitinib inhibits the reaction [HBEGF protein inhibits the reaction [sodium arsenite results in decreased phosphorylation of and results in decreased activity of EGFR protein]]; gefitinib inhibits the reaction [HBEGF protein inhibits the reaction [sodium arsenite results in decreased secretion of HBEGF protein]]; gefitinib inhibits the reaction [HBEGF protein inhibits the reaction [sodium arsenite results in increased expression of and results in increased secretion of and results in increased activity of MMP9 protein]]

PMID:15723263 PMID:29228391

NCBI chr18:28,106,284...28,116,167
Ensembl chr18:28,105,760...28,116,441

G

hypoxia inducible factor 1 subunit alpha

multiple interactions

gefitinib inhibits the reaction [Tobacco Smoke Pollution results in increased expression of HIF1A protein]

NCBI chr 6:92,624,059...92,669,262
Ensembl chr 6:92,624,390...92,669,261

G

high mobility group box 1

increases secretion

Gefitinib metabolite results in increased secretion of HMGB1 protein

NCBI chr12:5,972,950...5,979,658
Ensembl chr12:5,901,586...5,978,565
Ensembl chr16:5,901,586...5,978,565

G

heme oxygenase 1

increases expression
multiple interactions

gefitinib results in increased expression of HMOX1 mRNA; gefitinib results in increased expression of HMOX1 protein
[Buthionine Sulfoximine co-treated with Gefitinib] results in increased expression of HMOX1 mRNA

PMID:27084042 PMID:32741899

NCBI chr19:13,466,287...13,474,082
Ensembl chr19:13,467,244...13,474,079

G

heat shock protein 90 alpha family class A member 1

increases secretion

Gefitinib metabolite results in increased secretion of HSP90AA1 protein

NCBI chr 6:129,702,376...129,707,907
Ensembl chr 6:129,702,383...129,707,268

G

heat shock protein family A (Hsp70) member 1A

increases secretion

Gefitinib metabolite results in increased secretion of HSPA1A protein

NCBI chr20:3,870,765...3,873,221
Ensembl chr20:3,856,006...3,873,227

G

HtrA serine peptidase 1

increases expression
multiple interactions

Gefitinib results in increased expression of HTRA1 mRNA
Arsenic inhibits the reaction [Gefitinib results in increased expression of HTRA1 mRNA]

NCBI chr 1:185,497,815...185,547,380
Ensembl chr 1:185,497,735...185,547,379

G

insulin-like growth factor 1

decreases secretion

Gefitinib results in decreased secretion of IGF1 protein

NCBI chr 7:22,282,895...22,361,972
Ensembl chr 7:22,282,930...22,359,296

G

insulin-like growth factor 1 receptor

multiple interactions
increases phosphorylation

gefitinib promotes the reaction [IGF1R protein binds to EGFR protein]; tyrphostin AG 1024 inhibits the reaction [gefitinib results in increased phosphorylation of IGF1R protein]

NCBI chr 1:121,549,831...121,838,548
Ensembl chr 1:121,550,743...121,831,777

G

interleukin 1 beta

multiple interactions
increases expression

gefitinib inhibits the reaction [Cadmium Chloride results in increased expression of IL1B mRNA]; gefitinib inhibits the reaction [Cadmium Chloride results in increased expression of IL1B protein]
Gefitinib metabolite results in increased expression of IL1B protein

PMID:23948867 PMID:33132241

NCBI chr 3:116,577,005...116,583,386
Ensembl chr 3:116,577,010...116,583,415

G

integrin subunit alpha M

multiple interactions

2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [gefitinib promotes the reaction [arsenic trioxide results in increased expression of ITGAM protein]]; gefitinib promotes the reaction [arsenic trioxide results in increased expression of ITGAM mRNA]; gefitinib promotes the reaction [arsenic trioxide results in increased expression of ITGAM protein]

NCBI chr 1:182,659,047...182,709,501
Ensembl chr 1:182,659,000...182,709,503

G

integrin subunit alpha V

multiple interactions

gefitinib inhibits the reaction [TNF protein results in increased expression of ITGAV mRNA]

NCBI chr 3:68,838,514...68,926,653
Ensembl chr 3:68,838,189...68,926,639

G

integrin subunit beta 1

multiple interactions

[ITGB1 protein results in increased activity of EGFR protein] which results in decreased susceptibility to gefitinib

NCBI chr19:56,705,123...56,753,199
Ensembl chr19:56,705,171...56,753,195

G

kinase insert domain receptor

multiple interactions

gefitinib inhibits the reaction [TGFA protein results in decreased expression of KDR mRNA]

NCBI chr14:32,217,871...32,261,018
Ensembl chr14:32,217,871...32,261,018

G

Kelch-like ECH-associated protein 1

increases expression

gefitinib results in increased expression of KEAP1 mRNA

NCBI chr 8:19,768,375...19,777,862
Ensembl chr 8:19,768,375...19,777,862

G

KRAS proto-oncogene, GTPase

affects response to substance
decreases response to substance
multiple interactions

KRAS protein mutant form affects the susceptibility to gefitinib
KRAS protein results in decreased susceptibility to gefitinib
KRAS protein affects the reaction [EGFR protein affects the susceptibility to gefitinib]

PMID:17270025 PMID:28739874

NCBI chr 4:178,185,418...178,218,484

G

lipocalin 2

multiple interactions

Gefitinib promotes the reaction [Folic Acid results in increased expression of LCN2 protein]

NCBI chr 3:15,680,688...15,684,033
Ensembl chr 3:15,680,687...15,684,095

G

leptin receptor

decreases expression

gefitinib results in decreased expression of LEPR mRNA

NCBI chr 5:116,294,409...116,477,904
Ensembl chr 5:116,289,823...116,475,908

G

galectin 9

multiple interactions

[gefitinib co-treated with naphthalene] affects the expression of LGALS9 mRNA

NCBI chr10:63,907,018...63,930,224
Ensembl chr10:63,907,018...63,930,045

G

microtubule-associated protein 1 light chain 3 beta

multiple interactions

[MIR578 affects the susceptibility to Gefitinib] which affects the lipidation of MAP1LC3B protein; SOCS2 protein affects the reaction [[MIR578 affects the susceptibility to Gefitinib] which affects the lipidation of MAP1LC3B protein]

NCBI chr19:49,665,795...49,673,655
Ensembl chr19:49,665,791...49,677,690
Ensembl chr16:49,665,791...49,677,690

G

mitogen activated protein kinase 1

multiple interactions
increases phosphorylation
decreases phosphorylation
decreases expression

Gefitinib affects the reaction [ON123300 results in decreased phosphorylation of MAPK1 protein]; Gefitinib inhibits the reaction [[Promegestone co-treated with AREG protein] results in increased phosphorylation of MAPK1 protein]; Gefitinib inhibits the reaction [bisphenol A results in increased phosphorylation of MAPK1 protein]; Gefitinib inhibits the reaction [Dinoprostone results in increased phosphorylation of MAPK1 protein]; Gefitinib inhibits the reaction [EGF affects the localization of MAPK1]; Gefitinib inhibits the reaction [EGF protein results in increased phosphorylation of and results in increased activity of MAPK1 protein]; Gefitinib inhibits the reaction [EGF protein results in increased phosphorylation of MAPK1 protein]; Gefitinib inhibits the reaction [EGF results in increased activity of MAPK1 protein]; Gefitinib inhibits the reaction [Promegestone results in increased phosphorylation of MAPK1 protein]; Gefitinib inhibits the reaction [tetrachlorodian results in increased expression of MAPK1 mRNA]; Gefitinib inhibits the reaction [Tobacco Smoke Pollution results in increased phosphorylation of MAPK1 protein]; Gefitinib promotes the reaction [[Zoledronic Acid co-treated with 4-(5-(4-chlorophenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl)benzenesulfonamide] results in decreased phosphorylation of MAPK1 protein]; Gefitinib results in decreased expression of and affects the phosphorylation of MAPK1 protein; leptomycin B inhibits the reaction [Gefitinib results in decreased phosphorylation of MAPK1 protein]; Methionine promotes the reaction [Gefitinib results in decreased phosphorylation of MAPK1 protein]
Gefitinib promotes the reaction [Urethane results in increased phosphorylation of MAPK1 protein]; Methionine inhibits the reaction [Gefitinib promotes the reaction [Urethane results in increased phosphorylation of MAPK1 protein]]
gefitinib results in increased phosphorylation of MAPK1 protein
gefitinib inhibits the reaction [Diethylnitrosamine results in increased phosphorylation of MAPK1 protein]
gefitinib results in decreased expression of MAPK1 protein modified form

PMID:15660382 PMID:16322342 PMID:17145836 PMID:17805209 PMID:17898861 More...

NCBI chr11:83,957,813...84,023,629
Ensembl chr11:83,957,813...84,023,616

G

mitogen activated protein kinase 3

multiple interactions
increases phosphorylation
decreases expression
decreases phosphorylation

Gefitinib affects the reaction [ON123300 results in decreased phosphorylation of MAPK3 protein]; Gefitinib inhibits the reaction [[Promegestone co-treated with AREG protein] results in increased phosphorylation of MAPK3 protein]; Gefitinib inhibits the reaction [bisphenol A results in increased phosphorylation of MAPK3 protein]; Gefitinib inhibits the reaction [Dinoprostone results in increased phosphorylation of MAPK3 protein]; Gefitinib inhibits the reaction [EGF affects the localization of MAPK3]; Gefitinib inhibits the reaction [EGF protein results in increased phosphorylation of and results in increased activity of MAPK3 protein]; Gefitinib inhibits the reaction [EGF protein results in increased phosphorylation of MAPK3 protein]; Gefitinib inhibits the reaction [EGF results in increased activity of MAPK3 protein]; Gefitinib inhibits the reaction [Promegestone results in increased phosphorylation of MAPK3 protein]; Gefitinib inhibits the reaction [tetrachlorodian results in increased expression of MAPK3 mRNA]; Gefitinib inhibits the reaction [Tobacco Smoke Pollution results in increased phosphorylation of MAPK3 protein]; Gefitinib promotes the reaction [[Zoledronic Acid co-treated with 4-(5-(4-chlorophenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl)benzenesulfonamide] results in decreased phosphorylation of MAPK3 protein]; Gefitinib results in decreased expression of and affects the phosphorylation of MAPK3 protein; leptomycin B inhibits the reaction [Gefitinib results in decreased phosphorylation of MAPK3 protein]; Methionine promotes the reaction [Gefitinib results in decreased phosphorylation of MAPK3 protein]
Gefitinib promotes the reaction [Urethane results in increased phosphorylation of MAPK3 protein]; Methionine inhibits the reaction [Gefitinib promotes the reaction [Urethane results in increased phosphorylation of MAPK3 protein]]
gefitinib inhibits the reaction [Diethylnitrosamine results in increased phosphorylation of MAPK3 protein]
gefitinib results in increased phosphorylation of MAPK3 protein
gefitinib results in decreased expression of MAPK3 protein modified form

PMID:15660382 PMID:16322342 PMID:17145836 PMID:17805209 PMID:17898861 More...

NCBI chr 1:181,366,646...181,372,863
Ensembl chr 1:181,366,637...181,372,863

G

mitogen-activated protein kinase 6

multiple interactions

Gefitinib inhibits the reaction [tetrachlorodian results in increased expression of MAPK6 mRNA]

NCBI chr 8:76,146,650...76,169,767
Ensembl chr 8:76,146,690...76,169,720

G

mitogen-activated protein kinase 8

increases phosphorylation
multiple interactions
decreases phosphorylation

gefitinib results in increased phosphorylation of MAPK8 protein
Gefitinib inhibits the reaction [tetrachlorodian results in increased expression of MAPK8 mRNA]
Gefitinib results in decreased phosphorylation of MAPK8 protein

PMID:20846305 PMID:35317323 PMID:36190352

NCBI chr16:8,638,897...8,721,960
Ensembl chr16:8,638,924...8,721,981

G

MARVEL domain containing 1

decreases response to substance

MARVELD1 protein results in decreased susceptibility to Gefitinib

NCBI chr 1:240,954,050...240,958,101
Ensembl chr 1:240,954,452...240,958,384

G

midkine

multiple interactions

gefitinib inhibits the reaction [TGFA protein results in increased expression of MDK mRNA]

NCBI chr 3:77,901,134...77,903,997
Ensembl chr 3:77,901,158...77,903,130

G

MHC class I polypeptide-related sequence B

increases expression

Gefitinib results in increased expression of MICB protein

NCBI chr 1:78,495,779...78,513,030
Ensembl chr 1:78,495,779...78,512,827

G

MHC I like leukocyte 1

increases expression

Gefitinib results in increased expression of MICA protein

NCBI chr 1:78,372,798...78,398,932
Ensembl chr 1:78,372,802...78,398,930

G

marker of proliferation Ki-67

multiple interactions

[Gefitinib co-treated with betulin] results in decreased expression of MKI67 protein

NCBI chr 1:190,496,319...190,522,983
Ensembl chr 1:190,496,319...190,522,762

G

mutL homolog 1

decreases expression

gefitinib results in decreased expression of MLH1 mRNA

NCBI chr 8:111,196,468...111,233,721
Ensembl chr 8:111,196,468...111,233,617

G

matrix metallopeptidase 1

decreases expression

Gefitinib results in decreased expression of MMP1 mRNA

NCBI chr 8:4,658,588...4,679,099
Ensembl chr 8:4,658,588...4,679,097

G

matrix metallopeptidase 9

multiple interactions
decreases expression

gefitinib inhibits the reaction [TNF protein results in increased expression of MMP9 mRNA]
Gefitinib results in decreased expression of MMP9 mRNA; Gefitinib results in decreased expression of MMP9 protein
gefitinib inhibits the reaction [HBEGF protein inhibits the reaction [sodium arsenite results in increased expression of and results in increased secretion of and results in increased activity of MMP9 protein]]
gefitinib inhibits the reaction [EGF protein results in increased expression of MMP9 protein]; gefitinib inhibits the reaction [lysophosphatidic acid results in increased expression of MMP9 mRNA]; gefitinib promotes the reaction [resveratrol inhibits the reaction [EGF protein results in increased expression of MMP9 mRNA]]; gefitinib promotes the reaction [resveratrol inhibits the reaction [lysophosphatidic acid results in increased expression of MMP9 mRNA]]; resveratrol promotes the reaction [gefitinib inhibits the reaction [EGF protein results in increased expression of MMP9 mRNA]]; resveratrol promotes the reaction [gefitinib inhibits the reaction [lysophosphatidic acid results in increased expression of MMP9 mRNA]]

PMID:15841081 PMID:23127547 PMID:27087131 PMID:29228391 PMID:35317323 More...

NCBI chr 3:153,684,158...153,692,118
Ensembl chr 3:153,683,858...153,692,120

G

major histocompatibility complex, class I-related

affects expression

gefitinib affects the expression of MR1 mRNA

NCBI chr13:67,298,362...67,317,985
Ensembl chr13:67,299,585...67,317,970

G

metallothionein 2A

multiple interactions

[Buthionine Sulfoximine co-treated with Gefitinib] results in increased expression of MT2 mRNA

NCBI chr19:10,832,009...10,832,783
Ensembl chr19:10,832,002...10,832,784

G

mechanistic target of rapamycin kinase

decreases phosphorylation

gefitinib results in decreased phosphorylation of MTOR protein

NCBI chr 5:158,884,856...158,994,311
Ensembl chr 5:158,884,804...158,994,311

G

mucin 5AC, oligomeric mucus/gel-forming

multiple interactions

gefitinib inhibits the reaction [Tobacco Smoke Pollution results in increased expression of MUC5AC mRNA]; gefitinib inhibits the reaction [Tobacco Smoke Pollution results in increased expression of MUC5AC protein]

NCBI chr 1:196,864,336...196,896,475
Ensembl chr 1:196,864,336...196,896,475

G

murinoglobulin 1

multiple interactions

[gefitinib co-treated with naphthalene] affects the expression of MUG1 mRNA

NCBI chr 4:155,076,270...155,130,051
Ensembl chr 4:155,076,312...155,130,051

G

MYC proto-oncogene, bHLH transcription factor

decreases expression

gefitinib results in decreased expression of MYC protein

NCBI chr 7:93,593,705...93,598,633
Ensembl chr 7:93,593,705...93,598,630

G

myosin heavy chain 7

increases expression

gefitinib results in increased expression of MYH7 mRNA; gefitinib results in increased expression of MYH7 protein

NCBI chr15:28,446,550...28,469,888
Ensembl chr15:28,446,550...28,468,217

G

NADH:ubiquinone oxidoreductase complex assembly factor 4

multiple interactions

[gefitinib co-treated with naphthalene] affects the expression of NDUFAF4 mRNA

NCBI chr 5:38,605,169...38,610,341
Ensembl chr 5:38,605,153...38,610,336

G

nestin

multiple interactions

Gefitinib inhibits the reaction [astragaloside VI results in increased expression of NES protein]

NCBI chr 2:173,437,867...173,447,777
Ensembl chr 2:173,438,734...173,447,777

G

nuclear factor kappa B subunit 1

decreases expression

gefitinib results in decreased expression of NFKB1 mRNA

NCBI chr 2:224,016,214...224,132,135
Ensembl chr 2:224,016,214...224,110,404

G

NFKB inhibitor alpha

multiple interactions

[AURKA results in increased degradation of NFKBIA protein] which results in decreased susceptibility to gefitinib

NCBI chr 6:72,858,713...72,861,941
Ensembl chr 6:72,858,712...72,861,941

G

natriuretic peptide A

increases expression
multiple interactions

Gefitinib results in increased expression of NPPA mRNA; Gefitinib results in increased expression of NPPA protein
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one promotes the reaction [Gefitinib results in increased expression of NPPA mRNA]

NCBI chr 5:158,429,042...158,430,351
Ensembl chr 5:158,429,042...158,430,351

G

natriuretic peptide B

increases expression

gefitinib results in increased expression of NPPB mRNA; gefitinib results in increased expression of NPPB protein

NCBI chr 5:158,416,813...158,418,175
Ensembl chr 5:158,416,866...158,418,168

G

neuronal pentraxin 2

decreases expression

gefitinib results in decreased expression of NPTX2 mRNA

NCBI chr12:10,037,435...10,048,345
Ensembl chr12:10,037,435...10,048,345

G

neural retina leucine zipper

decreases expression

gefitinib results in decreased expression of NRL mRNA

NCBI chr15:29,007,059...29,011,480
Ensembl chr15:29,008,104...29,009,832

G

oncostatin M receptor

affects response to substance

OSMR protein affects the susceptibility to gefitinib

NCBI chr 2:55,907,119...55,961,373
Ensembl chr 2:55,907,132...55,961,262

G

poly (ADP-ribose) polymerase 1

multiple interactions
increases expression
increases cleavage

Betulinic Acid promotes the reaction [Gefitinib results in increased cleavage of PARP1 protein]; Gefitinib affects the reaction [Oxaliplatin results in increased cleavage of PARP1 protein]
[Gefitinib results in increased secretion of CCL2 protein] inhibits the reaction [Gefitinib results in increased expression of PARP1 protein modified form]
gefitinib results in increased cleavage of PARP1 protein

PMID:16243822 PMID:23523951 PMID:30136359 PMID:33248157

NCBI chr13:92,307,593...92,339,406
Ensembl chr13:92,307,586...92,339,404

G

proliferating cell nuclear antigen

multiple interactions

Gefitinib inhibits the reaction [Folic Acid results in increased expression of PCNA protein]

NCBI chr 3:119,499,039...119,502,911
Ensembl chr 3:119,498,810...119,502,995

G

pericentrin

decreases response to substance

PCNT protein results in decreased susceptibility to gefitinib

NCBI chr20:12,190,597...12,278,723
Ensembl chr20:12,191,648...12,278,710

G

PDZ domain containing 1

multiple interactions

Gefitinib inhibits the reaction [tetrachlorodian results in increased expression of PDZK1 mRNA]

NCBI chr 2:184,376,161...184,407,514
Ensembl chr 2:184,376,161...184,407,514

G

platelet and endothelial cell adhesion molecule 1

multiple interactions
decreases expression

gefitinib inhibits the reaction [TGFA protein results in decreased expression of PECAM1 mRNA]
Gefitinib results in decreased expression of PECAM1 protein

PMID:18424623 PMID:35317323

NCBI chr10:91,590,521...91,652,279
Ensembl chr10:91,590,521...91,652,116

G

progesterone receptor membrane component 1

decreases response to substance

PGRMC1 protein results in decreased susceptibility to gefitinib

NCBI chr X:115,832,865...115,841,060
Ensembl chr X:115,832,884...115,888,682

G

pleckstrin homology-like domain, family A, member 2

affects response to substance

PHLDA2 protein affects the susceptibility to gefitinib

NCBI chr 1:198,696,897...198,699,292
Ensembl chr 1:198,696,897...198,697,836

G

plasminogen activator, urokinase

multiple interactions

gefitinib inhibits the reaction [lysophosphatidic acid results in increased expression of PLAU mRNA]; gefitinib promotes the reaction [resveratrol inhibits the reaction [EGF protein results in increased expression of PLAU mRNA]]; gefitinib promotes the reaction [resveratrol inhibits the reaction [lysophosphatidic acid results in increased expression of PLAU mRNA]]; resveratrol promotes the reaction [gefitinib inhibits the reaction [EGF protein results in increased expression of PLAU mRNA]]; resveratrol promotes the reaction [gefitinib inhibits the reaction [lysophosphatidic acid results in increased expression of PLAU mRNA]]

NCBI chr15:3,456,230...3,462,732
Ensembl chr15:3,456,232...3,462,775

G

phospholipase B domain containing 1

affects response to substance

PLBD1 protein affects the susceptibility to gefitinib

NCBI chr 4:169,472,983...169,529,277
Ensembl chr 4:169,472,983...169,529,277

G

phosphatase and tensin homolog

multiple interactions
increases expression

2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one promotes the reaction [Gefitinib results in increased expression of PTEN mRNA]
Gefitinib results in increased expression of PTEN mRNA; Gefitinib results in increased expression of PTEN protein; Gefitinib results in increased expression of PTEN protein modified form

NCBI chr 1:230,630,443...230,697,070
Ensembl chr 1:230,630,338...230,696,838

G

prostaglandin-endoperoxide synthase 2

multiple interactions

gefitinib promotes the reaction [[zoledronic acid co-treated with 4-(5-(4-chlorophenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl)benzenesulfonamide] results in decreased expression of PTGS2 protein]
gefitinib inhibits the reaction [Cadmium Chloride results in increased expression of PTGS2 protein]

PMID:16322342 PMID:23948867

NCBI chr13:62,163,936...62,172,193
Ensembl chr13:62,163,932...62,172,188

G

PTTG1 regulator of sister chromatid separation, securin

multiple interactions
decreases response to substance

gefitinib results in decreased stability of and results in decreased expression of PTTG1 protein
PTTG1 protein results in decreased susceptibility to gefitinib

NCBI chr10:27,893,466...27,904,965
Ensembl chr10:27,893,689...27,904,837

G

quiescin sulfhydryl oxidase 1

increases expression

gefitinib results in increased expression of QSOX1 mRNA

NCBI chr13:67,949,780...67,987,434
Ensembl chr13:67,949,780...67,987,459

G

RAD51 recombinase

affects response to substance

RAD51 protein affects the susceptibility to Gefitinib

NCBI chr 3:106,099,753...106,125,038
Ensembl chr 3:106,100,381...106,125,035

G

RB transcriptional corepressor 1

multiple interactions
decreases expression

Betulinic Acid promotes the reaction [Gefitinib results in decreased expression of RB1 protein modified form]; Gefitinib promotes the reaction [Betulinic Acid results in decreased expression of RB1 protein modified form]

NCBI chr15:48,371,295...48,502,473
Ensembl chr15:48,371,296...48,502,302

G

RNA binding motif protein 7

affects response to substance

RBM7 protein affects the susceptibility to gefitinib

NCBI chr 8:48,831,894...48,838,399
Ensembl chr 8:48,831,894...48,838,411

G

RELA proto-oncogene, NF-kB subunit

multiple interactions
decreases response to substance

gefitinib inhibits the reaction [EGF protein results in increased phosphorylation of RELA protein]
RELA protein results in decreased susceptibility to gefitinib

PMID:19318490 PMID:21216229

NCBI chr 1:202,925,001...202,935,484
Ensembl chr 1:202,924,945...202,935,484

G

replication protein A1

increases expression

gefitinib results in increased expression of RPA1 mRNA

NCBI chr10:60,148,869...60,199,970
Ensembl chr10:60,148,793...60,199,949

G

ribosomal protein S6 kinase B1

decreases phosphorylation

gefitinib results in decreased phosphorylation of RPS6KB1 protein

NCBI chr10:71,323,777...71,367,908
Ensembl chr10:71,323,777...71,367,908

G

ribonucleotide reductase catalytic subunit M1

affects response to substance

RRM1 gene polymorphism affects the susceptibility to gefitinib

NCBI chr 1:156,823,960...156,848,262
Ensembl chr 1:156,823,960...156,848,261

G

RT1 class I, locus CE5

affects expression

gefitinib affects the expression of HLA-F mRNA

NCBI chr20:3,403,418...3,479,476

G

RT1 class II, locus Db1

affects expression

gefitinib affects the expression of HLA-DRB1 mRNA

NCBI chr20:4,548,664...4,558,237
Ensembl chr20:4,548,666...4,558,258

G

RT1 class II, locus DOa

affects expression

gefitinib affects the expression of HLA-DOA mRNA

NCBI chr20:4,753,587...4,756,590
Ensembl chr20:4,753,598...4,756,577

G

S100 calcium binding protein A6

multiple interactions

[gefitinib co-treated with naphthalene] affects the expression of S100A6 mRNA

NCBI chr 2:176,100,619...176,102,181
Ensembl chr 2:176,100,899...176,102,180

G

S100 calcium binding protein A8

multiple interactions

[gefitinib co-treated with naphthalene] affects the expression of S100A8 mRNA; [gefitinib co-treated with naphthalene] affects the expression of S100A8 protein

NCBI chr 2:176,166,517...176,167,645
Ensembl chr 2:176,167,124...176,167,643

G

serpin family F member 1

multiple interactions

gefitinib inhibits the reaction [TGFA protein results in increased expression of SERPINF1 mRNA]

NCBI chr10:60,250,198...60,262,593
Ensembl chr10:60,249,708...60,262,646

G

stratifin

decreases expression

gefitinib results in decreased expression of SFN mRNA

NCBI chr 5:145,826,722...145,827,994
Ensembl chr 5:145,826,201...145,831,314

G

Ski proto-oncogene

increases expression

gefitinib results in increased expression of SKI mRNA

NCBI chr 5:165,713,525...165,782,134
Ensembl chr 5:165,714,093...165,782,733

G

solute carrier family 10, member 3

multiple interactions

[gefitinib co-treated with naphthalene] affects the expression of SLC10A3 mRNA

NCBI chr X:152,154,757...152,158,563
Ensembl chr X:152,151,076...152,162,958

G

snail family transcriptional repressor 2

affects response to substance

SNAI2 protein affects the susceptibility to gefitinib

NCBI chr11:86,182,788...86,186,203
Ensembl chr11:86,181,909...86,186,200

G

suppressor of cytokine signaling 2

decreases expression
multiple interactions

Gefitinib results in decreased expression of SOCS2 mRNA
SOCS2 protein affects the reaction [[MIR578 affects the susceptibility to Gefitinib] which affects the expression of BECN1 protein]; SOCS2 protein affects the reaction [[MIR578 affects the susceptibility to Gefitinib] which affects the expression of SQSTM1 protein]; SOCS2 protein affects the reaction [[MIR578 affects the susceptibility to Gefitinib] which affects the lipidation of MAP1LC3B protein]; SOCS2 protein affects the reaction [MIR578 affects the susceptibility to Gefitinib]

NCBI chr 7:30,006,360...30,045,161
Ensembl chr 7:30,008,578...30,043,548

G

SRY-box transcription factor 17

decreases localization

gefitinib results in decreased localization of SOX17 protein

NCBI chr 5:15,016,660...15,022,228
Ensembl chr 5:15,016,731...15,022,228

G

sequestosome 1

multiple interactions
decreases expression

[Gefitinib co-treated with Cisplatin] results in decreased expression of SQSTM1 protein; [MIR578 affects the susceptibility to Gefitinib] which affects the expression of SQSTM1 protein; EGFR gene mutant form promotes the reaction [Gefitinib results in decreased expression of SQSTM1 protein]; SOCS2 protein affects the reaction [[MIR578 affects the susceptibility to Gefitinib] which affects the expression of SQSTM1 protein]

PMID:25979647 PMID:27639429 PMID:37948135

NCBI chr10:34,525,517...34,536,670
Ensembl chr10:34,525,519...34,536,673

G

sterol regulatory element binding transcription factor 1

multiple interactions

[Gefitinib co-treated with betulin] results in decreased expression of SREBF1 protein

NCBI chr10:45,007,637...45,029,650
Ensembl chr10:45,007,637...45,029,650

G

serum response factor

multiple interactions

Gefitinib inhibits the reaction [tetrachlorodian results in increased expression of SRF mRNA]

NCBI chr 9:14,426,453...14,435,734
Ensembl chr 9:14,426,472...14,435,733

G

signal transducer and activator of transcription 3

multiple interactions

[cucurbitacin B co-treated with Gefitinib] results in decreased phosphorylation of STAT3 protein; Gefitinib inhibits the reaction [EGF protein results in increased phosphorylation of STAT3 protein]; Gefitinib inhibits the reaction [EGF results in increased phosphorylation of STAT3 protein]
gefitinib inhibits the reaction [Cadmium Chloride results in increased expression of STAT3 mRNA]; gefitinib inhibits the reaction [Cadmium Chloride results in increased phosphorylation of STAT3 protein]

PMID:19318490 PMID:21787763 PMID:23948867 PMID:26183715

NCBI chr10:85,811,206...85,863,057
Ensembl chr10:85,811,218...85,863,057

G

synaptopodin

multiple interactions

[gefitinib co-treated with naphthalene] affects the expression of SYNPO mRNA

NCBI chr18:54,048,299...54,106,388
Ensembl chr18:54,026,152...54,102,126

G

TEK receptor tyrosine kinase

multiple interactions

gefitinib inhibits the reaction [TGFA protein results in decreased expression of TEK mRNA]

NCBI chr 5:109,607,077...109,733,805
Ensembl chr 5:109,607,077...109,733,804

G

telomerase reverse transcriptase

decreases expression

gefitinib results in decreased expression of TERT mRNA

NCBI chr 1:29,637,213...29,659,561
Ensembl chr 1:29,637,506...29,659,561

G

transcription factor AP-2 alpha

multiple interactions

gefitinib inhibits the reaction [TFAP2A protein binds to ULBP1 promoter]; Tetradecanoylphorbol Acetate inhibits the reaction [gefitinib inhibits the reaction [TFAP2A protein binds to ULBP1 promoter]]

PMID:21499124 PMID:21951556

NCBI chr17:24,028,716...24,047,507
Ensembl chr17:24,024,432...24,047,507

G

transforming growth factor alpha

decreases response to substance
multiple interactions

TGFA protein results in decreased susceptibility to gefitinib
gefitinib inhibits the reaction [TGFA protein results in decreased expression of EDNRB mRNA]; gefitinib inhibits the reaction [TGFA protein results in decreased expression of FOXF1 mRNA]; gefitinib inhibits the reaction [TGFA protein results in decreased expression of KDR mRNA]; gefitinib inhibits the reaction [TGFA protein results in decreased expression of PECAM1 mRNA]; gefitinib inhibits the reaction [TGFA protein results in decreased expression of TEK mRNA]; gefitinib inhibits the reaction [TGFA protein results in decreased expression of VEGFA mRNA]; gefitinib inhibits the reaction [TGFA protein results in increased expression of MDK mRNA]; gefitinib inhibits the reaction [TGFA protein results in increased expression of SERPINF1 mRNA]
5-((2,6-dichlorobenzyl)sulfonyl)-3-((3,5-dimethyl-4-((2-(pyrrolidin-1-ylmethyl)pyrrolidin-1-yl)carbonyl)-1H-pyrrol-2-yl)methylene)-1,3-dihydro-2H-indol-2-one promotes the reaction [gefitinib inhibits the reaction [TGFA protein results in increased susceptibility to 5-((2,6-dichlorobenzyl)sulfonyl)-3-((3,5-dimethyl-4-((2-(pyrrolidin-1-ylmethyl)pyrrolidin-1-yl)carbonyl)-1H-pyrrol-2-yl)methylene)-1,3-dihydro-2H-indol-2-one]]; gefitinib inhibits the reaction [irinotecan metabolite results in increased secretion of TGFA protein]; gefitinib inhibits the reaction [irinotecan results in increased secretion of TGFA protein]; gefitinib inhibits the reaction [TGFA protein results in increased susceptibility to 5-((2,6-dichlorobenzyl)sulfonyl)-3-((3,5-dimethyl-4-((2-(pyrrolidin-1-ylmethyl)pyrrolidin-1-yl)carbonyl)-1H-pyrrol-2-yl)methylene)-1,3-dihydro-2H-indol-2-one]

PMID:15723263 PMID:16230376 PMID:18424623 PMID:21266357

NCBI chr 4:118,618,043...118,700,897
Ensembl chr 4:118,618,269...118,700,894

G

tumor necrosis factor

multiple interactions
decreases expression

Gefitinib inhibits the reaction [Cadmium Chloride results in increased expression of TNF mRNA]; Gefitinib inhibits the reaction [Cadmium Chloride results in increased expression of TNF protein]; Gefitinib inhibits the reaction [TNF protein results in increased expression of ITGAV mRNA]; Gefitinib inhibits the reaction [TNF protein results in increased expression of MMP9 mRNA]
Gefitinib results in decreased expression of TNF mRNA
Gefitinib results in decreased expression of and results in decreased secretion of TNF protein

PMID:15841081 PMID:23948867 PMID:35317323

NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629

G

TNF receptor superfamily member 1B

decreases expression

gefitinib results in decreased expression of TNFRSF1B mRNA

NCBI chr 5:157,070,642...157,104,216
Ensembl chr 5:157,070,642...157,104,206

G

troponin I3, cardiac type

increases secretion

Gefitinib results in increased secretion of TNNI3 protein

NCBI chr 1:69,299,900...69,303,582
Ensembl chr 1:69,299,900...69,303,580

G

tumor protein p53

multiple interactions
increases expression
affects response to substance

[TP53 protein results in decreased expression of AURKA protein] which results in increased susceptibility to Gefitinib; Gefitinib inhibits the reaction [bisphenol A results in increased phosphorylation of TP53 protein]
gefitinib results in increased expression of TP53 mRNA; gefitinib results in increased expression of TP53 protein
TP53 protein affects the susceptibility to gefitinib

PMID:21216229 PMID:27084042 PMID:29383186

NCBI chr10:54,300,070...54,311,525
Ensembl chr10:54,300,048...54,311,524

G

tripartite motif-containing 23

multiple interactions

[gefitinib co-treated with naphthalene] affects the expression of TRIM23 mRNA

NCBI chr 2:35,302,405...35,335,746
Ensembl chr 2:35,302,409...35,335,743

G

TSC22 domain family, member 1

multiple interactions

[gefitinib co-treated with naphthalene] affects the expression of TSC22D1 mRNA

NCBI chr15:51,750,489...51,850,958
Ensembl chr15:51,749,510...51,850,958

G

twist family bHLH transcription factor 1

affects response to substance

TWIST1 protein affects the susceptibility to Gefitinib

NCBI chr 6:50,674,910...50,676,904
Ensembl chr 6:50,674,678...50,677,653

G

thymidylate synthetase

decreases expression
multiple interactions

Gefitinib results in decreased expression of TYMS mRNA; Gefitinib results in decreased expression of TYMS protein
Betulinic Acid promotes the reaction [Gefitinib results in decreased expression of TYMS protein]; Gefitinib promotes the reaction [Betulinic Acid results in decreased expression of TYMS protein]; TYMS protein affects the susceptibility to [Gefitinib co-treated with S 1 (combination)]

PMID:18347146 PMID:30136359

NCBI chr 9:113,313,454...113,329,551
Ensembl chr 9:113,313,452...113,329,536

G

UL16 binding protein 1

multiple interactions
increases expression

Gefitinib inhibits the reaction [TFAP2A protein binds to ULBP1 promoter]; Tetradecanoylphorbol Acetate inhibits the reaction [Gefitinib inhibits the reaction [TFAP2A protein binds to ULBP1 promoter]]; Tetradecanoylphorbol Acetate inhibits the reaction [Gefitinib results in increased expression of ULBP1 mRNA]
Gefitinib results in increased expression of ULBP1 mRNA; Gefitinib results in increased expression of ULBP1 protein

PMID:21499124 PMID:21951556

NCBI chr 1:1,694,255...1,716,160

G

vascular endothelial growth factor A

multiple interactions
decreases secretion
decreases expression

gefitinib inhibits the reaction [TGFA protein results in decreased expression of VEGFA mRNA]
Gefitinib results in decreased secretion of VEGFA protein
Gefitinib results in decreased expression of VEGFA mRNA; Gefitinib results in decreased expression of VEGFA protein
gefitinib results in decreased expression of VEGFA protein

PMID:15660382 PMID:18424623 PMID:35317323 PMID:38517198

NCBI chr 9:14,955,300...14,970,641
Ensembl chr 9:14,955,300...14,970,641

G

vimentin

multiple interactions
decreases expression

[Gefitinib results in increased secretion of CCL2 protein] which results in increased expression of VIM protein; Gefitinib inhibits the reaction [Folic Acid results in increased expression of VIM protein]
Gefitinib results in decreased expression of VIM protein

PMID:23255615 PMID:33248157 PMID:38517198

NCBI chr17:76,668,701...76,677,186
Ensembl chr17:76,668,647...76,677,187

G

X-ray repair cross complementing 1

affects response to substance

XRCC1 protein polymorphism affects the susceptibility to gefitinib

NCBI chr 1:80,140,495...80,168,705
Ensembl chr 1:80,141,207...80,168,701

G

zinc finger CCCH type containing 3

multiple interactions

[gefitinib co-treated with naphthalene] affects the expression of ZC3H3 mRNA

NCBI chr 7:107,440,694...107,525,451
Ensembl chr 7:107,440,694...107,525,451

osimertinib

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

AKT serine/threonine kinase 1

multiple interactions
decreases phosphorylation

osimertinib affects the reaction [EGF protein results in increased phosphorylation of AKT1 protein]; osimertinib inhibits the reaction [Derp2 allergen, Dermatophagoides pteronyssinus results in increased phosphorylation of AKT1 protein]; osimertinib results in decreased expression of and results in decreased phosphorylation of AKT1 protein
osimertinib decreases phosphorylation of AKT1 protein in lung
osimertinib results in decreased phosphorylation of AKT1 protein

CTD
RGD

PMID:30145802 PMID:30623574 PMID:30993382 PMID:36807944 PMID:32276600

NCBI chr 6:131,713,716...131,735,319
Ensembl chr 6:131,713,720...131,733,921

G

baculoviral IAP repeat-containing 5

decreases expression

osimertinib results in decreased expression of BIRC5 protein

NCBI chr10:103,072,530...103,081,382
Ensembl chr10:103,073,408...103,081,380

G

caspase 3

multiple interactions
increases expression

[ginsenoside Rg3 co-treated with osimertinib] results in increased cleavage of CASP3 protein; Acetylcysteine inhibits the reaction [osimertinib results in increased expression of CASP3 protein modified form]; CAT protein inhibits the reaction [osimertinib results in increased expression of CASP3 protein modified form]; Vitamin E inhibits the reaction [osimertinib results in increased expression of CASP3 protein modified form]

PMID:28237877 PMID:31916386

NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648

G

catalase

multiple interactions
decreases response to substance

CAT protein inhibits the reaction [osimertinib results in increased abundance of Hydrogen Peroxide]; CAT protein inhibits the reaction [osimertinib results in increased expression of CASP3 protein modified form]; CAT protein inhibits the reaction [osimertinib results in increased expression of PARP1 protein modified form]
CAT protein results in decreased susceptibility to osimertinib

NCBI chr 3:89,842,393...89,874,577
Ensembl chr 3:89,842,399...89,874,478

G

CF transmembrane conductance regulator

multiple interactions

osimertinib inhibits the reaction [Dronabinol results in decreased expression of and results in decreased activity of CFTR protein]

NCBI chr 4:46,561,269...46,728,759
Ensembl chr 4:46,560,885...46,728,756

G

epidermal growth factor

multiple interactions

osimertinib affects the reaction [EGF protein results in increased phosphorylation of AKT1 protein]; osimertinib affects the reaction [EGF protein results in increased phosphorylation of EGFR protein]; osimertinib affects the reaction [EGF protein results in increased phosphorylation of MAPK1 protein]; osimertinib affects the reaction [EGF protein results in increased phosphorylation of MAPK3 protein]; osimertinib affects the reaction [EGF protein results in increased phosphorylation of STAT3 protein]

NCBI chr 2:218,219,408...218,302,359
Ensembl chr 2:218,219,415...218,302,064

G

epidermal growth factor receptor

multiple interactions
decreases activity
decreases phosphorylation

osimertinib affects the reaction [EGF protein results in increased phosphorylation of EGFR protein]; osimertinib inhibits the reaction [EGFR protein mutant form results in decreased susceptibility to Gefitinib]; osimertinib promotes the reaction [Derp2 allergen, Dermatophagoides pteronyssinus results in increased phosphorylation of EGFR protein]; osimertinib results in decreased expression of and results in decreased phosphorylation of EGFR protein
osimertinib results in decreased activity of EGFR protein
osimertinib decreases phosphorylation of EGFR protein in lung
osimertinib results in decreased phosphorylation of EGFR protein

CTD
RGD

PMID:28237877 PMID:30145802 PMID:30623574 PMID:30993382 PMID:35970427 More...

NCBI chr14:91,176,979...91,349,722
Ensembl chr14:91,177,067...91,344,382

G

glutamic--pyruvic transaminase

increases secretion

osimertinib results in increased secretion of GPT protein

NCBI chr 7:108,416,646...108,419,495
Ensembl chr 7:108,416,642...108,419,494

G

interleukin 6

multiple interactions

osimertinib inhibits the reaction [Derp2 allergen, Dermatophagoides pteronyssinus results in increased expression of IL6 mRNA]; osimertinib inhibits the reaction [Derp2 allergen, Dermatophagoides pteronyssinus results in increased secretion of IL6 protein]

NCBI chr 4:5,214,602...5,219,178
Ensembl chr 4:5,213,394...5,219,178

G

lactate dehydrogenase A

increases secretion

osimertinib results in increased secretion of LDHA protein

NCBI chr 1:97,371,823...97,381,247
Ensembl chr 1:97,366,021...97,433,472

G

mitogen activated protein kinase 1

multiple interactions
decreases phosphorylation

osimertinib affects the reaction [EGF protein results in increased phosphorylation of MAPK1 protein]; osimertinib inhibits the reaction [Dronabinol results in increased phosphorylation of MAPK1 protein]; osimertinib results in decreased expression of and results in increased phosphorylation of MAPK1 protein
osimertinib results in decreased phosphorylation of MAPK1 protein

PMID:29928919 PMID:30623574 PMID:30993382 PMID:34861243 PMID:36807944

NCBI chr11:83,957,813...84,023,629
Ensembl chr11:83,957,813...84,023,616

G

mitogen activated protein kinase 3

multiple interactions
decreases phosphorylation

osimertinib affects the reaction [EGF protein results in increased phosphorylation of MAPK3 protein]; osimertinib inhibits the reaction [Dronabinol results in increased phosphorylation of MAPK3 protein]; osimertinib results in decreased expression of and results in increased phosphorylation of MAPK3 protein
osimertinib results in decreased phosphorylation of MAPK3 protein

PMID:29928919 PMID:30623574 PMID:30993382 PMID:34861243 PMID:36807944

NCBI chr 1:181,366,646...181,372,863
Ensembl chr 1:181,366,637...181,372,863

G

MCL1 apoptosis regulator, BCL2 family member

decreases expression

osimertinib decreases expression of MCL1 protein in lung

RGD

PMID:31301315 PMID:32276600

RGD:151356917, RGD:151357000

NCBI chr 2:183,219,137...183,235,676
Ensembl chr 2:183,219,220...183,222,303

G

MET proto-oncogene, receptor tyrosine kinase

multiple interactions

osimertinib results in decreased expression of and results in decreased phosphorylation of MET protein

NCBI chr 4:45,790,456...45,898,139
Ensembl chr 4:45,790,791...45,897,876

G

marker of proliferation Ki-67

multiple interactions

[ginsenoside Rg3 co-treated with osimertinib] results in decreased expression of MKI67 protein

NCBI chr 1:190,496,319...190,522,983
Ensembl chr 1:190,496,319...190,522,762

G

poly (ADP-ribose) polymerase 1

increases expression
multiple interactions
increases cleavage

osimertinib results in increased expression of PARP1 protein modified form
[ginsenoside Rg3 co-treated with osimertinib] results in increased cleavage of PARP1 protein; [TWIST1 protein results in decreased susceptibility to osimertinib] which results in decreased cleavage of PARP1 protein; Acetylcysteine inhibits the reaction [osimertinib results in increased expression of PARP1 protein modified form]; CAT protein inhibits the reaction [osimertinib results in increased expression of PARP1 protein modified form]; TWIST1 protein inhibits the reaction [osimertinib results in increased cleavage of PARP1 protein]; Vitamin E inhibits the reaction [osimertinib results in increased expression of PARP1 protein modified form]

PMID:28237877 PMID:30171258 PMID:31916386

NCBI chr13:92,307,593...92,339,406
Ensembl chr13:92,307,586...92,339,404

G

sequestosome 1

decreases expression

osimertinib results in decreased expression of SQSTM1 protein

NCBI chr10:34,525,517...34,536,670
Ensembl chr10:34,525,519...34,536,673

G

signal transducer and activator of transcription 3

multiple interactions
decreases phosphorylation

osimertinib affects the reaction [EGF protein results in increased phosphorylation of STAT3 protein]; osimertinib inhibits the reaction [Derp2 allergen, Dermatophagoides pteronyssinus results in increased phosphorylation of STAT3 protein]
osimertinib results in decreased phosphorylation of STAT3 protein

PMID:30623574 PMID:35970427

NCBI chr10:85,811,206...85,863,057
Ensembl chr10:85,811,218...85,863,057

G

twist family bHLH transcription factor 1

decreases response to substance
affects response to substance
multiple interactions

TWIST1 protein results in decreased susceptibility to osimertinib
TWIST1 protein affects the susceptibility to osimertinib
[TWIST1 protein results in decreased susceptibility to osimertinib] which results in decreased cleavage of PARP1 protein; TWIST1 protein inhibits the reaction [osimertinib results in increased cleavage of PARP1 protein]

PMID:30171258 PMID:30993382

NCBI chr 6:50,674,910...50,676,904
Ensembl chr 6:50,674,678...50,677,653

G

UDP glucuronosyltransferase family 1 member A1

multiple interactions
decreases activity

osimertinib inhibits the reaction [UGT1A1 protein results in increased glucuronidation of Hymecromone]
osimertinib results in decreased activity of UGT1A1 protein

NCBI chr 9:88,801,344...88,808,465
Ensembl chr 9:88,713,184...88,808,465

G

UDP glucuronosyltransferase 1 family, polypeptide A2

decreases activity

osimertinib results in decreased activity of UGT1A3 protein

NCBI chr 9:88,791,216...88,808,465
Ensembl chr 9:88,713,184...88,808,465

G

UDP glucuronosyltransferase family 1 member A6

decreases activity

osimertinib results in decreased activity of UGT1A6 protein

NCBI chr 9:88,747,213...88,808,465
Ensembl chr 9:88,713,184...88,808,465

G

UDP glucuronosyltransferase family 2 member B7

decreases activity

osimertinib results in decreased activity of UGT2B7 protein

NCBI chr14:20,896,682...20,919,604
Ensembl chr14:20,896,682...20,919,604

PD 168393

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

angiotensinogen

multiple interactions

PD168393 inhibits the reaction [AGT protein promotes the reaction [SP1 protein binds to TGFB1 promoter]]; PD168393 inhibits the reaction [AGT protein results in increased expression of SP1 mRNA]; PD168393 inhibits the reaction [AGT protein results in increased phosphorylation of AKT1 protein]; PD168393 inhibits the reaction [AGT protein results in increased phosphorylation of EGFR protein]

NCBI chr19:52,529,139...52,549,618
Ensembl chr19:52,529,185...52,540,977

G

AKT serine/threonine kinase 1

multiple interactions

PD168393 inhibits the reaction [AGT protein results in increased phosphorylation of AKT1 protein]

NCBI chr 6:131,713,716...131,735,319
Ensembl chr 6:131,713,720...131,733,921

G

BCL2-associated agonist of cell death

multiple interactions

[PD168393 co-treated with Paclitaxel] results in increased expression of BAD protein

NCBI chr 1:204,133,502...204,142,829
Ensembl chr 1:204,131,501...204,142,823

G

caspase 3

multiple interactions

[PD168393 co-treated with Paclitaxel] results in increased cleavage of and results in increased activity of CASP3 protein

NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648

G

C-C motif chemokine ligand 2

multiple interactions
increases expression

PD168393 results in increased expression of and results in increased secretion of CCL2 protein; polydatin inhibits the reaction [PD168393 results in increased expression of CCL2 mRNA]; Quercetin inhibits the reaction [PD168393 results in increased expression of CCL2 mRNA]; Resveratrol inhibits the reaction [PD168393 results in increased expression of CCL2 mRNA]

NCBI chr10:67,005,424...67,007,222
Ensembl chr10:67,005,424...67,007,226

G

cyclin-dependent kinase inhibitor 1A

multiple interactions

[PD168393 co-treated with Paclitaxel] results in increased expression of CDKN1A protein

NCBI chr20:7,149,177...7,159,727
Ensembl chr20:7,149,217...7,159,585

G

C-X-C motif chemokine ligand 10

multiple interactions
increases expression

acteoside inhibits the reaction [PD168393 results in increased secretion of CXCL10 protein]; PD168393 results in increased expression of and results in increased secretion of CXCL10 protein; polydatin inhibits the reaction [PD168393 results in increased expression of CXCL10 mRNA]; Quercetin inhibits the reaction [PD168393 results in increased expression of CXCL10 mRNA]; Resveratrol inhibits the reaction [PD168393 results in increased expression of CXCL10 mRNA]; Resveratrol inhibits the reaction [PD168393 results in increased secretion of CXCL10 protein]

NCBI chr14:15,704,772...15,706,969
Ensembl chr14:15,704,758...15,706,975

G

cytochrome c, somatic

multiple interactions

[PD168393 co-treated with Paclitaxel] affects the localization of CYCS protein

NCBI chr 4:79,651,894...79,653,994
Ensembl chr 4:79,651,378...79,654,054
Ensembl chr18:79,651,378...79,654,054

G

epidermal growth factor receptor

affects localization
multiple interactions
decreases phosphorylation

PD168393 affects the localization of EGFR protein; PD168393 affects the localization of EGFR protein modified form
PD168393 inhibits the reaction [AGT protein results in increased phosphorylation of EGFR protein]
[PD168393 co-treated with Paclitaxel] results in decreased phosphorylation of EGFR protein; PD168393 inhibits the reaction [Resveratrol results in increased phosphorylation of EGFR protein]; PD168393 inhibits the reaction [TGFA protein affects the localization of EGFR protein modified form]; PD168393 inhibits the reaction [TGFA protein affects the localization of EGFR protein]
PD168393 results in decreased phosphorylation of EGFR protein

PMID:16413505 PMID:21967610 PMID:23527233 PMID:25398788

NCBI chr14:91,176,979...91,349,722
Ensembl chr14:91,177,067...91,344,382

G

Janus kinase 3

multiple interactions

PD168393 inhibits the reaction [2,2',4,6,6'-pentachlorobiphenyl results in increased phosphorylation of JAK3 protein]

NCBI chr16:18,386,330...18,398,542
Ensembl chr16:18,386,405...18,398,536

G

mitogen activated protein kinase 1

multiple interactions
decreases phosphorylation

[PD168393 co-treated with Paclitaxel] results in decreased phosphorylation of and results in decreased activity of MAPK1 protein; PD168393 inhibits the reaction [2,2',4,6,6'-pentachlorobiphenyl results in increased phosphorylation of MAPK1 protein]; PD168393 inhibits the reaction [Resveratrol results in increased phosphorylation of MAPK1 protein]
PD168393 results in decreased phosphorylation of MAPK1 protein

PMID:16413505 PMID:16778083 PMID:23527233

NCBI chr11:83,957,813...84,023,629
Ensembl chr11:83,957,813...84,023,616

G

mitogen activated protein kinase 3

multiple interactions
decreases phosphorylation

[PD168393 co-treated with Paclitaxel] results in decreased phosphorylation of and results in decreased activity of MAPK3 protein; PD168393 inhibits the reaction [2,2',4,6,6'-pentachlorobiphenyl results in increased phosphorylation of MAPK3 protein]; PD168393 inhibits the reaction [resveratrol results in increased phosphorylation of MAPK3 protein]
PD168393 results in decreased phosphorylation of MAPK3 protein

PMID:16413505 PMID:16778083 PMID:23527233

NCBI chr 1:181,366,646...181,372,863
Ensembl chr 1:181,366,637...181,372,863

G

mitogen-activated protein kinase 8

multiple interactions

PD168393 inhibits the reaction [2,2',4,6,6'-pentachlorobiphenyl results in increased phosphorylation of MAPK8 protein]

NCBI chr16:8,638,897...8,721,960
Ensembl chr16:8,638,924...8,721,981

G

matrix metallopeptidase 3

multiple interactions

PD168393 inhibits the reaction [2,2',4,6,6'-pentachlorobiphenyl results in increased expression of MMP3 mRNA]

NCBI chr 8:4,640,397...4,653,963
Ensembl chr 8:4,640,416...4,653,961

G

Sp1 transcription factor

multiple interactions

PD168393 inhibits the reaction [AGT protein promotes the reaction [SP1 protein binds to TGFB1 promoter]]; PD168393 inhibits the reaction [AGT protein results in increased expression of SP1 mRNA]

NCBI chr 7:133,541,302...133,571,961
Ensembl chr 7:133,541,491...133,571,961

G

sterol regulatory element binding transcription factor 1

multiple interactions

PD168393 inhibits the reaction [Glucose results in increased activity of and results in increased cleavage of SREBF1 protein]

NCBI chr10:45,007,637...45,029,650
Ensembl chr10:45,007,637...45,029,650

G

transforming growth factor alpha

multiple interactions

PD168393 inhibits the reaction [TGFA protein affects the localization of EGFR protein modified form]; PD168393 inhibits the reaction [TGFA protein affects the localization of EGFR protein]

NCBI chr 4:118,618,043...118,700,897
Ensembl chr 4:118,618,269...118,700,894

G

transforming growth factor, beta 1

multiple interactions

PD168393 inhibits the reaction [AGT protein promotes the reaction [SP1 protein binds to TGFB1 promoter]]

NCBI chr 1:81,196,532...81,212,848
Ensembl chr 1:81,196,532...81,212,847

G

tumor protein p53

multiple interactions

[PD168393 co-treated with Paclitaxel] results in increased expression of TP53 protein

NCBI chr10:54,300,070...54,311,525
Ensembl chr10:54,300,048...54,311,524

tyrphostin AG 1478

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

ATP binding cassette subfamily C member 2

multiple interactions

RTKI cpd inhibits the reaction [estradiol-17 beta-glucuronide affects the localization of and results in decreased activity of ABCC2 protein]

NCBI chr 1:242,664,657...242,723,239
Ensembl chr 1:242,664,657...242,723,238

G

angiotensin I converting enzyme

multiple interactions

RTKI cpd inhibits the reaction [Aldosterone results in increased expression of ACE mRNA]

NCBI chr10:90,910,316...90,930,437
Ensembl chr10:90,910,316...90,931,131

G

actin alpha 2, smooth muscle

multiple interactions
decreases expression

RTKI cpd inhibits the reaction [sodium arsenite results in increased expression of ACTA2 protein]
RTKI cpd results in decreased expression of ACTA2 protein

NCBI chr 1:231,746,527...231,759,307
Ensembl chr 1:231,746,548...231,759,554

G

adrenoceptor beta 1

multiple interactions

RTKI cpd inhibits the reaction [Alprenolol promotes the reaction [[ADRB1 protein co-treated with EGFR protein] results in increased phosphorylation of MAPK1 protein]]; RTKI cpd inhibits the reaction [Alprenolol promotes the reaction [[ADRB1 protein co-treated with EGFR protein] results in increased phosphorylation of MAPK3 protein]]; RTKI cpd inhibits the reaction [Alprenolol promotes the reaction [ADRB1 protein results in increased phosphorylation of EGFR protein]]; RTKI cpd inhibits the reaction [Carvedilol promotes the reaction [[ADRB1 protein co-treated with EGFR protein] results in increased phosphorylation of MAPK1 protein]]; RTKI cpd inhibits the reaction [Carvedilol promotes the reaction [[ADRB1 protein co-treated with EGFR protein] results in increased phosphorylation of MAPK3 protein]]; RTKI cpd inhibits the reaction [Carvedilol promotes the reaction [ADRB1 protein results in increased phosphorylation of EGFR protein]]; RTKI cpd inhibits the reaction [Dobutamine promotes the reaction [[ADRB1 protein co-treated with EGFR protein] results in increased phosphorylation of MAPK1 protein]]; RTKI cpd inhibits the reaction [Dobutamine promotes the reaction [[ADRB1 protein co-treated with EGFR protein] results in increased phosphorylation of MAPK3 protein]]; RTKI cpd inhibits the reaction [Dobutamine promotes the reaction [ADRB1 protein results in increased phosphorylation of EGFR protein]]

NCBI chr 1:255,771,962...255,774,973
Ensembl chr 1:255,771,597...255,807,259

G

angiotensinogen

multiple interactions

RTKI cpd inhibits the reaction [AGT protein promotes the reaction [SP1 protein binds to TGFB1 promoter]]; RTKI cpd inhibits the reaction [AGT protein results in increased expression of SP1 mRNA]; RTKI cpd inhibits the reaction [AGT protein results in increased phosphorylation of AKT1 protein]; RTKI cpd inhibits the reaction [AGT protein results in increased phosphorylation of and results in increased activity of EGFR protein]; RTKI cpd inhibits the reaction [AGT protein results in increased phosphorylation of EGFR protein]

PMID:15849355 PMID:25398788

NCBI chr19:52,529,139...52,549,618
Ensembl chr19:52,529,185...52,540,977

G

AKT serine/threonine kinase 1

multiple interactions

RTKI cpd inhibits the reaction [AGT protein results in increased phosphorylation of AKT1 protein]; RTKI cpd inhibits the reaction [Cadmium Chloride results in increased phosphorylation of AKT1 protein]; RTKI cpd inhibits the reaction [EGF protein results in increased phosphorylation of AKT1 protein]; RTKI cpd inhibits the reaction [hexabromocyclododecane promotes the reaction [FSHB protein results in increased phosphorylation of AKT1 protein]]; RTKI cpd inhibits the reaction [Zinc Sulfate results in increased phosphorylation of AKT1 protein]
RTKI cpd inhibits the reaction [Cadmium Chloride results in increased cleavage of AKT1 protein]; RTKI cpd inhibits the reaction [EGF protein results in increased phosphorylation of and results in increased activity of AKT1 protein]; RTKI cpd inhibits the reaction [NTS protein results in increased phosphorylation of and results in increased activity of AKT1 protein]; RTKI cpd inhibits the reaction [Pyocyanine results in increased phosphorylation of AKT1 protein]; RTKI cpd inhibits the reaction [Tetrachlorodibenzodioxin results in increased phosphorylation of and results in increased activity of AKT1 protein]; RTKI cpd inhibits the reaction [TGFA protein results in increased phosphorylation of and results in increased activity of AKT1 protein]

PMID:11309286 PMID:15177934 PMID:15849355 PMID:19233221 PMID:19946718 More...

NCBI chr 6:131,713,716...131,735,319
Ensembl chr 6:131,713,720...131,733,921

G

albumin

multiple interactions

RTKI cpd inhibits the reaction [[Toluene 2,4-Diisocyanate binds to ALB protein] which results in increased expression of CSF2 protein]; RTKI cpd inhibits the reaction [[Toluene 2,4-Diisocyanate binds to ALB protein] which results in increased expression of CXCL8 protein]; RTKI cpd inhibits the reaction [[Toluene 2,4-Diisocyanate binds to ALB protein] which results in increased phosphorylation of MAPK1 protein]; RTKI cpd inhibits the reaction [[Toluene 2,4-Diisocyanate binds to ALB protein] which results in increased phosphorylation of MAPK3 protein]

NCBI chr14:17,607,397...17,622,814
Ensembl chr14:17,607,381...17,622,836

G

arachidonate 5-lipoxygenase

multiple interactions

[RTKI cpd co-treated with AG 1879] inhibits the reaction [Nicotine results in increased expression of ALOX5 protein]; RTKI cpd inhibits the reaction [Nicotine results in increased expression of ALOX5 protein]
RTKI cpd inhibits the reaction [Acrolein results in increased expression of ALOX5 protein]

PMID:14569062 PMID:20153347

NCBI chr 4:149,531,329...149,578,696
Ensembl chr 4:149,531,515...149,578,743

G

angiopoietin 1

multiple interactions

RTKI cpd inhibits the reaction [Iloprost results in increased expression of ANGPT1 mRNA]

NCBI chr 7:73,528,345...73,783,953
Ensembl chr 7:73,531,486...73,784,067

G

angiopoietin 2

multiple interactions

RTKI cpd inhibits the reaction [Iloprost results in increased expression of ANGPT2 mRNA]

NCBI chr16:71,088,364...71,138,805
Ensembl chr16:71,088,364...71,138,804

G

androgen receptor

multiple interactions

RTKI cpd inhibits the reaction [EGF protein results in decreased expression of AR protein]; RTKI cpd inhibits the reaction [Particulate Matter results in increased secretion of AR protein]; RTKI cpd inhibits the reaction [Vehicle Emissions results in increased secretion of AR protein]

PMID:16472761 PMID:24555532

NCBI chr X:63,104,771...63,273,934
Ensembl chr X:63,104,771...63,273,925

G

amphiregulin

multiple interactions
decreases activity

RTKI cpd inhibits the reaction [[AREG protein co-treated with Estradiol] results in increased phosphorylation of EGFR protein]
RTKI cpd results in decreased activity of AREG protein

PMID:15706222 PMID:21185374

NCBI chr14:16,972,185...16,981,443
Ensembl chr14:16,972,187...16,981,535

G

activating transcription factor 1

multiple interactions

RTKI cpd inhibits the reaction [4-(N-methyl-N-nitrosamino)-1-(3-pyridyl)-1-butanone results in increased phosphorylation of ATF1 protein]

NCBI chr 7:131,361,962...131,404,677
Ensembl chr 7:131,362,450...131,404,670

G

ATPase Na+/K+ transporting subunit alpha 2

multiple interactions

RTKI cpd inhibits the reaction [Ammonia results in increased expression of ATP1A2 mRNA]; RTKI cpd inhibits the reaction [Ammonia results in increased expression of ATP1A2 protein]

NCBI chr13:84,729,597...84,754,544
Ensembl chr13:84,729,601...84,754,544

G

BCL2 associated X, apoptosis regulator

multiple interactions

RTKI cpd results in increased expression of and results in increased activity of BAX protein
RTKI cpd inhibits the reaction [NRG1 protein inhibits the reaction [Diethylhexyl Phthalate results in increased expression of BAX mRNA]]; RTKI cpd inhibits the reaction [NRG1 protein inhibits the reaction [Diethylhexyl Phthalate results in increased expression of BAX protein]]
ESR1 protein alternative form promotes the reaction [RTKI cpd inhibits the reaction [Estradiol results in decreased expression of BAX protein]]; RTKI cpd inhibits the reaction [Estradiol results in decreased expression of BAX protein]

PMID:18371937 PMID:34724321 PMID:35716406

NCBI chr 1:95,940,001...95,945,407
Ensembl chr 1:95,938,808...95,945,368

G

BCL2, apoptosis regulator

multiple interactions

ESR1 protein alternative form promotes the reaction [RTKI cpd inhibits the reaction [Estradiol results in increased expression of BCL2 protein]]; RTKI cpd inhibits the reaction [Estradiol results in increased expression of BCL2 protein]
RTKI cpd inhibits the reaction [NRG1 protein inhibits the reaction [Diethylhexyl Phthalate results in decreased expression of BCL2 mRNA]]; RTKI cpd inhibits the reaction [NRG1 protein inhibits the reaction [Diethylhexyl Phthalate results in decreased expression of BCL2 protein]]

PMID:34724321 PMID:35716406

NCBI chr13:22,689,783...22,853,920
Ensembl chr13:22,684,989...22,853,743
Ensembl chr13:22,684,989...22,853,743

G

Bcl2-like 1

decreases expression

RTKI cpd results in decreased expression of BCL2L1 mRNA; RTKI cpd results in decreased expression of BCL2L1 protein

NCBI chr 3:141,253,508...141,304,582
Ensembl chr 3:141,253,523...141,303,479
Ensembl chr 1:141,253,523...141,303,479

G

baculoviral IAP repeat-containing 5

multiple interactions
decreases expression

[RTKI cpd results in decreased activity of EGFR protein] which results in decreased expression of BIRC5 protein
RTKI cpd results in decreased expression of BIRC5 protein

PMID:21268125 PMID:29974605

NCBI chr10:103,072,530...103,081,382
Ensembl chr10:103,073,408...103,081,380

G

bone morphogenetic protein 4

multiple interactions

RTKI cpd inhibits the reaction [antimonite results in decreased expression of BMP4 mRNA]; RTKI cpd inhibits the reaction [arsenite results in decreased expression of BMP4 mRNA]

NCBI chr15:19,618,538...19,633,494
Ensembl chr15:19,618,542...19,623,306

G

caspase 3

multiple interactions

RTKI cpd promotes the reaction [Cadmium Chloride results in increased cleavage of CASP3 protein]
RTKI cpd inhibits the reaction [NRG1 protein inhibits the reaction [Diethylhexyl Phthalate results in increased expression of CASP3 mRNA]]
ESR1 protein alternative form promotes the reaction [RTKI cpd inhibits the reaction [Estradiol results in decreased cleavage of CASP3 protein]]; RTKI cpd inhibits the reaction [Estradiol results in decreased cleavage of CASP3 protein]

PMID:19233221 PMID:34724321 PMID:35716406

NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648

G

caveolin 1

multiple interactions

RTKI cpd inhibits the reaction [Rosiglitazone results in increased expression of CAV1]

NCBI chr 4:45,640,624...45,673,708
Ensembl chr 4:45,634,918...45,673,705

G

cyclin B1

multiple interactions

RTKI cpd inhibits the reaction [Cadmium Chloride results in increased expression of CCNB1 protein]; RTKI cpd inhibits the reaction [EGF protein results in increased expression of CCNB1 protein]

NCBI chr 2:31,912,190...31,921,163
Ensembl chr 2:31,912,193...31,921,172

G

cyclin D1

multiple interactions
decreases expression

RTKI cpd inhibits the reaction [[Fulvestrant co-treated with bisphenol A] results in decreased expression of CCND1 mRNA]
RTKI cpd results in decreased expression of CCND1 protein

PMID:28446726 PMID:29974605

NCBI chr 1:200,089,002...200,098,524
Ensembl chr 1:200,089,002...200,098,602

G

cyclin E1

multiple interactions
decreases expression

RTKI cpd inhibits the reaction [Cadmium Chloride results in increased expression of CCNE1 protein]; RTKI cpd inhibits the reaction [EGF protein results in increased expression of CCNE1 protein]
RTKI cpd results in decreased expression of CCNE1 protein

PMID:15923621 PMID:26385184

NCBI chr 1:90,781,947...90,791,188
Ensembl chr 1:90,781,949...90,791,101

G

cadherin 1

increases expression

RTKI cpd results in increased expression of CDH1 protein

NCBI chr19:34,492,371...34,561,775
Ensembl chr19:34,492,371...34,561,775

G

cyclin-dependent kinase 1

multiple interactions

RTKI cpd inhibits the reaction [Cadmium Chloride results in increased expression of CDK1 protein]; RTKI cpd inhibits the reaction [EGF protein results in increased expression of CDK1 protein]

NCBI chr20:19,266,226...19,281,417
Ensembl chr20:19,266,248...19,281,408

G

cyclin dependent kinase 2

multiple interactions

RTKI cpd inhibits the reaction [Cadmium Chloride results in increased expression of CDK2 protein]; RTKI cpd inhibits the reaction [EGF protein results in increased expression of CDK2 protein]

NCBI chr 7:1,129,878...1,137,431
Ensembl chr 7:1,129,811...1,137,403

G

cyclin-dependent kinase inhibitor 1A

multiple interactions

RTKI cpd inhibits the reaction [Arsenic Trioxide results in increased expression of CDKN1A protein]; RTKI cpd inhibits the reaction [sodium arsenite results in increased expression of CDKN1A protein]

PMID:15734884 PMID:16283431

NCBI chr20:7,149,177...7,159,727
Ensembl chr20:7,149,217...7,159,585

G

cAMP responsive element binding protein 1

multiple interactions

RTKI cpd inhibits the reaction [4-(N-methyl-N-nitrosamino)-1-(3-pyridyl)-1-butanone results in increased phosphorylation of CREB1 protein]
RTKI cpd inhibits the reaction [Metribolone results in increased phosphorylation of CREB1 protein]
RTKI cpd inhibits the reaction [Asbestos, Crocidolite results in increased phosphorylation of CREB1 protein]; RTKI cpd inhibits the reaction [Colforsin results in increased phosphorylation of CREB1 protein]

PMID:16671086 PMID:17272394 PMID:17322281

NCBI chr 9:65,903,511...65,972,562
Ensembl chr 9:65,903,547...65,970,816

G

colony stimulating factor 2

multiple interactions

RTKI cpd inhibits the reaction [[Toluene 2,4-Diisocyanate binds to ALB protein] which results in increased expression of CSF2 protein]; RTKI cpd inhibits the reaction [Particulate Matter results in increased secretion of CSF2 protein]

PMID:16908450 PMID:19460412 PMID:22581348

NCBI chr10:38,386,945...38,388,926
Ensembl chr10:38,386,945...38,389,199

G

catenin beta 1

multiple interactions
decreases expression

RTKI cpd inhibits the reaction [arsenite affects the localization of CTNNB1 protein]
RTKI cpd results in decreased expression of CTNNB1 protein

PMID:17400267 PMID:29974605

NCBI chr 8:120,640,008...120,667,110
Ensembl chr 8:120,639,995...120,667,111

G

CYLD lysine 63 deubiquitinase

increases expression

[RTKI cpd results in increased expression of CYLD protein] which results in increased expression of NFKBIA protein; RTKI cpd results in increased expression of CYLD mRNA; RTKI cpd results in increased expression of CYLD protein

NCBI chr19:18,310,632...18,373,696
Ensembl chr19:18,314,019...18,373,658

G

DNA methyltransferase 3 alpha

multiple interactions

RTKI cpd inhibits the reaction [lead nitrate results in decreased expression of DNMT3A mRNA]

NCBI chr 6:26,791,517...26,902,161
Ensembl chr 6:26,822,609...26,896,687

G

endothelin 1

multiple interactions

RTKI cpd inhibits the reaction [Doxorubicin results in increased expression of EDN1 mRNA]
RTKI cpd inhibits the reaction [Doxorubicin results in increased expression of EDN1 mRNA]; RTKI cpd inhibits the reaction [EGFR protein affects the reaction [EDN1 protein results in increased phosphorylation of MAPK1 protein]]; RTKI cpd inhibits the reaction [EGFR protein affects the reaction [EDN1 protein results in increased phosphorylation of MAPK3 protein]]

PMID:16261333 PMID:17974986

NCBI chr17:22,454,924...22,460,812
Ensembl chr17:22,454,420...22,460,885

G

epidermal growth factor

multiple interactions

RTKI cpd inhibits the reaction [EGF protein affects the localization of FOXO3 protein]; RTKI cpd inhibits the reaction [EGF protein results in decreased expression of and results in decreased secretion of KLK3 protein]; RTKI cpd inhibits the reaction [EGF protein results in decreased expression of AR protein]; RTKI cpd inhibits the reaction [EGF protein results in increased abundance of Calcium]; RTKI cpd inhibits the reaction [EGF protein results in increased activity of STAT3 protein]; RTKI cpd inhibits the reaction [EGF protein results in increased expression of CCNB1 protein]; RTKI cpd inhibits the reaction [EGF protein results in increased expression of CCNE1 protein]; RTKI cpd inhibits the reaction [EGF protein results in increased expression of CDK1 protein]; RTKI cpd inhibits the reaction [EGF protein results in increased expression of CDK2 protein]; RTKI cpd inhibits the reaction [EGF protein results in increased expression of FOS protein]; RTKI cpd inhibits the reaction [EGF protein results in increased expression of GPER1 protein]; RTKI cpd inhibits the reaction [EGF protein results in increased phosphorylation of and results in increased activity of AKT1 protein]; RTKI cpd inhibits the reaction [EGF protein results in increased phosphorylation of and results in increased activity of MAPK1 protein]; RTKI cpd inhibits the reaction [EGF protein results in increased phosphorylation of and results in increased activity of MAPK3 protein]; RTKI cpd inhibits the reaction [EGF protein results in increased phosphorylation of EGFR protein]; RTKI cpd inhibits the reaction [EGF protein results in increased phosphorylation of MAPK1 protein]; RTKI cpd inhibits the reaction [EGF protein results in increased phosphorylation of MAPK3 protein]; RTKI cpd inhibits the reaction [EGF protein results in increased phosphorylation of SRC protein]; RTKI cpd inhibits the reaction [EGF protein results in increased secretion of MMP1 protein]; RTKI cpd inhibits the reaction [Estradiol promotes the reaction [EGF protein results in increased phosphorylation of EGFR protein]]; RTKI cpd promotes the reaction [Amiodarone inhibits the reaction [EGF protein results in increased phosphorylation of EGFR protein]]
RTKI cpd inhibits the reaction [EGF protein results in increased phosphorylation of MAPK7 protein]
RTKI cpd inhibits the reaction [EGF protein results in increased activity of MAPK1 protein]; RTKI cpd inhibits the reaction [EGF protein results in increased activity of MAPK3 protein]; RTKI cpd inhibits the reaction [EGF protein results in increased phosphorylation of AKT1 protein]; RTKI cpd inhibits the reaction [EGF protein results in increased susceptibility to Desoxycorticosterone]

PMID:10516208 PMID:11309286 PMID:11527950 PMID:11751714 PMID:14737115 More...

NCBI chr 2:218,219,408...218,302,359
Ensembl chr 2:218,219,415...218,302,064

G

epidermal growth factor receptor

multiple interactions
decreases expression
decreases phosphorylation
decreases activity

[RTKI cpd results in decreased activity of EGFR protein] inhibits the reaction [Cadmium Chloride results in increased phosphorylation of FOXO3 protein]; [RTKI cpd results in decreased activity of EGFR protein] inhibits the reaction [Equol results in increased chemical synthesis of Oxygen]; [RTKI cpd results in decreased activity of EGFR protein] inhibits the reaction [Equol results in increased phosphorylation of and results in increased activity of NOS3 protein]; [RTKI cpd results in decreased activity of EGFR protein] inhibits the reaction [Equol results in increased phosphorylation of MAPK1 protein]; [RTKI cpd results in decreased activity of EGFR protein] inhibits the reaction [Equol results in increased phosphorylation of MAPK3 protein]; [RTKI cpd results in decreased activity of EGFR protein] inhibits the reaction [FSHB protein results in increased chemical synthesis of Hyaluronic Acid]; [RTKI cpd results in decreased activity of EGFR protein] inhibits the reaction [FSHB protein results in increased chemical synthesis of Progesterone]; [RTKI cpd results in decreased activity of EGFR protein] inhibits the reaction [Hexachlorobenzene results in increased phosphorylation of and results in increased activity of MAPK1 protein]; [RTKI cpd results in decreased activity of EGFR protein] inhibits the reaction [Hexachlorobenzene results in increased phosphorylation of and results in increased activity of MAPK3 protein]; [RTKI cpd results in decreased activity of EGFR protein] inhibits the reaction [Hexachlorobenzene results in increased phosphorylation of and results in increased activity of STAT5B protein]; [RTKI cpd results in decreased activity of EGFR protein] which results in decreased susceptibility to 5-methoxy-1,2-dimethyl-3-((4-nitrophenoxy)methyl)indole-4,7-dione; [RTKI cpd results in decreased activity of EGFR protein] which results in decreased susceptibility to FSHB protein; [RTKI cpd results in decreased activity of EGFR protein] which results in decreased susceptibility to Hexachlorobenzene; [RTKI cpd results in decreased activity of EGFR protein] which results in decreased susceptibility to Topotecan; RTKI cpd inhibits the reaction [(3R)-((2,3-dihydro-5-methyl-3-((4-morpholinyl)methyl)pyrrolo-(1,2,3-de)-1,4-benzoxazin-6-yl)(1-naphthalenyl))methanone results in increased phosphorylation of EGFR protein]; RTKI cpd inhibits the reaction [[AREG protein co-treated with Estradiol] results in increased phosphorylation of EGFR protein]; RTKI cpd inhibits the reaction [Acrolein results in increased phosphorylation of EGFR protein]; RTKI cpd inhibits the reaction [Alprenolol promotes the reaction [[ADRB1 protein co-treated with EGFR protein] results in increased phosphorylation of MAPK1 protein]]; RTKI cpd inhibits the reaction [Alprenolol promotes the reaction [[ADRB1 protein co-treated with EGFR protein] results in increased phosphorylation of MAPK3 protein]]; RTKI cpd inhibits the reaction [Alprenolol promotes the reaction [ADRB1 protein results in increased phosphorylation of EGFR protein]]; RTKI cpd inhibits the reaction [Cadmium Chloride results in increased phosphorylation of EGFR protein]; RTKI cpd inhibits the reaction [Cadmium results in increased activity of EGFR protein]; RTKI cpd inhibits the reaction [Cadmium results in increased phosphorylation of EGFR protein]; RTKI cpd inhibits the reaction [Capsaicin results in increased phosphorylation of EGFR protein]; RTKI cpd inhibits the reaction [Carvedilol promotes the reaction [[ADRB1 protein co-treated with EGFR protein] results in increased phosphorylation of MAPK1 protein]]; RTKI cpd inhibits the reaction [Carvedilol promotes the reaction [[ADRB1 protein co-treated with EGFR protein] results in increased phosphorylation of MAPK3 protein]]; RTKI cpd inhibits the reaction [Carvedilol promotes the reaction [ADRB1 protein results in increased phosphorylation of EGFR protein]]; RTKI cpd inhibits the reaction [Dobutamine promotes the reaction [[ADRB1 protein co-treated with EGFR protein] results in increased phosphorylation of MAPK1 protein]]; RTKI cpd inhibits the reaction [Dobutamine promotes the reaction [[ADRB1 protein co-treated with EGFR protein] results in increased phosphorylation of MAPK3 protein]]; RTKI cpd inhibits the reaction [Dobutamine promotes the reaction [ADRB1 protein results in increased phosphorylation of EGFR protein]]; RTKI cpd inhibits the reaction [EGF protein results in increased phosphorylation of EGFR protein]; RTKI cpd inhibits the reaction [EGFR protein binds to GPER1 protein]; RTKI cpd inhibits the reaction [Estradiol promotes the reaction [EGF protein results in increased phosphorylation of EGFR protein]]; RTKI cpd inhibits the reaction [Estradiol results in increased phosphorylation of EGFR protein]; RTKI cpd inhibits the reaction [lead acetate results in increased phosphorylation of EGFR protein]; RTKI cpd inhibits the reaction [lead nitrate results in increased phosphorylation of EGFR protein]; RTKI cpd inhibits the reaction [NTS protein results in increased phosphorylation of and results in increased activity of EGFR protein]; RTKI cpd inhibits the reaction [sodium arsenite results in increased phosphorylation of and results in increased activity of EGFR protein]; RTKI cpd inhibits the reaction [sodium arsenite results in increased phosphorylation of EGFR protein]; RTKI cpd promotes the reaction [Amiodarone inhibits the reaction [EGF protein results in increased phosphorylation of EGFR protein]]
RTKI cpd results in decreased expression of EGFR protein modified form
RTKI cpd results in decreased phosphorylation of EGFR protein
[RTKI cpd results in decreased activity of EGFR protein] inhibits the reaction [Genistein results in increased secretion of Testosterone]; RTKI cpd inhibits the reaction [AGT protein results in increased phosphorylation of and results in increased activity of EGFR protein]; RTKI cpd inhibits the reaction [AGT protein results in increased phosphorylation of EGFR protein]; RTKI cpd inhibits the reaction [Cadmium Chloride results in increased phosphorylation of EGFR protein]; RTKI cpd inhibits the reaction [EGFR protein affects the reaction [EDN1 protein results in increased phosphorylation of MAPK1 protein]]; RTKI cpd inhibits the reaction [EGFR protein affects the reaction [EDN1 protein results in increased phosphorylation of MAPK3 protein]]; RTKI cpd inhibits the reaction [estradiol-17 beta-glucuronide results in increased phosphorylation of and results in increased activity of EGFR protein]; RTKI cpd inhibits the reaction [LHB protein results in increased phosphorylation of EGFR protein]; RTKI cpd inhibits the reaction [sodium arsenite promotes the reaction [SHC1 protein modified form binds to EGFR protein binds to GRB protein]]; RTKI cpd inhibits the reaction [sodium arsenite results in increased phosphorylation of EGFR protein]
[[RTKI cpd results in decreased activity of EGFR protein] co-treated with [SU 6656 results in decreased activity of SRC protein]] inhibits the reaction [Cadmium Chloride results in increased phosphorylation of and results in increased activity of STAT3 protein]; [RTKI cpd results in decreased activity of EGFR protein] inhibits the reaction [Cadmium Chloride results in increased expression of MT2 protein]; [RTKI cpd results in decreased activity of EGFR protein] inhibits the reaction [Cadmium Chloride results in increased phosphorylation of and results in increased activity of MAPK1 protein]; [RTKI cpd results in decreased activity of EGFR protein] inhibits the reaction [Cadmium Chloride results in increased phosphorylation of and results in increased activity of MAPK3 protein]; [RTKI cpd results in decreased activity of EGFR protein] which results in decreased expression of BIRC5 protein; [RTKI cpd results in decreased activity of EGFR protein] which results in decreased phosphorylation of STAT3 protein; [RTKI cpd results in decreased activity of EGFR protein] which results in decreased susceptibility to butaprost; RTKI cpd inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Capsaicin] results in increased phosphorylation of EGFR protein]; RTKI cpd inhibits the reaction [Arsenic affects the localization of EGFR protein]; RTKI cpd inhibits the reaction [evodiamine results in increased phosphorylation of EGFR protein]; RTKI cpd inhibits the reaction [Fluoxetine results in increased phosphorylation of EGFR protein]; RTKI cpd inhibits the reaction [LHB protein results in increased phosphorylation of and results in increased activity of EGFR protein]; RTKI cpd inhibits the reaction [Sodium Chloride results in increased phosphorylation of EGFR protein]; RTKI cpd results in decreased phosphorylation of and results in decreased activity of EGFR protein

PMID:9710602 PMID:12794006 PMID:15177934 PMID:15459120 PMID:15504454 More...

NCBI chr14:91,176,979...91,349,722
Ensembl chr14:91,177,067...91,344,382

G

early growth response 1

multiple interactions

RTKI cpd inhibits the reaction [sodium arsenite results in increased expression of EGR1 protein]

NCBI chr18:26,462,967...26,466,766
Ensembl chr18:26,462,981...26,466,766

G

erb-b2 receptor tyrosine kinase 2

multiple interactions

[RTKI cpd co-treated with AG-879] results in decreased phosphorylation of ERBB2 protein
RTKI cpd inhibits the reaction [NRG1 protein inhibits the reaction [Diethylhexyl Phthalate results in decreased expression of ERBB2 mRNA]]

PMID:18618485 PMID:35716406

NCBI chr10:83,411,197...83,435,078
Ensembl chr10:83,411,313...83,435,078

G

erb-b2 receptor tyrosine kinase 4

multiple interactions

RTKI cpd inhibits the reaction [NRG1 protein inhibits the reaction [Diethylhexyl Phthalate results in decreased expression of ERBB4 mRNA]]

NCBI chr 9:69,523,733...70,596,743
Ensembl chr 9:69,531,481...70,596,595

G

ERBB receptor feedback inhibitor 1

decreases expression

RTKI cpd results in decreased expression of ERRFI1 protein

NCBI chr 5:161,323,981...161,337,289
Ensembl chr 5:161,323,998...161,337,282

G

estrogen receptor 1

multiple interactions

RTKI cpd inhibits the reaction [bisphenol A results in increased phosphorylation of ESR1 protein]
ESR1 protein alternative form promotes the reaction [RTKI cpd inhibits the reaction [Estradiol results in decreased cleavage of CASP3 protein]]; ESR1 protein alternative form promotes the reaction [RTKI cpd inhibits the reaction [Estradiol results in decreased expression of BAX protein]]; ESR1 protein alternative form promotes the reaction [RTKI cpd inhibits the reaction [Estradiol results in increased expression of BCL2 protein]]

PMID:21813366 PMID:34724321

NCBI chr 1:41,106,335...41,499,104
Ensembl chr 1:41,210,475...41,495,002

G

F11 receptor

multiple interactions

RTKI cpd inhibits the reaction [Poly I-C results in decreased expression of F11R protein]

NCBI chr13:83,873,797...83,897,388
Ensembl chr13:83,873,797...83,897,402

G

fibroblast growth factor 2

multiple interactions

RTKI cpd inhibits the reaction [Iloprost results in increased expression of FGF2 mRNA]

NCBI chr 2:120,236,328...120,290,673
Ensembl chr 2:120,236,328...120,291,221

G

Fms related receptor tyrosine kinase 1

multiple interactions

RTKI cpd inhibits the reaction [Asbestos, Crocidolite results in increased secretion of FLT1 protein]; RTKI cpd inhibits the reaction [calcium silicate results in increased secretion of FLT1 protein]

NCBI chr12:7,296,899...7,468,626
Ensembl chr12:7,297,292...7,468,626

G

Fos proto-oncogene, AP-1 transcription factor subunit

multiple interactions

RTKI cpd inhibits the reaction [afimoxifene results in increased expression of FOS mRNA]; RTKI cpd inhibits the reaction [afimoxifene results in increased expression of FOS protein]; RTKI cpd inhibits the reaction [Atrazine results in increased expression of FOS protein]; RTKI cpd inhibits the reaction [EGF protein results in increased expression of FOS protein]; RTKI cpd inhibits the reaction [Estradiol results in increased expression of FOS protein]; RTKI cpd inhibits the reaction [Genistein results in increased expression of FOS protein]; RTKI cpd inhibits the reaction [Quercetin results in increased expression of FOS protein]; RTKI cpd inhibits the reaction [TGFA protein results in increased expression of FOS protein]
RTKI cpd inhibits the reaction [1-(4-(6-bromobenzo(1,3)dioxol-5-yl)-3a,4,5,9b-tetrahydro-3H-cyclopenta(c)quinolin-8-yl)ethanone results in increased expression of FOS mRNA]; RTKI cpd inhibits the reaction [4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol results in increased expression of FOS mRNA]; RTKI cpd inhibits the reaction [[Fulvestrant co-treated with bisphenol A] results in increased expression of FOS mRNA]; RTKI cpd inhibits the reaction [Asbestos, Crocidolite results in increased expression of FOS mRNA]; RTKI cpd inhibits the reaction [bisphenol A promotes the reaction [FOS protein binds to GPER1 promoter]]; RTKI cpd inhibits the reaction [bisphenol A results in increased expression of FOS mRNA]; RTKI cpd inhibits the reaction [Estradiol results in increased expression of FOS mRNA]; RTKI cpd inhibits the reaction [Fluoxetine results in increased expression of FOS mRNA]
RTKI cpd inhibits the reaction [Asbestos, Crocidolite results in increased expression of FOS mRNA]; RTKI cpd inhibits the reaction [sodium arsenite results in increased expression of FOS mRNA]

PMID:9710602 PMID:10516208 PMID:12154012 PMID:15090535 PMID:18758753 More...

NCBI chr 6:105,121,170...105,124,036
Ensembl chr 6:105,121,170...105,124,036

G

FosB proto-oncogene, AP-1 transcription factor subunit

multiple interactions

RTKI cpd inhibits the reaction [Fluoxetine results in increased expression of FOSB mRNA]; RTKI cpd inhibits the reaction [Fluoxetine results in increased expression of FOSB protein]

NCBI chr 1:78,954,312...78,961,492
Ensembl chr 1:78,954,115...78,961,465

G

forkhead box O3

multiple interactions

[RTKI cpd results in decreased activity of EGFR protein] inhibits the reaction [Cadmium Chloride results in increased phosphorylation of FOXO3 protein]; RTKI cpd inhibits the reaction [1-(4-(6-bromobenzo(1,3)dioxol-5-yl)-3a,4,5,9b-tetrahydro-3H-cyclopenta(c)quinolin-8-yl)ethanone affects the localization of FOXO3 protein]; RTKI cpd inhibits the reaction [EGF protein affects the localization of FOXO3 protein]; RTKI cpd inhibits the reaction [Estradiol affects the localization of FOXO3 protein]

PMID:23673518 PMID:26470790

NCBI chr20:45,669,708...45,764,606
Ensembl chr20:45,672,995...45,764,561

G

follicle stimulating hormone subunit beta

multiple interactions

[RTKI cpd results in decreased activity of EGFR protein] inhibits the reaction [FSHB protein results in increased chemical synthesis of Hyaluronic Acid]; [RTKI cpd results in decreased activity of EGFR protein] inhibits the reaction [FSHB protein results in increased chemical synthesis of Progesterone]; [RTKI cpd results in decreased activity of EGFR protein] which results in decreased susceptibility to FSHB protein
RTKI cpd inhibits the reaction [FSHB protein results in increased phosphorylation of MAPK1 protein]; RTKI cpd inhibits the reaction [FSHB protein results in increased phosphorylation of MAPK3 protein]; RTKI cpd inhibits the reaction [hexabromocyclododecane inhibits the reaction [FSHB protein results in increased expression of LHCGR mRNA]]; RTKI cpd inhibits the reaction [hexabromocyclododecane promotes the reaction [FSHB protein results in increased phosphorylation of AKT1 protein]]; RTKI cpd inhibits the reaction [hexabromocyclododecane promotes the reaction [FSHB protein results in increased phosphorylation of MAPK1 protein]]; RTKI cpd inhibits the reaction [hexabromocyclododecane promotes the reaction [FSHB protein results in increased phosphorylation of MAPK3 protein]]; RTKI cpd promotes the reaction [FSHB protein results in increased expression of LHCGR mRNA]

PMID:21520325 PMID:24071787

NCBI chr 3:93,548,560...93,552,370
Ensembl chr 3:93,548,560...93,552,370

G

gastrin

multiple interactions

RTKI cpd inhibits the reaction [lead acetate results in increased expression of GAST mRNA]

NCBI chr10:85,264,832...85,269,393
Ensembl chr10:85,264,832...85,267,496

G

glutamate-cysteine ligase, catalytic subunit

multiple interactions
decreases expression

Doxorubicin promotes the reaction [RTKI cpd results in decreased expression of GCLC protein]

NCBI chr 8:78,629,899...78,668,547
Ensembl chr 8:78,630,127...78,668,544

G

G protein subunit alpha q

multiple interactions

RTKI cpd inhibits the reaction [GNAQ protein promotes the reaction [Phenylephrine results in increased expression of NPPA protein]]

NCBI chr 1:213,425,631...213,671,947
Ensembl chr 1:213,424,465...213,667,672

G

G protein-coupled estrogen receptor 1

multiple interactions

RTKI cpd inhibits the reaction [EGF protein results in increased expression of GPER1 protein]; RTKI cpd inhibits the reaction [EGFR protein binds to GPER1 protein]; RTKI cpd inhibits the reaction [TGFA protein results in increased expression of GPER1 protein]
RTKI cpd inhibits the reaction [[1-(4-(6-bromobenzo(1,3)dioxol-5-yl)-3a,4,5,9b-tetrahydro-3H-cyclopenta(c)quinolin-8-yl)ethanone binds to and results in increased activity of GPER1 protein] which results in increased expression of SLC1A2 protein]
RTKI cpd inhibits the reaction [bisphenol A promotes the reaction [FOS protein binds to GPER1 promoter]]; RTKI cpd inhibits the reaction [bisphenol A results in increased expression of GPER1 mRNA]; RTKI cpd inhibits the reaction [bisphenol A results in increased expression of GPER1 protein]

PMID:19749156 PMID:22645130 PMID:23274518

NCBI chr12:15,217,217...15,222,679
Ensembl chr12:15,217,442...15,221,889

G

hyaluronan synthase 2

multiple interactions

RTKI cpd inhibits the reaction [LHB protein results in increased expression of HAS2 mRNA]

NCBI chr 7:88,113,326...88,139,337
Ensembl chr 7:88,113,326...88,128,933

G

heparin-binding EGF-like growth factor

multiple interactions
increases expression
decreases expression

RTKI cpd inhibits the reaction [vanadium pentoxide results in increased expression of HBEGF mRNA]
RTKI cpd results in increased expression of HBEGF mRNA
RTKI cpd results in decreased expression of HBEGF mRNA; RTKI cpd results in decreased expression of HBEGF protein

PMID:11159045 PMID:22048644 PMID:26800359

NCBI chr18:28,106,284...28,116,167
Ensembl chr18:28,105,760...28,116,441

G

hes family bHLH transcription factor 1

multiple interactions

RTKI cpd inhibits the reaction [arsenite results in decreased expression of HES1 mRNA]

NCBI chr11:70,705,763...70,708,176
Ensembl chr11:70,705,764...70,708,192

G

heme oxygenase 1

multiple interactions

RTKI cpd inhibits the reaction [arsenite results in increased expression of HMOX1 protein]

NCBI chr19:13,466,287...13,474,082
Ensembl chr19:13,467,244...13,474,079

G

5-hydroxytryptamine receptor 2B

multiple interactions

RTKI cpd inhibits the reaction [[Fluoxetine results in increased activity of HTR2B protein] which results in increased phosphorylation of MAPK1 protein]; RTKI cpd inhibits the reaction [[Fluoxetine results in increased activity of HTR2B protein] which results in increased phosphorylation of MAPK3 protein]

NCBI chr 9:86,735,793...86,756,638
Ensembl chr 9:86,742,102...86,755,108

G

interleukin 6

multiple interactions
decreases expression

RTKI cpd affects the reaction [Capsaicin results in increased secretion of IL6 protein]; RTKI cpd inhibits the reaction [hexabromocyclododecane results in increased expression of IL6 protein]; RTKI cpd inhibits the reaction [pentabromodiphenyl ether results in increased expression of IL6 protein]; RTKI cpd inhibits the reaction [Silicon Dioxide analog results in increased secretion of IL6 protein]; RTKI cpd inhibits the reaction [tetrabromobisphenol A results in increased expression of IL6 protein]
RTKI cpd results in decreased expression of IL6 protein

PMID:20619260 PMID:24184330 PMID:24844442 PMID:26718265

NCBI chr 4:5,214,602...5,219,178
Ensembl chr 4:5,213,394...5,219,178

G

involucrin

multiple interactions
increases expression

RTKI cpd inhibits the reaction [arsenite results in decreased expression of IVL mRNA]
RTKI cpd results in increased expression of IVL protein

NCBI chr 2:178,146,694...178,160,807
Ensembl chr 2:178,147,061...178,149,100

G

jagged canonical Notch ligand 1

multiple interactions

RTKI cpd inhibits the reaction [arsenite results in decreased expression of JAG1 mRNA]; RTKI cpd inhibits the reaction [arsenite results in decreased expression of JAG1 protein]

NCBI chr 3:124,406,783...124,442,220
Ensembl chr 3:124,406,794...124,442,209

G

Janus kinase 3

multiple interactions

RTKI cpd results in decreased phosphorylation of and results in decreased activity of JAK3 protein

NCBI chr16:18,386,330...18,398,542
Ensembl chr16:18,386,405...18,398,536

G

Jun proto-oncogene, AP-1 transcription factor subunit

multiple interactions

RTKI cpd inhibits the reaction [Acrolein results in increased phosphorylation of JUN protein]
RTKI cpd inhibits the reaction [sodium arsenite results in increased expression of JUN mRNA]
RTKI cpd inhibits the reaction [Asbestos, Crocidolite results in increased expression of JUN mRNA]

PMID:9710602 PMID:11329622 PMID:12154012

NCBI chr 5:109,894,175...109,897,268
Ensembl chr 5:109,893,145...109,897,656

G

kallikrein 1-related peptidase C10

multiple interactions

RTKI cpd inhibits the reaction [EGF protein results in decreased expression of and results in decreased secretion of KLK3 protein]

NCBI chr 1:94,402,993...94,407,052
Ensembl chr 1:94,402,993...94,407,052

G

keratin 1

increases expression

RTKI cpd results in increased expression of KRT1 protein

NCBI chr 7:132,976,618...132,981,844
Ensembl chr 7:132,976,620...132,981,844

G

keratin 10

multiple interactions

RTKI cpd inhibits the reaction [arsenite results in decreased expression of KRT10 mRNA]; RTKI cpd inhibits the reaction [arsenite results in decreased expression of KRT10 protein]

NCBI chr10:84,338,695...84,343,279
Ensembl chr10:84,338,706...84,343,701

G

luteinizing hormone subunit beta

multiple interactions

RTKI cpd inhibits the reaction [LHB protein results in increased phosphorylation of and results in increased activity of EGFR protein]; RTKI cpd inhibits the reaction [LHB protein results in increased phosphorylation of and results in increased activity of MAPK1 protein]; RTKI cpd inhibits the reaction [LHB protein results in increased phosphorylation of and results in increased activity of MAPK3 protein]
RTKI cpd inhibits the reaction [LHB protein results in increased expression of HAS2 mRNA]; RTKI cpd inhibits the reaction [LHB protein results in increased expression of PTGS2 mRNA]; RTKI cpd inhibits the reaction [LHB protein results in increased expression of TNFAIP6 mRNA]; RTKI cpd inhibits the reaction [LHB protein results in increased phosphorylation of EGFR protein]

PMID:15459120 PMID:21220312

NCBI chr 1:95,898,269...95,901,973
Ensembl chr 1:95,900,984...95,901,972
Ensembl chr 1:95,900,984...95,901,972

G

luteinizing hormone/choriogonadotropin receptor

multiple interactions

RTKI cpd inhibits the reaction [hexabromocyclododecane inhibits the reaction [FSHB protein results in increased expression of LHCGR mRNA]]; RTKI cpd promotes the reaction [FSHB protein results in increased expression of LHCGR mRNA]

NCBI chr 6:5,661,871...5,728,109
Ensembl chr 6:5,661,871...5,724,521

G

mitogen activated protein kinase kinase 1

multiple interactions

RTKI cpd inhibits the reaction [Oleylethanolamide results in increased phosphorylation of MAP2K1 protein]

NCBI chr 8:64,683,449...64,754,900
Ensembl chr 8:64,683,449...64,755,147

G

mitogen activated protein kinase kinase 2

multiple interactions

RTKI cpd inhibits the reaction [Oleylethanolamide results in increased phosphorylation of MAP2K2 protein]

NCBI chr 7:8,590,729...8,610,279
Ensembl chr 7:8,580,905...8,610,243

G

mitogen activated protein kinase 1

multiple interactions
decreases phosphorylation

[RTKI cpd results in decreased activity of EGFR protein] inhibits the reaction [Equol results in increased phosphorylation of MAPK1 protein]; [RTKI cpd results in decreased activity of EGFR protein] inhibits the reaction [Hexachlorobenzene results in increased phosphorylation of and results in increased activity of MAPK1 protein]; RTKI cpd inhibits the reaction [4-(N-methyl-N-nitrosamino)-1-(3-pyridyl)-1-butanone results in increased phosphorylation of MAPK1 protein]; RTKI cpd inhibits the reaction [[Toluene 2,4-Diisocyanate binds to ALB protein] which results in increased phosphorylation of MAPK1 protein]; RTKI cpd inhibits the reaction [Acrolein results in increased phosphorylation of MAPK1 protein]; RTKI cpd inhibits the reaction [Alprenolol promotes the reaction [[ADRB1 protein co-treated with EGFR protein] results in increased phosphorylation of MAPK1 protein]]; RTKI cpd inhibits the reaction [arsenic acid results in increased activity of MAPK1 protein]; RTKI cpd inhibits the reaction [arsenite results in increased activity of MAPK1 protein]; RTKI cpd inhibits the reaction [Asbestos, Crocidolite results in increased phosphorylation of MAPK1 protein]; RTKI cpd inhibits the reaction [Atrazine results in increased phosphorylation of MAPK1 protein]; RTKI cpd inhibits the reaction [bisphenol A results in increased phosphorylation of MAPK1 protein]; RTKI cpd inhibits the reaction [Cadmium Chloride results in increased phosphorylation of and results in increased activity of MAPK1 protein]; RTKI cpd inhibits the reaction [Cadmium Chloride results in increased phosphorylation of MAPK1 protein]; RTKI cpd inhibits the reaction [Cadmium results in increased activity of MAPK1 protein]; RTKI cpd inhibits the reaction [Cadmium results in increased phosphorylation of MAPK1 protein]; RTKI cpd inhibits the reaction [Calcitriol results in increased phosphorylation of and results in increased activity of MAPK1 protein]; RTKI cpd inhibits the reaction [calcium silicate results in increased phosphorylation of MAPK1 protein]; RTKI cpd inhibits the reaction [Carvedilol promotes the reaction [[ADRB1 protein co-treated with EGFR protein] results in increased phosphorylation of MAPK1 protein]]; RTKI cpd inhibits the reaction [Diacetyl results in increased phosphorylation of MAPK1 protein]; RTKI cpd inhibits the reaction [Dobutamine promotes the reaction [[ADRB1 protein co-treated with EGFR protein] results in increased phosphorylation of MAPK1 protein]]; RTKI cpd inhibits the reaction [EGF protein results in increased phosphorylation of and results in increased activity of MAPK1 protein]; RTKI cpd inhibits the reaction [EGF protein results in increased phosphorylation of MAPK1 protein]; RTKI cpd inhibits the reaction [Estradiol results in increased phosphorylation of and results in increased activity of MAPK1 protein]; RTKI cpd inhibits the reaction [Estradiol results in increased phosphorylation of MAPK1 protein]; RTKI cpd inhibits the reaction [Histamine results in increased phosphorylation of MAPK1 protein]; RTKI cpd inhibits the reaction [Iloprost results in increased phosphorylation of and results in increased activity of MAPK1 protein]; RTKI cpd inhibits the reaction [lead acetate results in increased phosphorylation of MAPK1 protein]; RTKI cpd inhibits the reaction [lead nitrate results in increased phosphorylation of MAPK1 protein]; RTKI cpd inhibits the reaction [Lead results in increased phosphorylation of MAPK1 protein]; RTKI cpd inhibits the reaction [NTS protein results in increased phosphorylation of and results in increased activity of MAPK1 protein]; RTKI cpd inhibits the reaction [Pyocyanine results in increased phosphorylation of MAPK1 protein]; RTKI cpd inhibits the reaction [sodium arsenite results in increased phosphorylation of and results in increased activity of MAPK1 protein]; RTKI cpd inhibits the reaction [sodium arsenite results in increased phosphorylation of MAPK1 protein]; RTKI cpd inhibits the reaction [TAC1 protein results in increased phosphorylation of and results in increased activity of MAPK1 protein]; RTKI cpd inhibits the reaction [Tetrachlorodibenzodioxin results in increased phosphorylation of and results in increased activity of MAPK1 protein]; RTKI cpd inhibits the reaction [TGFA protein results in increased phosphorylation of and results in increased activity of MAPK1 protein]; RTKI cpd inhibits the reaction [Thrombin results in increased phosphorylation of MAPK1 protein]; RTKI cpd results in decreased phosphorylation of and results in decreased activity of MAPK1 protein
[RTKI cpd results in decreased activity of EGFR protein] inhibits the reaction [Cadmium Chloride results in increased phosphorylation of and results in increased activity of MAPK1 protein]; RTKI cpd inhibits the reaction [[Fluoxetine results in increased activity of HTR2B protein] which results in increased phosphorylation of MAPK1 protein]; RTKI cpd inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Capsaicin] results in increased phosphorylation of MAPK1 protein]; RTKI cpd inhibits the reaction [Acrolein results in increased phosphorylation of MAPK1 protein]; RTKI cpd inhibits the reaction [Asbestos, Crocidolite results in increased phosphorylation of MAPK1 protein]; RTKI cpd inhibits the reaction [bisphenol A results in increased phosphorylation of MAPK1 protein]; RTKI cpd inhibits the reaction [evodiamine results in increased phosphorylation of MAPK1 protein]; RTKI cpd inhibits the reaction [Homocysteine results in increased phosphorylation of MAPK1 protein]; RTKI cpd inhibits the reaction [Hydrogen Peroxide results in increased phosphorylation of MAPK1 protein]; RTKI cpd inhibits the reaction [LHB protein results in increased phosphorylation of and results in increased activity of MAPK1 protein]; RTKI cpd inhibits the reaction [Phenylephrine results in increased phosphorylation of and results in increased activity of MAPK1 protein]
RTKI cpd inhibits the reaction [7-ketocholesterol results in increased phosphorylation of MAPK1 protein]; RTKI cpd inhibits the reaction [Cadmium Chloride results in increased phosphorylation of MAPK1 protein]; RTKI cpd inhibits the reaction [cholesterol alpha-oxide results in increased phosphorylation of MAPK1 protein]; RTKI cpd inhibits the reaction [Doxorubicin results in increased phosphorylation of and results in increased activity of MAPK1 protein]; RTKI cpd inhibits the reaction [EGF protein results in increased activity of MAPK1 protein]; RTKI cpd inhibits the reaction [EGFR protein affects the reaction [EDN1 protein results in increased phosphorylation of MAPK1 protein]]; RTKI cpd inhibits the reaction [FSHB protein results in increased phosphorylation of MAPK1 protein]; RTKI cpd inhibits the reaction [hexabromocyclododecane promotes the reaction [FSHB protein results in increased phosphorylation of MAPK1 protein]]; RTKI cpd inhibits the reaction [Hydrogen Peroxide results in increased activity of MAPK1 protein]; RTKI cpd inhibits the reaction [Metribolone results in increased phosphorylation of MAPK1 protein]; RTKI cpd inhibits the reaction [Oleylethanolamide results in increased phosphorylation of MAPK1 protein]; RTKI cpd inhibits the reaction [Phenylephrine results in increased phosphorylation of and results in increased activity of MAPK1 protein]; RTKI cpd inhibits the reaction [sodium arsenite results in increased phosphorylation of and results in increased activity of MAPK1 protein]; RTKI cpd inhibits the reaction [Uridine Triphosphate results in increased phosphorylation of and results in increased activity of MAPK1 protein]; RTKI cpd inhibits the reaction [Zinc Sulfate results in increased phosphorylation of MAPK1 protein]
RTKI cpd results in decreased phosphorylation of MAPK1 protein

PMID:9710602 PMID:10516208 PMID:11309286 PMID:11329622 PMID:12761878 More...

NCBI chr11:83,957,813...84,023,629
Ensembl chr11:83,957,813...84,023,616

G

mitogen activated protein kinase 14

multiple interactions

RTKI cpd inhibits the reaction [Acrolein results in increased phosphorylation of MAPK14 protein]

NCBI chr20:6,749,646...6,810,590
Ensembl chr20:6,749,670...6,810,589

G

mitogen activated protein kinase 3

multiple interactions
decreases phosphorylation

[RTKI cpd results in decreased activity of EGFR protein] inhibits the reaction [Equol results in increased phosphorylation of MAPK3 protein]; [RTKI cpd results in decreased activity of EGFR protein] inhibits the reaction [Hexachlorobenzene results in increased phosphorylation of and results in increased activity of MAPK3 protein]; RTKI cpd inhibits the reaction [4-(N-methyl-N-nitrosamino)-1-(3-pyridyl)-1-butanone results in increased phosphorylation of MAPK3 protein]; RTKI cpd inhibits the reaction [[Toluene 2,4-Diisocyanate binds to ALB protein] which results in increased phosphorylation of MAPK3 protein]; RTKI cpd inhibits the reaction [Acrolein results in increased phosphorylation of MAPK3 protein]; RTKI cpd inhibits the reaction [Alprenolol promotes the reaction [[ADRB1 protein co-treated with EGFR protein] results in increased phosphorylation of MAPK3 protein]]; RTKI cpd inhibits the reaction [arsenic acid results in increased activity of MAPK3 protein]; RTKI cpd inhibits the reaction [arsenite results in increased activity of MAPK3 protein]; RTKI cpd inhibits the reaction [Asbestos, Crocidolite results in increased phosphorylation of MAPK3 protein]; RTKI cpd inhibits the reaction [Atrazine results in increased phosphorylation of MAPK3 protein]; RTKI cpd inhibits the reaction [bisphenol A results in increased phosphorylation of MAPK3 protein]; RTKI cpd inhibits the reaction [Cadmium Chloride results in increased phosphorylation of and results in increased activity of MAPK3 protein]; RTKI cpd inhibits the reaction [Cadmium Chloride results in increased phosphorylation of MAPK3 protein]; RTKI cpd inhibits the reaction [Cadmium results in increased activity of MAPK3 protein]; RTKI cpd inhibits the reaction [Cadmium results in increased phosphorylation of MAPK3 protein]; RTKI cpd inhibits the reaction [Calcitriol results in increased phosphorylation of and results in increased activity of MAPK3 protein]; RTKI cpd inhibits the reaction [calcium silicate results in increased phosphorylation of MAPK3 protein]; RTKI cpd inhibits the reaction [Carvedilol promotes the reaction [[ADRB1 protein co-treated with EGFR protein] results in increased phosphorylation of MAPK3 protein]]; RTKI cpd inhibits the reaction [Diacetyl results in increased phosphorylation of MAPK3 protein]; RTKI cpd inhibits the reaction [Dobutamine promotes the reaction [[ADRB1 protein co-treated with EGFR protein] results in increased phosphorylation of MAPK3 protein]]; RTKI cpd inhibits the reaction [EGF protein results in increased phosphorylation of and results in increased activity of MAPK3 protein]; RTKI cpd inhibits the reaction [EGF protein results in increased phosphorylation of MAPK3 protein]; RTKI cpd inhibits the reaction [Estradiol results in increased phosphorylation of and results in increased activity of MAPK3 protein]; RTKI cpd inhibits the reaction [Estradiol results in increased phosphorylation of MAPK3 protein]; RTKI cpd inhibits the reaction [Histamine results in increased phosphorylation of MAPK3 protein]; RTKI cpd inhibits the reaction [Iloprost results in increased phosphorylation of and results in increased activity of MAPK3 protein]; RTKI cpd inhibits the reaction [lead acetate results in increased phosphorylation of MAPK3 protein]; RTKI cpd inhibits the reaction [lead nitrate results in increased phosphorylation of MAPK3 protein]; RTKI cpd inhibits the reaction [Lead results in increased phosphorylation of MAPK3 protein]; RTKI cpd inhibits the reaction [NTS protein results in increased phosphorylation of and results in increased activity of MAPK3 protein]; RTKI cpd inhibits the reaction [Pyocyanine results in increased phosphorylation of MAPK3 protein]; RTKI cpd inhibits the reaction [sodium arsenite results in increased phosphorylation of and results in increased activity of MAPK3 protein]; RTKI cpd inhibits the reaction [sodium arsenite results in increased phosphorylation of MAPK3 protein]; RTKI cpd inhibits the reaction [TAC1 protein results in increased phosphorylation of and results in increased activity of MAPK3 protein]; RTKI cpd inhibits the reaction [Tetrachlorodibenzodioxin results in increased phosphorylation of and results in increased activity of MAPK3 protein]; RTKI cpd inhibits the reaction [TGFA protein results in increased phosphorylation of and results in increased activity of MAPK3 protein]; RTKI cpd inhibits the reaction [Thrombin results in increased phosphorylation of MAPK3 protein]; RTKI cpd results in decreased phosphorylation of and results in decreased activity of MAPK3 protein
[RTKI cpd results in decreased activity of EGFR protein] inhibits the reaction [Cadmium Chloride results in increased phosphorylation of and results in increased activity of MAPK3 protein]; RTKI cpd inhibits the reaction [[Fluoxetine results in increased activity of HTR2B protein] which results in increased phosphorylation of MAPK3 protein]; RTKI cpd inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Capsaicin] results in increased phosphorylation of MAPK3 protein]; RTKI cpd inhibits the reaction [Acrolein results in increased phosphorylation of MAPK3 protein]; RTKI cpd inhibits the reaction [Asbestos, Crocidolite results in increased phosphorylation of MAPK3 protein]; RTKI cpd inhibits the reaction [bisphenol A results in increased phosphorylation of MAPK3 protein]; RTKI cpd inhibits the reaction [evodiamine results in increased phosphorylation of MAPK3 protein]; RTKI cpd inhibits the reaction [Homocysteine results in increased phosphorylation of MAPK3 protein]; RTKI cpd inhibits the reaction [Hydrogen Peroxide results in increased phosphorylation of MAPK3 protein]; RTKI cpd inhibits the reaction [LHB protein results in increased phosphorylation of and results in increased activity of MAPK3 protein]; RTKI cpd inhibits the reaction [Phenylephrine results in increased phosphorylation of and results in increased activity of MAPK3 protein]
RTKI cpd inhibits the reaction [7-ketocholesterol results in increased phosphorylation of MAPK3 protein]; RTKI cpd inhibits the reaction [Cadmium Chloride results in increased phosphorylation of MAPK3 protein]; RTKI cpd inhibits the reaction [cholesterol alpha-oxide results in increased phosphorylation of MAPK3 protein]; RTKI cpd inhibits the reaction [Doxorubicin results in increased phosphorylation of and results in increased activity of MAPK3 protein]; RTKI cpd inhibits the reaction [EGF protein results in increased activity of MAPK3 protein]; RTKI cpd inhibits the reaction [EGFR protein affects the reaction [EDN1 protein results in increased phosphorylation of MAPK3 protein]]; RTKI cpd inhibits the reaction [FSHB protein results in increased phosphorylation of MAPK3 protein]; RTKI cpd inhibits the reaction [hexabromocyclododecane promotes the reaction [FSHB protein results in increased phosphorylation of MAPK3 protein]]; RTKI cpd inhibits the reaction [Hydrogen Peroxide results in increased activity of MAPK3 protein]; RTKI cpd inhibits the reaction [Metribolone results in increased phosphorylation of MAPK3 protein]; RTKI cpd inhibits the reaction [Oleylethanolamide results in increased phosphorylation of MAPK3 protein]; RTKI cpd inhibits the reaction [Phenylephrine results in increased phosphorylation of and results in increased activity of MAPK3 protein]; RTKI cpd inhibits the reaction [sodium arsenite results in increased phosphorylation of and results in increased activity of MAPK3 protein]; RTKI cpd inhibits the reaction [Uridine Triphosphate results in increased phosphorylation of and results in increased activity of MAPK3 protein]; RTKI cpd inhibits the reaction [Zinc Sulfate results in increased phosphorylation of MAPK3 protein]
RTKI cpd results in decreased phosphorylation of MAPK3 protein

PMID:9710602 PMID:10516208 PMID:11309286 PMID:11329622 PMID:12761878 More...

NCBI chr 1:181,366,646...181,372,863
Ensembl chr 1:181,366,637...181,372,863

G

mitogen-activated protein kinase 7

multiple interactions

RTKI cpd inhibits the reaction [EGF protein results in increased phosphorylation of MAPK7 protein]

NCBI chr10:46,170,264...46,176,262
Ensembl chr10:46,170,167...46,176,267

G

mitogen-activated protein kinase 8

multiple interactions

RTKI cpd inhibits the reaction [Acrolein results in increased phosphorylation of MAPK8 protein]; RTKI cpd inhibits the reaction [Cadmium results in increased phosphorylation of MAPK8 protein]
RTKI cpd inhibits the reaction [Hydrogen Peroxide results in increased activity of MAPK8 protein]

PMID:11329622 PMID:15574683 PMID:26514923

NCBI chr16:8,638,897...8,721,960
Ensembl chr16:8,638,924...8,721,981

G

mitogen-activated protein kinase 9

multiple interactions

RTKI cpd inhibits the reaction [Cadmium results in increased phosphorylation of MAPK9 protein]

NCBI chr10:34,169,661...34,211,138
Ensembl chr10:34,169,675...34,210,178

G

MCL1 apoptosis regulator, BCL2 family member

decreases expression

RTKI cpd results in decreased expression of MCL1 mRNA; RTKI cpd results in decreased expression of MCL1 protein

NCBI chr 2:183,219,137...183,235,676
Ensembl chr 2:183,219,220...183,222,303

G

microRNA 126a

multiple interactions

RTKI cpd promotes the reaction [Asbestos, Crocidolite results in increased expression of MIR126 mRNA]

NCBI chr 3:9,415,063...9,415,180
Ensembl chr 3:9,415,063...9,415,180

G

microRNA 21

multiple interactions

RTKI cpd inhibits the reaction [1-(4-(6-bromobenzo(1,3)dioxol-5-yl)-3a,4,5,9b-tetrahydro-3H-cyclopenta(c)quinolin-8-yl)ethanone results in increased expression of MIR21 mRNA]; RTKI cpd inhibits the reaction [Dehydroepiandrosterone results in increased expression of MIR21 mRNA]

NCBI chr10:71,405,257...71,405,348
Ensembl chr10:71,405,257...71,405,348

G

microRNA 222

multiple interactions

RTKI cpd inhibits the reaction [Asbestos, Crocidolite results in increased expression of MIR222 mRNA]

NCBI chr X:3,428,904...3,429,006
Ensembl chr X:3,428,904...3,429,006

G

matrix metallopeptidase 1

multiple interactions

RTKI cpd inhibits the reaction [EGF protein results in increased secretion of MMP1 protein]; RTKI cpd inhibits the reaction [Histamine results in increased expression of MMP1 mRNA]; RTKI cpd inhibits the reaction [Histamine results in increased secretion of MMP1 protein]

NCBI chr 8:4,658,588...4,679,099
Ensembl chr 8:4,658,588...4,679,097

G

matrix metallopeptidase 13

multiple interactions

RTKI cpd inhibits the reaction [Asbestos, Serpentine results in increased expression of MMP13 mRNA]

NCBI chr 8:4,497,960...4,508,239
Ensembl chr 8:4,497,960...4,508,239

G

matrix metallopeptidase 14

multiple interactions

RTKI cpd inhibits the reaction [Acrolein results in increased expression of MMP14 mRNA]

NCBI chr15:27,887,795...27,897,020
Ensembl chr15:27,887,727...27,899,864

G

matrix metallopeptidase 2

multiple interactions

RTKI cpd inhibits the reaction [bisphenol A results in increased expression of MMP2 protein]; RTKI cpd inhibits the reaction [Hexachlorobenzene results in increased expression of MMP2 protein]

PMID:23462309 PMID:25312822

NCBI chr19:14,154,657...14,182,870
Ensembl chr19:14,154,657...14,182,870

G

matrix metallopeptidase 7

multiple interactions

RTKI cpd inhibits the reaction [antimonite results in increased expression of MMP7 mRNA]; RTKI cpd inhibits the reaction [arsenite results in increased expression of MMP7 mRNA]

NCBI chr 8:4,848,186...4,855,908
Ensembl chr 8:4,848,186...4,855,902

G

matrix metallopeptidase 9

multiple interactions

RTKI cpd inhibits the reaction [Acrolein results in increased expression of MMP9 mRNA]; RTKI cpd inhibits the reaction [bisphenol A results in increased expression of MMP9 protein]; RTKI cpd inhibits the reaction [Cadmium results in increased expression of MMP9 mRNA]; RTKI cpd inhibits the reaction [Hexachlorobenzene results in increased secretion of and results in increased activity of MMP9 protein]; RTKI cpd inhibits the reaction [sodium arsenite results in increased secretion of MMP9 protein]

PMID:15504454 PMID:18006877 PMID:23462309 PMID:25312822 PMID:26514923

NCBI chr 3:153,684,158...153,692,118
Ensembl chr 3:153,683,858...153,692,120

G

metallothionein 2A

multiple interactions

[RTKI cpd results in decreased activity of EGFR protein] inhibits the reaction [Cadmium Chloride results in increased expression of MT2 protein]

NCBI chr19:10,832,009...10,832,783
Ensembl chr19:10,832,002...10,832,784

G

mechanistic target of rapamycin kinase

multiple interactions

RTKI cpd inhibits the reaction [7-ketocholesterol results in increased phosphorylation of MTOR protein]; RTKI cpd inhibits the reaction [cholesterol alpha-oxide results in increased phosphorylation of MTOR protein]

NCBI chr 5:158,884,856...158,994,311
Ensembl chr 5:158,884,804...158,994,311

G

mucin 5AC, oligomeric mucus/gel-forming

multiple interactions

RTKI cpd inhibits the reaction [[Smoke results in increased abundance of Particulate Matter] which results in increased expression of MUC5AC mRNA]; RTKI cpd inhibits the reaction [Hydrogen Peroxide results in increased expression of MUC5AC mRNA]; RTKI cpd inhibits the reaction [Hydrogen Peroxide results in increased expression of MUC5AC protein]; RTKI cpd inhibits the reaction [Particulate Matter results in increased expression of MUC5AC mRNA]; RTKI cpd inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of MUC5AC mRNA]

PMID:10640773 PMID:20971882 PMID:22820758 PMID:31944254

NCBI chr 1:196,864,336...196,896,475
Ensembl chr 1:196,864,336...196,896,475

G

NFE2 like bZIP transcription factor 2

multiple interactions
decreases phosphorylation

[2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one co-treated with RTKI cpd] inhibits the reaction [Pyocyanine affects the localization of NFE2L2 protein]; RTKI cpd inhibits the reaction [Pyocyanine affects the localization of NFE2L2 protein]
RTKI cpd results in decreased phosphorylation of NFE2L2 protein

PMID:24015256 PMID:33148531

NCBI chr 3:60,594,239...60,621,712
Ensembl chr 3:60,594,242...60,621,737

G

NFKB inhibitor alpha

increases expression

[RTKI cpd results in increased expression of CYLD protein] which results in increased expression of NFKBIA protein

NCBI chr 6:72,858,713...72,861,941
Ensembl chr 6:72,858,712...72,861,941

G

nitric oxide synthase 3

multiple interactions

[RTKI cpd results in decreased activity of EGFR protein] inhibits the reaction [Equol results in increased phosphorylation of and results in increased activity of NOS3 protein]

NCBI chr 4:10,793,834...10,814,170
Ensembl chr 4:10,793,834...10,814,166

G

notch receptor 1

multiple interactions
increases expression

RTKI cpd inhibits the reaction [arsenite results in decreased expression of NOTCH1 protein modified form]; RTKI cpd inhibits the reaction [Cadmium Chloride results in increased cleavage of NOTCH1 protein]
RTKI cpd results in increased expression of NOTCH1 protein modified form

PMID:18633435 PMID:25118938

NCBI chr 3:9,277,955...9,323,531
Ensembl chr 3:9,278,086...9,323,531

G

NADPH oxidase 4

multiple interactions
increases expression

Doxorubicin promotes the reaction [RTKI cpd results in increased expression of NOX4 mRNA]

NCBI chr 1:140,900,886...141,078,844
Ensembl chr 1:140,901,097...141,077,406

G

natriuretic peptide A

multiple interactions

RTKI cpd inhibits the reaction [GNAQ protein promotes the reaction [Phenylephrine results in increased expression of NPPA protein]]

NCBI chr 5:158,429,042...158,430,351
Ensembl chr 5:158,429,042...158,430,351

G

neuregulin 1

multiple interactions

RTKI cpd inhibits the reaction [NRG1 protein inhibits the reaction [Diethylhexyl Phthalate results in decreased expression of BCL2 mRNA]]; RTKI cpd inhibits the reaction [NRG1 protein inhibits the reaction [Diethylhexyl Phthalate results in decreased expression of BCL2 protein]]; RTKI cpd inhibits the reaction [NRG1 protein inhibits the reaction [Diethylhexyl Phthalate results in decreased expression of ERBB2 mRNA]]; RTKI cpd inhibits the reaction [NRG1 protein inhibits the reaction [Diethylhexyl Phthalate results in decreased expression of ERBB4 mRNA]]; RTKI cpd inhibits the reaction [NRG1 protein inhibits the reaction [Diethylhexyl Phthalate results in decreased expression of PIK3R1 mRNA]]; RTKI cpd inhibits the reaction [NRG1 protein inhibits the reaction [Diethylhexyl Phthalate results in increased expression of BAX mRNA]]; RTKI cpd inhibits the reaction [NRG1 protein inhibits the reaction [Diethylhexyl Phthalate results in increased expression of BAX protein]]; RTKI cpd inhibits the reaction [NRG1 protein inhibits the reaction [Diethylhexyl Phthalate results in increased expression of CASP3 mRNA]]

NCBI chr16:59,250,658...60,304,519
Ensembl chr16:59,250,854...60,296,884

G

neurotensin

multiple interactions

RTKI cpd inhibits the reaction [NTS protein results in increased expression of CXCL8 mRNA]; RTKI cpd inhibits the reaction [NTS protein results in increased phosphorylation of and results in increased activity of AKT1 protein]; RTKI cpd inhibits the reaction [NTS protein results in increased phosphorylation of and results in increased activity of EGFR protein]; RTKI cpd inhibits the reaction [NTS protein results in increased phosphorylation of and results in increased activity of MAPK1 protein]; RTKI cpd inhibits the reaction [NTS protein results in increased phosphorylation of and results in increased activity of MAPK3 protein]; RTKI cpd inhibits the reaction [NTS protein results in increased secretion of CXCL8 protein]

PMID:15177934 PMID:15247267

NCBI chr 7:37,564,944...37,574,350
Ensembl chr 7:37,564,533...37,574,423

G

proliferating cell nuclear antigen

decreases expression

RTKI cpd results in decreased expression of PCNA protein

NCBI chr 3:119,499,039...119,502,911
Ensembl chr 3:119,498,810...119,502,995

G

phosphoinositide-3-kinase regulatory subunit 1

multiple interactions

RTKI cpd inhibits the reaction [NRG1 protein inhibits the reaction [Diethylhexyl Phthalate results in decreased expression of PIK3R1 mRNA]]

NCBI chr 2:32,878,942...32,963,668
Ensembl chr 2:32,882,032...32,963,631

G

phospholipase A2 group 4A

multiple interactions

RTKI cpd inhibits the reaction [[lead nitrate results in increased expression of PLA2G4A mRNA] which results in increased secretion of Dinoprostone]; RTKI cpd inhibits the reaction [lead nitrate results in increased expression of PLA2G4A mRNA]
RTKI cpd inhibits the reaction [Fluoxetine results in increased expression of PLA2G4A mRNA]; RTKI cpd inhibits the reaction [Fluoxetine results in increased expression of PLA2G4A protein]

PMID:19662385 PMID:20850495

NCBI chr13:61,877,818...62,022,261
Ensembl chr13:61,877,813...62,022,266

G

peroxisome proliferator-activated receptor delta

multiple interactions

RTKI cpd inhibits the reaction [antimonite results in increased expression of PPARD mRNA]; RTKI cpd inhibits the reaction [arsenite results in increased expression of PPARD mRNA]

NCBI chr20:6,298,785...6,363,970
Ensembl chr20:6,298,785...6,363,968

G

peroxisome proliferator-activated receptor gamma

multiple interactions

RTKI cpd inhibits the reaction [bisphenol A results in increased expression of PPARG mRNA]

NCBI chr 4:148,423,102...148,548,471
Ensembl chr 4:148,423,194...148,548,468

G

protein kinase C, alpha

multiple interactions

RTKI cpd inhibits the reaction [evodiamine results in increased phosphorylation of PRKCA protein]

NCBI chr10:92,889,390...93,288,013
Ensembl chr10:92,894,012...93,288,012

G

protein kinase C, delta

multiple interactions

RTKI cpd inhibits the reaction [sodium arsenite affects the expression of PRKCD protein]; RTKI cpd inhibits the reaction [sodium arsenite results in decreased phosphorylation of PRKCD protein]

NCBI chr16:5,769,217...5,799,380
Ensembl chr16:5,769,215...5,799,352

G

prostaglandin-endoperoxide synthase 2

multiple interactions

RTKI cpd inhibits the reaction [[lead nitrate results in increased expression of PTGS2 mRNA] which results in increased secretion of Dinoprostone]; RTKI cpd inhibits the reaction [lead nitrate results in increased expression of PTGS2 mRNA]; RTKI cpd inhibits the reaction [lead nitrate results in increased expression of PTGS2 protein]
RTKI cpd inhibits the reaction [LHB protein results in increased expression of PTGS2 mRNA]
RTKI cpd inhibits the reaction [TRPV1 gene mutant form promotes the reaction [[Tetradecanoylphorbol Acetate co-treated with Capsaicin] results in increased expression of PTGS2 protein]]

PMID:15459120 PMID:20660715 PMID:20850495 PMID:24639330

NCBI chr13:62,163,936...62,172,193
Ensembl chr13:62,163,932...62,172,188

G

protein tyrosine kinase 2

multiple interactions

[RTKI cpd co-treated with bisphenol A] results in increased phosphorylation of PTK2 protein

NCBI chr 7:105,126,725...105,331,848
Ensembl chr 7:105,126,728...105,331,783

G

RB transcriptional corepressor 1

multiple interactions

RTKI cpd inhibits the reaction [lead nitrate results in increased expression of RB1 mRNA]; RTKI cpd inhibits the reaction [lead nitrate results in increased expression of RB1 protein]

NCBI chr15:48,371,295...48,502,473
Ensembl chr15:48,371,296...48,502,302

G

RUNX family transcription factor 2

decreases expression

RTKI cpd results in decreased expression of RUNX2 mRNA

NCBI chr 9:16,167,504...16,492,826
Ensembl chr 9:16,167,482...16,492,167

G

SHC adaptor protein 1

multiple interactions

RTKI cpd inhibits the reaction [Hydrogen Peroxide results in increased phosphorylation of SHC1 protein alternative form]; RTKI cpd inhibits the reaction [Norepinephrine results in increased phosphorylation of SHC1 protein alternative form]; RTKI cpd inhibits the reaction [sodium arsenite promotes the reaction [SHC1 protein modified form binds to EGFR protein binds to GRB protein]]; RTKI cpd inhibits the reaction [sodium arsenite results in increased phosphorylation of SHC1 protein]

PMID:9710602 PMID:19168439

NCBI chr 2:174,837,937...174,849,538
Ensembl chr 2:174,837,930...174,849,536

G

solute carrier family 1 member 2

multiple interactions

RTKI cpd inhibits the reaction [2,3-bis(4-hydroxyphenyl)-propionitrile results in increased expression of SLC1A2 protein]; RTKI cpd inhibits the reaction [4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol results in increased expression of SLC1A2 protein]; RTKI cpd inhibits the reaction [[1-(4-(6-bromobenzo(1,3)dioxol-5-yl)-3a,4,5,9b-tetrahydro-3H-cyclopenta(c)quinolin-8-yl)ethanone binds to and results in increased activity of GPER1 protein] which results in increased expression of SLC1A2 protein]; RTKI cpd inhibits the reaction [Raloxifene Hydrochloride results in increased expression of SLC1A2 mRNA]; RTKI cpd inhibits the reaction [Raloxifene Hydrochloride results in increased expression of SLC1A2 protein]

PMID:22645130 PMID:24782323

NCBI chr 3:89,005,129...89,135,469
Ensembl chr 3:89,005,129...89,126,498

G

Sp1 transcription factor

multiple interactions

RTKI cpd inhibits the reaction [AGT protein promotes the reaction [SP1 protein binds to TGFB1 promoter]]; RTKI cpd inhibits the reaction [AGT protein results in increased expression of SP1 mRNA]

NCBI chr 7:133,541,302...133,571,961
Ensembl chr 7:133,541,491...133,571,961

G

SRC proto-oncogene, non-receptor tyrosine kinase

multiple interactions

[[RTKI cpd results in decreased activity of EGFR protein] co-treated with [SU 6656 results in decreased activity of SRC protein]] inhibits the reaction [Cadmium Chloride results in increased phosphorylation of and results in increased activity of STAT3 protein]
RTKI cpd inhibits the reaction [estradiol-17 beta-glucuronide results in increased phosphorylation of and results in increased activity of SRC protein]
RTKI cpd inhibits the reaction [EGF protein results in increased phosphorylation of SRC protein]; RTKI cpd inhibits the reaction [Nicotine results in increased phosphorylation of SRC protein]

PMID:14569062 PMID:23376140 PMID:25813982 PMID:25856345

NCBI chr 3:146,091,969...146,139,492
Ensembl chr 3:146,091,841...146,139,476

G

sterol regulatory element binding transcription factor 1

multiple interactions

RTKI cpd inhibits the reaction [Glucose results in increased activity of and results in increased cleavage of SREBF1 protein]

NCBI chr10:45,007,637...45,029,650
Ensembl chr10:45,007,637...45,029,650

G

steroidogenic acute regulatory protein

multiple interactions

RTKI cpd inhibits the reaction [bisphenol A results in increased expression of STAR mRNA]

NCBI chr16:66,267,094...66,274,368
Ensembl chr16:66,264,807...66,271,672

G

signal transducer and activator of transcription 3

multiple interactions
decreases expression

RTKI cpd inhibits the reaction [bisphenol A results in increased expression of STAT3 mRNA]; RTKI cpd inhibits the reaction [EGF protein results in increased activity of STAT3 protein]
RTKI cpd results in decreased expression of STAT3 protein modified form
[[RTKI cpd results in decreased activity of EGFR protein] co-treated with [SU 6656 results in decreased activity of SRC protein]] inhibits the reaction [Cadmium Chloride results in increased phosphorylation of and results in increased activity of STAT3 protein]; [RTKI cpd results in decreased activity of EGFR protein] which results in decreased phosphorylation of STAT3 protein

PMID:21268125 PMID:21909620 PMID:23376140 PMID:25841994 PMID:29974605

NCBI chr10:85,811,206...85,863,057
Ensembl chr10:85,811,218...85,863,057

G

signal transducer and activator of transcription 5B

multiple interactions

[RTKI cpd results in decreased activity of EGFR protein] inhibits the reaction [Hexachlorobenzene results in increased phosphorylation of and results in increased activity of STAT5B protein]

NCBI chr10:85,704,841...85,775,856
Ensembl chr10:85,705,670...85,775,668

G

tachykinin, precursor 1

multiple interactions

RTKI cpd inhibits the reaction [TAC1 protein results in increased phosphorylation of and results in increased activity of MAPK1 protein]; RTKI cpd inhibits the reaction [TAC1 protein results in increased phosphorylation of and results in increased activity of MAPK3 protein]

NCBI chr 4:35,679,183...35,687,180
Ensembl chr 4:35,679,704...35,687,178

G

transcription factor AP-2 alpha

multiple interactions

RTKI cpd inhibits the reaction [butylbenzyl phthalate affects the localization of TFAP2A protein]; RTKI cpd inhibits the reaction [Dibutyl Phthalate affects the localization of TFAP2A protein]

NCBI chr17:24,028,716...24,047,507
Ensembl chr17:24,024,432...24,047,507

G

transforming growth factor alpha

multiple interactions

RTKI cpd inhibits the reaction [Particulate Matter results in increased secretion of TGFA protein]; RTKI cpd inhibits the reaction [TGFA protein results in increased expression of FOS protein]; RTKI cpd inhibits the reaction [TGFA protein results in increased expression of GPER1 protein]; RTKI cpd inhibits the reaction [TGFA protein results in increased phosphorylation of and results in increased activity of AKT1 protein]; RTKI cpd inhibits the reaction [TGFA protein results in increased phosphorylation of and results in increased activity of MAPK1 protein]; RTKI cpd inhibits the reaction [TGFA protein results in increased phosphorylation of and results in increased activity of MAPK3 protein]; RTKI cpd inhibits the reaction [Vehicle Emissions results in increased secretion of TGFA protein]

PMID:11309286 PMID:19749156 PMID:24555532

NCBI chr 4:118,618,043...118,700,897
Ensembl chr 4:118,618,269...118,700,894

G

transforming growth factor, beta 1

multiple interactions
decreases expression

RTKI cpd inhibits the reaction [AGT protein promotes the reaction [SP1 protein binds to TGFB1 promoter]]
RTKI cpd inhibits the reaction [sodium arsenite results in increased expression of TGFB1 protein]
RTKI cpd results in decreased expression of TGFB1 protein

PMID:25398788 PMID:35850069

NCBI chr 1:81,196,532...81,212,848
Ensembl chr 1:81,196,532...81,212,847

G

tumor necrosis factor

multiple interactions

RTKI cpd inhibits the reaction [Poly I-C results in increased secretion of TNF protein]

NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629

G

TNF alpha induced protein 6

multiple interactions

RTKI cpd inhibits the reaction [LHB protein results in increased expression of TNFAIP6 mRNA]

NCBI chr 3:36,502,250...36,521,652
Ensembl chr 3:36,502,188...36,521,649

G

tumor protein p53

multiple interactions

RTKI cpd inhibits the reaction [sodium arsenite results in increased expression of TP53 protein]

NCBI chr10:54,300,070...54,311,525
Ensembl chr10:54,300,048...54,311,524

G

transient receptor potential cation channel, subfamily V, member 1

multiple interactions

RTKI cpd inhibits the reaction [TRPV1 gene mutant form promotes the reaction [[Tetradecanoylphorbol Acetate co-treated with Capsaicin] results in increased expression of PTGS2 protein]]

NCBI chr10:57,851,428...57,876,513
Ensembl chr10:57,851,428...57,876,513

G

vascular endothelial growth factor A

multiple interactions

RTKI cpd inhibits the reaction [Asbestos, Crocidolite results in increased secretion of VEGFA protein]; RTKI cpd inhibits the reaction [calcium silicate results in increased secretion of VEGFA protein]

NCBI chr 9:14,955,300...14,970,641
Ensembl chr 9:14,955,300...14,970,641

G

vimentin

decreases expression
multiple interactions

RTKI cpd results in decreased expression of VIM protein
RTKI cpd inhibits the reaction [sodium arsenite results in increased expression of VIM protein]; RTKI cpd inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of VIM protein]

PMID:25856345 PMID:26971374 PMID:35850069

NCBI chr17:76,668,701...76,677,186
Ensembl chr17:76,668,647...76,677,187

Term paths to the root

Path 1
Term	Annotations
CHEBI ontology	19899
role	19869
biological role	19867
pharmacological role	19101
antagonist	17266
epidermal growth factor receptor antagonist	340
2-(3,4-dimethoxyphenyl)-9-[3-methyl-4-(4-methylpiperazin-1-yl)phenyl]purine-6-carboxamide	0
AEE788	0
BI-4020	0
N-\{4-[(3-bromophenyl)amino]quinazolin-6-yl\}but-2-ynamide	0
PD 168393	19
PD-153035	0
PD-153035 hydrochloride	0
dacomitinib	2
erlotinib +	135
gefitinib +	181
osimertinib	23
osimertinib mesylate	0
poziotinib	0
sapitinib	0
semicochliodinol A	0
semicochliodinol B	0
tesevatinib	0
tyrphostin AG 1478	125
tyrphostin AG 825	0
varlitinib	0
Path 2
Term	Annotations
CHEBI ontology	19899
role	19869
biological role	19867
inhibitor	18947
enzyme inhibitor	18775
EC 2.* (transferase) inhibitor	14981
EC 2.7.* (P-containing group transferase) inhibitor	14393
protein kinase inhibitor	14002
epidermal growth factor receptor antagonist	340
2-(3,4-dimethoxyphenyl)-9-[3-methyl-4-(4-methylpiperazin-1-yl)phenyl]purine-6-carboxamide	0
AEE788	0
BI-4020	0
N-\{4-[(3-bromophenyl)amino]quinazolin-6-yl\}but-2-ynamide	0
PD 168393	19
PD-153035	0
PD-153035 hydrochloride	0
dacomitinib	2
erlotinib +	135
gefitinib +	181
osimertinib	23
osimertinib mesylate	0
poziotinib	0
sapitinib	0
semicochliodinol A	0
semicochliodinol B	0
tesevatinib	0
tyrphostin AG 1478	125
tyrphostin AG 825	0
varlitinib	0

paths to the root